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ABSTRACT OF DISSERTATION

THE ABSENCE OF ABCD2 REVEALS A NOVEL ROLE FOR PEROXISOMES IN THE
PROTECTION FROM METABOLIC SYNDROME
ABCD2 (D2) is a peroxisomal ATP binding cassette (ABC) transporter that is
expressed in brain, adrenal and liver. D2 is transcriptionally regulated by key
transcriptional factors that control lipid and glucose metabolism. Therefore, we
examined its role in adipose tissue. These studies revealed that D2 is highly
abundant in adipose tissue and upregulated during adipogenesis. However, D2
deficiency does not affect either adipogenesis or lipid accumulation. An examination
of the lipid profile of adipose tissue revealed the accumulation of C20 and C22 fatty
acids in D2 deficient (D2‐/‐) mice. When challenged with a diet enriched in erucic
acid (C22:1, 10% kcal), this lipid accumulated in both liver and adipose tissue.
Following 8 weeks of diet, D2‐/‐ mice showed increased adiposity, glucose
intolerance, dyslipidemia and steatosis. Analysis of the hepatic lipid profile showed
significant changes away from poly unsaturated fatty acids (PUFAs) and toward
C18‐22 mono‐unsaturated fatty acids (MUFA). RT‐PCR of the mRNA from the
adipose tissue and liver revealed significant changes in lipogenic (ACC, SCD1 & 2)
and PUFA synthesis (∆5 & 6‐desaturase) genes in D2‐/‐ mice. The molecular
mechanisms by which D2 regulates lipid metabolism in adipose tissue remains
unclear. To explore potential mechanisms, the subcellular localization of D2 in
adipose tissue was determined. Our results demonstrated that D2 resides in a
distinct subclass of peroxisomes that does not containing classical peroxisomal
markers such as pex19 or PMP70, but are positive for pex14. In conclusion, our
studies reveal a novel role of D2 and peroxisomes in the protection from disruptions
of lipid metabolism induced by dietary erucic acid and that D2 resides in a unique
compartment within adipocytes that plays a yet to be elucidated role in the
regulation of lipid metabolism.
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1. Chapter 1: Introduction
1.1. Obesity
Obesity is defined by World Health Organization as excess weight gain for a
given height (BMI ≥ 30 kg/m2). The over consumption of energy dense foods that
contain high proportions of simple carbohydrates and saturated fats in Western
societies directly contributes to the high incidence of obesity. The United States has
the highest obesity rate in the world with 33.8% being obese (BMI ≥ 30) and 68.0%
being overweight or obese (BMI ≥ 25) as of 2007(1). The hallmarks of obesity are
expanded adipose tissue, impaired adipocyte function and chronic low degree
inflammation. Obesity increases the risk of other diseases including type 2 diabetes
mellitus (T2D), cardiovascular diseases (CVD), hypertension, and nonalcoholic fatty
liver disease (NAFLD).
Adipose tissue serves as body’s largest energy reservoir by storing
triacylglycerols (TAGs) in lipid droplets during the fed state and releasing non‐
esterified free fatty acids (NEFA) during the fasted state for use in other tissues as
fuel (Figure 1.1‐1). Recently, studies have revealed an important role of adipose
tissue as an active endocrine organ that secretes a variety of adipokines, adipose
derived cytokines that regulate metabolic homeostasis, appetite, insulin sensitivity,
inflammation and energy expenditure(2). Due to the disruption of the endocrine
function of adipose tissue in obese patients, fat becomes a source of inflammation.
TNF‐α, IL‐6, and free fatty acids create a proinflammatory environment and
promote insulin resistance in liver, skeletal muscle and adipose tissue.
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Figure 1.1‐1. Coordination of fat storage and mobilization in white adipose
tissue.
Figure is adapted from (3).

In the postprandial period, insulin is secreted from pancreatic β‐cells in
response to elevated blood glucose. As an important hormone that regulates energy
and glucose homeostasis, insulin exerts three main functions: 1) lowering the
postprandially elevated blood glucose level by increasing the disposal of glucose in
liver and skeletal muscle and inhibiting gluconeogenesis, 2) promoting lipid
synthesis in liver, and 3) lowering circulating NEFA by inhibit lipases that promote
TAG hydrolysis in adipose tissue. In insulin resistant patients, glucose disposal by
peripheral tissues is reduced and the antilipolytic action of insulin in adipose tissue
is impaired. When NEFA are delivered to liver, they exacerbate hepatic insulin
resistance, resulting in ectopic lipid accumulation and ER stress and contributing to
NAFLD. In addition, hyperinsulinemia can further promote hepatic lipid
accumulation by stimulating hepatic lipid synthesis(4, 5).
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NAFLD is characterized by lipid accumulation, especially TAG, in the absence of
significant alcohol consumption. The prevalence of NAFLD in the world‐wide
general population is estimated to be between 14% and 24%(6‐8), and is around
30% in the United States adult population(9). Hepatic lipid accumulation results
from the imbalance between lipid availability (fatty acid uptake from circulation and
de novo lipid synthesis) and lipid disposal (fatty acid β‐oxidation or triglyceride rich
lipoprotein secretion)(10). NAFLD is typically diagnosed in patients with insulin
resistance and other metabolic syndromes (obesity, dyslipidemia and diabetes).
Consequently, in obese individuals, the prevalence of NAFLD increases significantly
to between 74% and 90%(4, 11).
To provide information for treatment, kinetic studies have been conducted to
identify the origin of TAGs accumulated in the livers of NAFLD patients. The major
sources are (Figure 1.1‐2):
1) Lipid stored in adipose tissue in the form of TAG. Under energy demanding
conditions, lipolysis of TAG generates and releases NEFA into circulation, which
can be taken‐up by liver and used for energy via β‐oxidation (pathway 1),
2) Fatty acids made in liver through de novo lipogenesis (DNL) from acetyl‐CoA
generated in Krebs cycle (pathway 2),
3) Dietary fatty acids, which can enter liver through spillover into plasma NEFA
pool (pathway 3),
4) Internalization of chylomicron remnants (pathway 4).

3

Figure 1.1‐2. Model of lipid flux through the liver (12).
Boxed numbers indicate the metabolic pathways traced using stable
(nonradioactive) isotopes. DNL indicates new fat synthesis from 2‐carbon
precursors (e.g., dietary carbohydrate); chylomicrons are lipoproteins made in the
intestine that carry dietary fat. FA, cellular fatty acids (fatty acids not esterified to
glycerol but bound to a carrier protein).

The relative importance and contribution of each source to the content of liver
TAGs accumulation has been studied(12). Using a multiple‐stable‐isotope labeling
approach in patients of NAFLD, Donnelly et al. reported that this method labels up to
64% (mean ± SD, 38 ± 16%) of the hepatic lipids. Of the labeled TAGs in liver, 59%
TAGs are from the plasma NEFA pool (pathway 1, 59.0% ± 9.9%,), 26% are from
DNL (pathway 2, 26.1% ± 6.7%) and 15% are from the diet (pathway 3 and 4, 14.9%
± 7.0%).
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Also, the relative contribution of these sources to very‐low‐density lipoproteins
(VLDL) TAGs paralleled the liver TAGs(10). In the fasting period, the NEFA, DNL and
dietary NEFA pools contribute 81%, 7% and 10% of VLDL TAGs, respectively. In the
fed period, the contribution of NEFA, DNL and dietary NEFA to VLDL TAGs are 61%,
9% and 26%. These data demonstrate that NEFA from adipose tissue contribute the
most to both liver and VLDL in NAFLD patients, suggesting that lipid composition of
adipose tissue will greatly affect the lipid composition of liver.
To better understand the development of NAFLD, important metabolic pathways
of lipids will be discussed in detail below: 1) lipid absorption 2) hepatic de novo
lipogenesis, 3) lipid storage and 4) lipid utilization.

1.2. Lipid metabolism
1.2.1. Lipid absorption
Dietary fat exists mostly in the form of triglycerides and represents about one
third of the average daily caloric intake of humans. The fats in ingested foods are
insoluble in water and aggregate into large lipid droplets in the upper portion of the
stomach. The large lipid droplets are broken into smaller lipid droplets by
contractile activity at the lower portion of the stomach and small intestine.
Phospholipids and bile salts, which are secreted in the bile, serve as emulsifying
agents and prevent the smaller droplets from reaggregating back into large droplets
(Figure 1.2‐1). Fat digestion occurs almost entirely in the small intestine. Fats are
mostly digested by pancreatic lipase, which breaks the ester bond at the first and
third carbon atoms of triglyceride, releasing two free fatty acids and a
monoglyceride. Since pancreatic lipase is a water‐soluble enzyme, it can only digest
lipids at the surface of a lipid droplet. The emulsification process greatly increases
lipid droplet surface area, providing access to the lipase and accelerating the rate of
digestion.
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The free fatty acids and monoglyceride then cluster together with bile salts and
phospholipids to form micelles with the polar ends of each molecule oriented
toward the surface and the nonpolar portions toward the core. When micelles break
down, their contents diffuse across the luminal plasma membranes of the epithelial
cells. During their passage through the epithelial cells, fatty acids and
monoglycerides are resynthesized into triglycerides in the smooth endoplasmic
reticulum and aggregates into small lipid droplets. The droplets are secreted in
vesicles, which then fuse with the plasma membrane and releases chylomicrons into
the interstitial fluid. The chylomicrons pass into lacteals, lymphatic capillaries in the
intestinal villi, enter the lymph and eventually empty into systemic veins via the
thoracic duct(13).
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Figure 1.2‐1 Fat absorption across the walls of the small intestine (from (13))
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1.2.2. Lipid synthesis and regulation
Normally, the contribution of DNL to total hepatic TAG accumulation is small and
accounts for only about 5% of FAs incorporated into secreted VLDL‐TAG(14, 15) in
healthy people; In patients with NAFLD, the contributon of DNL increases to 15%
and 23% of FAs within hepatic triglycerides and VLDL‐TAG(12, 15). Moreover, DNL
pathway also serves as a metabolic regulator by affecting other pathways like FA
oxidation. For example, Omega‐3 PUFA (polyunsaturated fatty acids) synthesized by
DNL and their metabolites are endogenous ligands for PPARα, which stimulates
fatty acid uptake and oxidation. Also, malonyl‐CoA, the precursor for DNL, inhibits
CPT‐1 (carnitine palmitoyltransferase 1 activity) and reduces FA β‐oxidation
rate(16).

1.2.2.1.

Lipid synthesis

The general nomenclature of fatty acids is showed in Figure 1.2‐2. Fatty acids
that are referenced in this thesis are listed in Table 1.2‐1.

Figure 1.2‐2. Fatty acid nomenclature.
As an example, the structure of linoleic acid (C18:2, n‐6) is given.
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Table 1.2‐1. Common names of various fatty acids referred in thesis
Class

Symbol
C16:0
C18:0
C20:0
C22:0
C24:0

Common Name
Palmitic acid
Stearic acid
Arachidic acid
Behenic acid
Lignoceric acid

Monounsaturated
fatty acids

C16:1 (n‐7)
C16:1 (n‐10)
C18:1 (n‐9)
C20:1 (n‐9)
C22:1 (n‐9)

Palmitoleic acid
Sapienic acid
Oleic acid
Gadoleic acid
Erucic acid

n‐6 and n‐3
polyunsaturated fatty
acids

C18:2 (n‐6)
C20:4 (n‐6)
C22:5 (n‐6)
C18:3 (n‐3)
C20:5 (n‐3)
C22:6 (n‐3)

Linoleic acid
Arachidonic acid
Docosapentaenoic acid
α‐linoleic acid
Eicosapentaenoic acid
Docosahexaenoic acid

Saturated fatty acids

Citrate formed in the Krebs cycle is shuttled to the cytosol and converted to
acetyl‐CoA by ATP citrate lyase (ACL). ACC1 (acetyl‐CoA carboxylase 1) then
converts acetyl‐CoA to malonyl‐CoA, which can by used by FAS (fatty acid synthase)
for the sequential 2‐carbon elongation reactions that produce palmitic acid (C16:0)
in the cytosol (Figure 1.2‐3).
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Glucose

Pentose phosphate shunt

Glucosel-6-phsphate

NADPH

ME
Malate

Pyruvate

Oxaloacetate
Acetyl-CoA

Citrate

Citrate

Acetyl-CoA

ACL

!"#$%

ACC
Malonyl-CoA
FAS

Mitochondria
Palmitate

Figure 1.2‐3. Pathways for fatty acid biosynthesis.
(bold, italic letters) Enzymes: ACC, Acetyl‐coenzyme A carboxylase; ACL, ATP citrate
lyase; CoA, coenzyme A; FAS, fatty acid synthase; GPAT, glycerol‐3‐phosphate
acyltransferase; ME, malic enzyme.

Palmitic acid can be elongated by the long chain fatty acyl elongase (ELOVL) to
form stearic acid (C18:0). Both palmitic acid and stearic acid can be desaturated by
SCD1 (stearoyl‐CoA desaturase 1) to form palmitoleic acid (C16:1, n‐9) and oleic
acid (C18:1, n‐9) (Figure 1.2‐4). Oleic acid (37~49.7% mol%), palmitic acid
(18.1~23.5 mol%) and linoleic acid (C18:2, n‐6), (8.6~24.9 mol%) are the most
abundant fatty acids of TAG in human adipose tissue(17).
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Figure 1.2‐4. Synthesis of fatty acids in mammals(18)

1.2.2.1.1.

Acetyl‐CoA Carboxylase (ACC)

ACC catalyzes the first committed step in fatty acid synthesis. There are two
isoforms of ACC in rodents and humans. ACC1 is highly enriched in the cytosol of
hepatocytes and adipocytes, whereas ACC2 is located in mitochondria membrane in
heart, skeletal muscle and liver(19). ACC1 generated malonyl‐CoA is used by FAS as
a 2‐carbon donor for fatty acid synthesis in the cytosol. In contrast, ACC2 generates
malonyl‐CoA in the vicinity of CPT1 in mitochondria to allosterically inhibit CPT1, a
protein responsible for transport of long chain FAs into mitochondria for β‐
oxidation(16). Thus, the intermediate of fatty acid synthesis inhibit the generation of
acetyl CoA from oxidation to prevent fatal cycling.
ACC is regulated by three different mechanisms. 1) At the transcriptional level,
ACC is regulated by SREBP‐1c, ChREBP and LXRs (20‐22). Insulin induces LXR,
which transcriptionally stimulates SREBP‐1c (23). SREBP‐1c then promotes the
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transcription of ACC. Glucose activates ChREBP independent of insulin. ChREBP
then induces lipogenic genes including ACC(24). 2) The short‐term control of ACC
activity is achieved via reversible phosphorylation and allosteric regulation.
Phosphorylation of ACC by AMPK inhibits enzyme activity(25), whereas
dephosphorylation of ACC by insulin signaling in the fed state increases enzyme
activity(26). 3) Citrate generated in Krebs cycle is a feedforward activator of ACC
with different potency for ACC1 and ACC2 (Ka is around 2mM)(27, 28). Citrate is
converted by ACL (ATP citrate lyase) to acetyl‐CoA, which is the substrate of ACC.
High concentration of citrate induces the polymerization of ACC and thereby
increases ACC activity. However, the concentrations of citrate required to increase
ACC activity (> 5 mM) are much higher than its physiological concentration in cells
(0.1‐1mM)(29, 30). A novel regulator of ACC named MIG12 has recently been
identified (31). MIG12 expression is regulated by SREBP‐1c in a manner similar to
other genes involved in fatty acid synthesis. MIG12 binds to ACC and significantly
lowers the threshold for citrate activation into the physiological range (< 1 mM).
Overexpression of MIG12 in liver induces ACC polymerization, increases FA
synthesis, and results in TG accumulation and fatty liver.
ACC1 deletion is embryonically lethal(32). Liver specific ACC1 deletion of
(LACC1KO) provided direct evidence that ACC1 is the principal pathway for
conversion of acetyl–CoA to malonyl‐CoA. LACC1KO mice displayed a 70‐75%
reduction in ACC activity and malonyl‐CoA levels. When challenged with a fat‐free
diet, these mice showed significant decrease in de novo fatty acid synthesis and TAG
accumulation in the liver, despite upregulation of PPARγ and lipogenic genes(33).
In contrast, ACC2‐/‐ mice have a normal life span, but eat more food and gain less
weight than their WT controls due to increased fatty acid oxidation rates(16). ACC2‐
/‐

mice are resistant to high fat/high carbohydrate diet induced obesity and insulin

resistance(34).
In rats with high‐fat diet‐induced hepatic steatosis and insulin resistance, liver‐
specific ASO inhibition of both ACC1 and ACC2 expression reduces hepatic TAG, long
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chain acyl‐CoA and DAG (diacylglycerol) content and improves hepatic insulin
sensitivity(35). This study suggested a promising therapeutic effect of ACC
inhibition for treating multiple metabolic disorders.
1.2.2.1.2.

Fatty acid synthase (FAS)

FAS catalyzes the biosynthesis of saturated fatty acids myristate (C14:0),
stearate (C18:0) and mainly palmitate (C16:0) by using malonyl‐CoA as
substrate(36). FAS functions as a homodimer. Each monomer is about 260 kDa in
size and contains eight functional domains. Six harbor the enzyme activities
required for the initiation of synthesis and the elongation of fatty acid chains by two
carbon increments: acyl transferase, β‐ketoacyl synthase, β‐ketoacyl reductase,
β−hydroxylacyl dehydrase, enoyl reductase, and β−ketoacyl synthase. One domain,
thioesterase, represents the enzyme activity required for releasing the mature fatty
acid from the enzyme. The eighth domain represents the acyl carrier protein, the
site to which the growing fatty acid is tethered during synthesis.
Deletion of FAS results in embryonic lethality(37). Liver specific FAS knockout
mice, when challenged with low fat diet, develop hypoglycemia and hepatic steatosis
due to a reduction in β‐oxidation. These phenotypes were corrected with a PPARα
agonist, which enhances fatty acid β‐oxidation(38).
1.2.2.1.3.

Stearoyl‐CoA desaturase (SCD)

SCD, also known as D9D (delta9 desaturase) is essential for the synthesis of
monounsaturated fatty acids (MUFA) from saturated fatty acids (SFA) (39). The
enzyme introduces the first cis‐double bond at the 9,10 position from the carboxyl
end of fatty acyl‐CoA with 12 to 19 carbon chains. The desaturation reaction takes
place in ER and involves cytochrome b5, NADH (P)‐cytochrome b5 reductase, and
molecular oxygen.
Four isoforms of SCD have been cloned and characterized in mice (SCD1‐4),
whereas only two human SCD genes have been identified(40‐45). In adult mice,
SCD1 is the predominant isoform in most lipogenic tissues and is markedly induced
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in liver in response to high carbohydrate diet(40, 41, 46). SCD2, was recently shown
to be required for adipogenesis in 3T3‐L1 cells due to a requirement for adequate
levels of peroxisome proliferator‐activated receptor (PPAR)‐γ(47). Human SCD1
shares 85% sequence identity with mouse SCD1 genes, while human SCD5 shares
limited identity to mouse SCD genes and is unique to primates(45, 48). The main
products of SCD are oleic acid (C16:1) and palmitoleic acids (C18:1), which are the
major MUFA in fat depots and membrane phospholipids.
SCD1 deficient mice (asebia mice, homozygous for a natural mutation of SCD1
gene) display low levels of hepatic cholesterol esters and triglycerides, have loss of
body weight, hypoglycemia and hypercholesterolemia in response to high‐
carbohydrate feeding(49‐51). SCD is required for cholesteryl ester (CE) synthesis in
liver, as evidenced by the fact that dietary supplementation of C18:1 or C16:1 to
SCD1‐/‐ mice failed to restore the C18:1 and C16:1 levels of cholesterol ester despite
the presence of normal activities of acyl‐CoA:cholesterol acyltransferase (ACAT), the
enzyme responsible for cholesterol ester synthesis in liver (49). SCD1 deficient mice
also have increased energy expenditure, enhanced fatty acid oxidation and
thermogenesis in liver, muscle, and brown adipose tissue(52‐54). SCD1‐/‐ mice are
thus protected from both high‐fat diet and leptin deficiency‐induced obesity and
hepatic steatosis(55, 56). However, SCD1 deficiency exacerbates diabetes(55).
SCD1 is considered as one of the main factors preventing the progression of
simple steatosis to steatohepatitis(57). The mechanism of action may be based on
the fact that monounsaturated free fatty acids are necessary for normal rates of
synthesis of TAG and esterification of free cholesterol (58). MUFA are more easily
incorporated into triglycerides and then safely stored in lipid droplets than
saturated free fatty acid, thus reducing the risk of lipotoxicity(59‐61). Moreover,
endogenously synthesized MUFA, which are the preferred substrates for ACAT, are
utilized to esterify free cholesterol, thus reducing its lipotoxicity and increase the
availability of cholesterol esters for secretion in the form of VLDL(49).
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SCD1 gene expression is regulated by number of nutrients (i.e. glucose and fatty
acids) and hormones (i.e. insulin, leptin, thyroid hormone). SCD1 expression is
positively regulated by LXR by directly binding an LXR response element in the
SCD1 promoter, and indirectly via LXR‐mediated activation of SREBP‐1c(62‐64).
Cholesterol supplementation in the diet can induce SCD1 mRNA levels and enzyme
activity(39). Dietary carbohydrates increase hepatic SCD1 through ChREBP and
insulin stimulated activation of SREBP1c (21, 65). Dietary n‐3 and n‐6 PUFA
suppress SCD1 gene expression by decreasing the binding of SREBP‐1 with the
SREBP response element of SCD1 promoter and repression of SREBP‐1c
maturation(39). In contrast, saturated fatty acids can induce SCD1 expression, in a
mechanism that may involve fatty acid upregulation of PPARγ coactivator 1β and
subsequent coactivation of SREBP‐1c and LXR(39, 66, 67). Leptin, a key regulator of
energy homeostasis and satiety, represses the expression of the SCD1 gene(56).
1.2.2.2.

Biosynthesis of polyunsaturated fatty acids (PUFA)

In the eukaryotic cell, fatty acids synthesized from DNL in the cytosol and
absorbed from the diet can be further desaturated and/or elongated into long‐chain
(C16, 18) and very‐long‐chain fatty acids (C≥20, VLCFA) with different of degrees of
saturation. PUFA, such as arachidonic acid (AA, C20:4, n‐6) and docosahexaenoic
acid (DHA, C22:6, n‐3) are important fatty acids because they are required for
various physiological functions such as maintenance of membrane fluidity,
regulation of lipid metabolism and eicosanoid signaling(68‐70). Due to the lack of
either delta12 desaturase or delta15 desaturase, mammals cannot synthesize PUFAs
from malonyl CoA. Thus, C18:2 (n‐6) and C18:3 (n‐3) are essential fatty acids that
must be supplied from the diet to serve as precursors for PUFA biosynthesis. The
synthesis of PUFA requires various desaturases and elongases in the endoplasmic
reticulum (ER) and β‐oxidation enzymes in peroxisomes (71).
D6D is the rate‐determining enzyme in LCPUFAs synthesis, catalyzing the first
step in the pathway for both n‐3 and n‐6 families and the final desaturation step of
DHA synthesis (Figure 1.2‐4). Dietary linoleic acid (9, 12‐cis‐C18:2) is desaturated
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by D6D at delta 6 position, sequentially elongated by two carbons to become 8, 11,
14‐cis‐C20:3. C20:3 is then desaturated by D5D, to generate AA (5, 8, 11, 14‐cis‐
C20:4, n‐6).
The synthesis of DHA (4, 7, 10, 13, 16, 19‐cis‐C22:6) shares a pathway with 20:4,
n‐6 up to the 20:5 n‐3 step(72). After two cycles of elongation, D6D converts 9, 12,
15, 18, 21‐C24:5 to 6, 9, 12, 15, 18, 21‐C24:6. C24:6 is then shorted by peroxisomal
β‐oxidation to yield DHA (4, 7, 10, 13, 16, 19‐cis‐C22:6, n‐3).
1.2.2.2.1.

Desaturases

Delta‐6 desaturase (D6D, FADS2: fatty acid desaturase 2) and delta‐5 desaturase
(D5D, FADS1: fatty acid desaturase 1) are required for PUFA synthesis in mammals.
Both D6D and D5D are membrane‐bound, front‐end desaturase because it
introduces a double bond between the pre‐existing double bond and the carboxyl
(front) end of the fatty acid. Human D5D gene shares 61% amino acid identity and
75% similarity with the human D6D(73, 74). Human D5D and D6D genes are
localized in chromosome 11 (11q12‐q13.1) as a cluster in a head‐to‐head
orientation(18). Both desaturase are widely expressed in human tissues, with the
highest levels in liver.
PUFA levels in serum phospholipids in healthy adults are maintained in a
narrow range despite differences in precursor PUFA intake(75). Animal studies
yielded similar results, suggesting that the activity of desaturases is tightly
regulated(76, 77). Indeed, desaturases are primarily regulated at transcription level
by SREBP‐1c by binding with SRE in their promoters(20, 78). Both n‐3 and n‐6
PUFAs can suppress D6D and D5D through inhibition of SREBP‐1c. Dietary PUFAs
can reduce the active, nuclear form SREBP‐1c and reduce SREBP‐1c mRNA
stability(79‐82). Both precursors and products of D5D and D6D are able to suppress
SREBP‐1c. The potency of unsaturated fatty acids increases with increasing chain
length and degree of unsaturation. Therefore, the products of desaturases, known as
highly unsaturated fatty acids (HUFA), are more potent than the precursors (79).
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Desaturase activity is also suppressed by low levels of circulating insulin(18, 83) and
excess of steroids(84), both of which are also mediated by inhibition of SREBP‐1c.
D6D is also controlled by PPARα. D6D expression in rat liver can be induced by
PPARα ligands such fibrates and Wy14643(85‐87). Similarly, long‐chain NEFA are
considered endogenous ligands for PPARα and can induce D6D(88, 89). It has been
shown that D6D was not induced in PPARα‐/‐ mice by essential fatty acid deficient
diet, indicating the requirement of PPARα for PUFA feedback regulation of D6D(90).
1.2.2.2.2.

Elongases

PUFA synthesis requires elongation of C18 fatty acids by elongases localized in
ER(91). Microsomal fatty acid elongation adds two‐carbon units to fatty acyl‐CoA
using malonyl‐CoA as the donor and NADPH as the reducing agent(92). Fatty acid
elongation is achieved with four sequential reactions (Figure 1.2‐4)(93):
condensation between fatty acyl‐CoA and malonyl‐CoA to generate 3‐ketoacyl‐CoA;
reduction of 3‐ketoacyl‐CoA using NADPH to form 3‐hydroxyacyl‐CoA; dehydration
of 3‐hydroxyacyl‐CoA to trans‐2‐enoyl‐CoA; and reduction of trans‐2‐enoyl‐CoA to
fully elongated n+2 fatty acyl‐CoA. Each reaction is catalyzed by a different enzyme
that is encoded by separate gene.
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Figure 1.2‐5. Enzymatic steps in long‐chain fatty acid elongation.
Figure from (93). ELOVL: elongation of very‐long‐chain fatty acids; KAR, 3‐ Ketoacyl‐
CoA reductase; HADC, 3‐hydroxyacyl‐CoA dehydratase; TER, trans‐2,3,‐enoyl‐CoA
reductase

Elongation of very long chain fatty acids is catalyzed by elongases (ELOVLs) (92,
94, 95). Seven ELOVL enzymes (ELOVL1‐7) have been identified in mammals(96‐
100). Each ELOVL has a distinct tissue distribution and exhibits different substrate
preferences. ELOVL1 and ELOVL3 catalyze the elongation of very long chain (C>20)
saturated and monounsaturated fatty acids(101). ELOVL2 elongates C20 and C22
PUFAs(98, 102) and ELOVL4 elongates fatty acids with chain longer than C26(103,
104). ELOVL6 catalyzes the elongation of long chain (C12‐C16) saturated and
monounsaturated fatty acids. ELOVL5 is involved in the elongation of C18 and C20
PUFAs(105‐107).
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PUFA synthesis requires ELOVL5 and ELOVL2(92). However, ELOVL2 is less
abundant, shows very little sensitivity to metabolic mediators and increases its
transcription level only as a result of the overexpression of SREBP‐1c(107). ELOVL5
is expressed in all tissues tested to date, with the highest levels in liver, testis and
adrenal gland(96). Overexpression of ELOVL5 in rat primary hepatocytes promotes
elongation of C20:4, n‐6 and C20:5, n‐3 to C22:4, n‐6 and C22:5, n‐3,
respectively(108). ELOVL5 transcription is regulated by SREBP‐1c and LXRα.
Similar to the regulation of D5D and D6D, ELOVL5 is transcriptionally activated by
LXRα through SREBP‐1c. PUFAs are also able to suppress ELOVL5 expression by
suppressing SREBP‐1c(80, 109). ELOLVL5‐/‐ mice have elevated TAG level in liver
and develop hepatic steatosis(110). This is due to the impaired synthesis of PUFA
and loss of PUFA mediated inhibition on SREBP‐1c activation and its target genes.
Dietary supplementation of AA plus DHA reversed the phenotypes in these mice,
highlighting the importance of maintaining constant level of PUFAs(80).
1.2.2.2.3.

Peroxisomal β‐oxidation

The last step of DHA synthesis requires chain‐shortening of C24:6 by
peroxisomal β‐oxidation. This will be discussed in detail in section 1.2.4.2
1.2.2.3.

Regulation of de novo lipogenesis (DNL)

1.2.2.3.1.

Nuclear transcription factors

1.2.2.3.1.1.

SREBP

Sterol regulatory element‐binding proteins (SREBPs) are a family of helix‐loop‐
helix leucine zipper transcription factors. SREBPs regulate genes involved in fatty
acids, cholesterol biosynthesis and adipocyte differentiation(20, 111‐113).
Three isoforms of SREBPs have been identified: SREBP‐1a and ‐1c and ‐2.
SREBP‐1a and ‐1c are encoded by a single gene, generated through alternative
splicing, and only differ in the first exon(20, 113, 114). SREBP‐1a and ‐1c promote
lipogenesis by upregulating genes involved in fatty acid synthesis such as ACC, FAS
and SCD‐1 (115). SREBP‐1a is the predominant expression form in cultured cells

19

and liver, while SREBP‐1c is predominantly expressed in most of the tissue of mice
and human, including liver, adipose tissue, adrenal gland and brain. SREBP‐2 is
encoded by different gene and regulates cholesterol synthesis genes including HMG‐
CoA reductase and HMG‐CoA synthase.
The precursor SREBPs contain three domains: 1) NH2 terminal of about 480
amino acids (function as a transcriptional factor that can bind with DNA in nucleus
when released); 2) two transmembrane domain connected by short loop of 30
amino acids; and 3) COOH terminal of about 590 amino acids which is involved in its
regulation.
The precursor of SREBPs binds with SCAP (SREBP cleavage activating protein)
and Insig and is trapped in ER membrane(113). SCAP functions as a sensor for
cholesterol concentration, when cholesterol concentration is low, Insig dissociates
from SCAP and SREBPs, SCAP then escorts SREBPs to Golgi, where it can be
sequentially cleaved by protease (site‐1 protease, S1P and site‐2 protease, S2P) and
releases the active NH2 terminal of the protein. The nuclear SREBPs (nSREBPs)
translocates to nucleus, binds with sterol response element (SRE) in the
promoter/enhancer regions of its target genes and activates their transcription.
This regulation mechanism only occurs to SREBP‐1a and SREBP2, while SREBP‐1c is
regulated differently.
SREBP‐1c is induced by LXRα. LXRα is a transcription factor that is highly
expressed in liver and activated endogenously by oxysterol to induce expression of
genes involved in cholesterol efflux and clearance(116, 117). Animals lacking
LXRα showed a reduced expression of SREBP‐1c and lipogenic genes like FAS (115),
ACC and SCD‐1(116, 118). Animals fed with high cholesterol diet or LXRα agonist
showed enhanced SREBP‐1c transcription and nSREBP‐1c processing, as well as
increased lipogenic gene expression(117, 119). This effect of LXRα is mediated by
binding of LXR/RXR with LXR response element in promoter region of SREBP‐1c
and other genes(120).
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SREBP‐1c expression is also sensitive to energy status. Its mRNA is suppressed
during the fasted stage and upregulated when animals are refed(121, 122). This
induction of SREBP‐1c after refeeding is mediated by insulin. In rat primary
hepatocytes, expression of a dominant negative SREBP‐1c blocked the effect of
insulin on transcriptional activation of genes involved in fatty acid synthesis,
whereas expression of dominant positive SREBP‐1c mimicked the insulin
effect(123).
Insulin is secreted by pancreas in response to elevated plasma glucose, to
stimulate glucose uptake, lipogenesis and suppress gluconeogenesis. The insulin
signaling pathway is initiated by binding of insulin with its receptor, followed by
receptor‐mediated tyrosine phosphorylation of insulin receptor substrate‐1 (IRS‐1)
and/or IRS‐2. IRS‐1/2 can then activate PI3K, which activates Akt. The inhibition
effect of insulin on gluconeogenesis is mediated through IRS‐2, while the lipogenic
effect is mediated through IRS‐1. The induction of SREBP‐1c transcription by insulin
is dependent on the integrity of two LXRα binding sites located in the promoter of
SREBP‐1c(23, 124, 125). In insulin resistant mice, despite the disinhibition of
glucose production by downregulated IRS‐2, Induction of SREBP‐1c and its target
lipogenic genes is still active, promotes fatty acid synthesis and accelerates TAG
accumulation. The combination of these two actions leads to hyperglycemia and
hypertriglyceridemia which characterizes fatty liver and diabetic states(126, 127).
Studies of knockout and transgenic mice of each SREBP isoform have provided
information of their function. Knockout of SREBP‐1a or SREBP‐2 is embryonic lethal,
whereas knockout of SREBP‐1c is not(128). When both SREBP‐1a and ‐1c are
eliminated, SREBP‐2 mRNA and protein is overexpressed to compensate the loss of
SREBP‐1a and ‐1c(64, 129).
Overexpression of SREBP‐1a in mice leads to hepatic steatosis characterized by a
26‐fold increase in triglyceride and a 5‐fold increase in cholesterol synthesis rates.
The massive accumulation of TAG and cholesterol in these mice indicates that
SREBP‐1a is able to regulate genes controlling both TAG and cholesterol synthesis,
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but favors TAG synthesis(114, 130). SREBP‐1c transgenic mice also develop fatty
liver disease, but with only increase in TAG and no changes in cholesterol synthesis,
suggesting that, as the predominant isoform of SREBP in liver of mice and human,
SREBP‐1c exclusively controls TAG synthesis(131, 132). SREBP‐1c is elevated in the
fatty liver of insulin resistant, ob/ob mice(126, 133). Knockout of SREBP‐1c in ob/ob
mice markedly attenuates the fatty liver disease by reducing approximately 50% of
hepatic triglycerides(134). SREBP‐2 transgenic mice only show upregulation of the
cholesterol biosynthesis pathway (75 fold increase) and much less upregulation in
fatty acid synthesis (4 fold increase), suggesting that SREBP‐2 is predominantly a
regulator of cholesterol biosynthesis rather than TAG(135).

1.2.2.3.1.2.

ChREBP

Dietary carbohydrate consumption results in elevated blood glucose levels
which stimulates insulin secretion from pancreas β‐cells. Glucose and insulin
synergistically induce glycolytic and lipogenic gene expression. Liang et al, observed
that in SREBP‐1c deficient mice fed with carbohydrate diet, which fail to upregulate
lipogenic genes in response to insulin, there was only 50% reduction in fatty acid
synthesis rate, suggesting the existence of another insulin independent, glucose
triggered regulatory pathway(64). This led to the discovery of a basic/helix‐loop‐
helix/leucine zipper (bHLH/LZ) transcription factor named ChREBP (carbohydrate
responsive element binding protein)(136).
ChREBP is a large protein (864 amino acids) that contains several domains
including nuclear export and import signals, a DNA binding motif of the bHLH/LZ
type, and proline‐rich regions implicated in protein‐protein interactions. ChREBP is
predominantly expressed in liver, kidney, and both white and brown adipose
tissue(137, 138). ChREBP stimulates the expression of most lipogenic genes and L‐
PK (liver‐type pyruvate kinase), a key regulator in glycolysis that catalyzes the
conversion of PEP (phosphoenolpyruvate) to pyruvate.

22

ChREBP is regulated in a reciprocal manner by glucose and cAMP(139). At low
glucose concentrations, the inactive phosphorylated ChREBP is localized in the
cytosol, when stimulated by high glucose concentration, it interacts with Mlx(Max‐
like protein) to form a heterotetramer, translocates to the nucleus, binds to ChoRE
(carbohydrate response element) elements and promotes transcription of its target
genes(136).
Both liver and primary hepatocyte from ChREBP‐/‐ mice showed decreased
lipogenic gene expression and reduced fatty acid synthesis rates, suggesting the
essential role of ChREBP in liver to utilize glucose for DNL(21, 140). ChREBP gene
expression and nuclear protein content were markedly increased in the liver of
ob/ob mice under both fasted and fed conditions. Liver specific inhibition of
ChREBP in ob/ob mice markedly improved hepatic steatosis by decreasing lipogenic
rates, decreasing plasma TAG and NEFA levels after 7 days of adenoviral delivery of
a shRNA against ChREBP. Insulin signaling in liver, skeletal muscle and white
adipose tissue and overall glucose tolerance were also restored(141).
1.2.2.3.1.3.

PPARs

Peroxisome proliferator‐activated receptors (PPARs) were initially
characterized for their capacity to increase peroxisome numbers in the livers of
mice and rats in response to fibrates or xenobiotics. Three isoforms of PPAR have
been cloned: 1) PPARα is mainly expressed in liver, digestive tract and kidney; 2)
PPARβ, δ or NUC‐1 (respectively cloned in Xenopus, mouse and human) are
ubiquitously expressed and often at higher levels than PPARα and γ; and 3) PPARγ
(γ1, γ2, γ3 arising from an alternative splicing of a single gene) is mainly expressed
in adipose tissue and in macrophages.
Like LXRs, PPARs are part of the nuclear receptor superfamily. PPARs form
heterodimers with the retinoid X receptor (RXR). The PPAR/RXR heterodimers,
when bound to a ligand, change conformation and bind to specific response
elements located in the 5’ end region of their target genes resulting in gene
transcription(142).
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PPARα is expressed in the liver and other metabolically active tissues including
striated muscle, kidney and pancreas(143, 144). Endogenous PPARα ligands include
n‐3 PUFAs and eicosanoids. PPARα regulates both mitochondrial and peroxisomal
fatty acid oxidation by directly controlling the expression of key enzymes. In
mitochondria, its target genes include acyl‐CoA synthetase, the carnitine
palmitoyltransferase I (CPT‐1), the very long‐chain acyl‐CoA dehydrogenase and the
tri‐functional protein encoding genes(145‐148). In peroxisomes, PPARα activates
the transcription of acyl‐CoA synthetase, the straight‐chain acyl‐CoA oxidase, the L‐
bifunctional protein and the 3‐ketoacyl‐CoA thiolase(147‐150).
Transgenic mice over‐expressing PPARα in the muscle exhibit increased fatty
acid oxidation(151). Bezafibrate, a potent PPARα agonist, prevents liver TAG
accumulation and improves hepatic steatosis in mice fed a methionine‐ and choline‐
deficient diet(152). PPARα‐/‐ mice develop hepatic steatosis during fasting or high
fat diet feeding due to the insufficient fatty acid oxidation accompanied by increased
lipolysis and fatty acid delivery to liver(153, 154).
There are important differences in PPARα activity between rodents and humans.
PPARα DNA binding activity and PPARα expression in human hepatocytes is less
than 10‐fold that observed in mice(155, 156). Despite the beneficial effects of PPARα
activation on hepatic lipid homeostasis in rodent models, the similar effects of
PPARα in human NAFLD patients are either minimal or not seen(157‐159).
n‐3 PUFAs present in fish oil, and their metabolites are potent endogenous
ligands of PPARα. PUFAs inhibit de novo lipogenesis by antagonizing activation of
LXR, thus reducing expression of SREBP‐1c. n‐3 PUFA supplementation in mice
improves hepatic steatosis and insulin sensitivity, decreases fasting NEFA
concentrations and serum TAG levels(160). Similarly, a number of pre‐clinical and
clinical studies have demonstrated an ameliorative effect of supplemental fish oil,
seal oil and purified LC‐n‐3 FAs in reducing hepatic lipid content in NAFLD(161,
162).
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PPARγ is highly expressed in adipose tissue and to a lesser degree in hepatocytes.
PPARγ is involved in adipocyte differentiation, lipid storage in adipocytes and
insulin sensitivity regulation.
PPARγ promotes adipocyte differentiation and expression of proteins in
adipocytes involved in fatty acid uptake, fatty acid transport and fatty acid
synthesis(160). PPARγ promotes lipid storage in adipocytes by inducing the
expression of lipogenic genes such as fatty acid synthase(163). PPARγ also promotes
the release of fatty acids from lipoproteins and their uptake into adipocytes(164).
PPARγ increases insulin sensitivity by upregulating GLUT4, an insulin dependent
glucose transporter in adipose tissue and skeletal muscle(165).
Patients with dominant negative mutations in PPARγ have NAFLD and
lipodystrophy, suggesting increased lipid delivery to the liver(166). Liver specific
PPARγ deficient mice are protected against the development of steatosis suggesting
a critical role for hepatic PPARγ in liver triglyceride accumulation(167, 168).
Thiazolidinediones (TZD), ligands for PPARγ have been shown to improve
glycemic control in patients with type 2 diabetes mellitus by increasing insulin
sensitivity in adipose tissue, liver and skeletal muscle(169‐171). Rosiglitazone and
pioglitazone treatment are associated with reduction in aminotransferase levels and
improvement in liver histology in patients with NAFLD(169, 172‐175).
PPARδ has been implicated in energy consumption in peripheral tissues by
controlling β‐oxidation. Skeletal muscle cells are an important site of action where
PPARδ regulates genes such as FABP3, lipoprotein lipase, FAT, CPT‐1, long‐chain
acyl‐CoA dehydrogenase and uncoupling proteins (UCPs)(176). Activation of PPARδ
by fatty acids enhances fatty acid transport and oxidation, improves glucose
homeostasis via inhibition of hepatic glucose output, reduces macrophage
inflammatory responses, and dramatically increases circulating high density
lipoprotein levels(10). Several studies have demonstrated the potential of agonists
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to target multiple components of the metabolic syndrome including obesity,
dyslipidemia, hyperglycemia, insulin resistance, and NAFLD(152, 177).
1.2.2.3.1.4.

LXR

LXRs are nuclear transcriptional factors that can sense elevated intracellular
cholesterol levels in the form of oxysterols (22(R)‐hydroxycholesterol, 24(S)‐
hydroxycholesterol, 27‐hydroxycholesterol and 24(S), 25‐epoxycholesterol) in
hepatocytes and other cell types(178). When activated, LXR forms heterodimers
with the RXR, which bind to LXR‐responsive elements (LXREs) in DNA consisting of
direct repeats (DRs) of the core sequence AGGTCA separated by 4 nucleotides.
(DR4)(179).
There are two LXRs: LXRα and LXRβ, which share considerable sequence
homology and respond to the same ligands(180). LXRα Is highly expressed in the
liver, adipose tissue and macrophages. Whereas LXRβ is ubiquitously
expressed(143).
LXRs play a critical role in cholesterol homeostasis by regulating a set of genes
that participate in reverse cholesterol transport, the process transports excess
cholesterol from peripheral tissue to the liver for elimination(181). This effect of
LXRs is dependent on the ability of LXRs to induce the expression of members of the
ABC superfamily of membrane transporters that are involved in the efflux of
cholesterol, including ABCA1, ABCG5 & G8, and ABCG1(182‐188). Activation of LXRs
with a synthetic ligand increases HDL levels and net cholesterol secretion in vivo
(182).
In addition to their ability to modulate cholesterol metabolism, LXRs are also
key regulators of hepatic lipogenesis. LXRα directly activates ACC, FAS, SCD‐1 and
SREBP‐1c transcription(22, 117, 120). Administration of synthetic LXR agonists in
mice elevates triglyceride levels in the liver as well as transiently in the plasma(22,
117). Activation of LXRα is associated with massive liver steatosis and larger VLDL
with a 2.5‐fold increase in their serum levels(189). These effects pose a significant
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obstacle for the development of LXR agonists as human therapeutics. LXRs also
induces several enzymes involved in lipoprotein remodeling, including lipoprotein
lipase, human cholesterol ester transport protein (CETP), and the phospholipid
transfer protein (PLTP)(190).
LXRα‐/‐ mice display marked cholesterol ester accumulation in livers when
challenged with a cholesterol‐rich diet(118). LXR deficient mice are resistant to
obesity when challenged with a high‐fat, high‐cholesterol diet. Remarkably, this
phenotype was dependent on the presence of cholesterol in the diet and was largely
attributed to increased peripheral utilization of dietary fat as manifested by a
marked enhance metabolic rate(190, 191).
1.2.2.3.2.

Long chain PUFAs and nonalcoholic fatty liver disease

(NAFLD)
1.2.2.3.2.1.

Decreased bioavailability of PUFAs in NAFLD

A growing body of evidence has demonstrated the importance of long‐chain
PUFAs (LCPUFAs) in the regulation of energy metabolism(192, 193). Reduced
bioavailability of LCPUFAS have been associated with pathologies of many
metabolic diseases, such as obesity(194), type II diabetes(195) and NAFLD(196,
197). Of particular biological interest are three specific LCPUFAs, arachidonic acid,
an omega‐6 (n‐6) fatty acid and omega‐3 (n‐3) fatty acids eicosapentaenoic acid
(EPA) and DHA(198).
It has been reported that hepatic TAG accumulation resulting from steatosis is
associated with a decrease of EPA in liver(199). Other studies also supported the
notion that NAFLD patients have significant decreases in hepatic levels of n‐3 and n‐
6 LCPUFAs, highlighting the importance of maintaining adequate levels of PUFAs(57,
196, 200, 201).
Araya J. et al. analyzed fatty acid composition of liver and adipose tissue from 11
control subjects and 19 NAFLD patients, within which 10 patients were grouped as
steatosis with the presence of macrovesicular steatosis alone in liver histology, and
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9 patients are grouped as steatohepatitis with steatosis and lobular inflammation
with hepatocyte ballooning in liver histology (184). They reported a depletion in the
level of n‐6 (32% decrease in steatosis patients and 36% decrease in steatohepatitis
patients) and n‐3 (76 and 86% decrease) LCPUFAs in liver total lipids, with
decreased C20:4, n‐6/C18:2, n‐6 and (C20:5, n‐3 + C22:6, n‐3)/18:3, n‐3 ratios,
indicating the impairment in PUFA synthesis. An elevation in MUFA but not SFA was
also observed in NAFLD patients. Consistently, Puri et al reported a decrease in 20:4,
n‐6 in FFA, TAG and PC, C20:5 n‐3 and C22:6 n‐3 in TAG of NAFLD patients(188).
The decrease in levels of PUFAs could be due to several reasons: 1) decrease in
ingestion of essential fatty acid precursors, 2) impaired PUFA biosynthesis and 3)
increased degradation of PUFA.
As discussed in section 4.2, biosynthesis of PUFA depends on the enzyme activity
of desaturases, elongases and peroxisomal β‐oxidation. In obese mice (lep ob/ob)
with NAFLD, the activity of both elongases is not impaired. This suggests that the
elongation continues to occur during NAFLD and that elongases are not responsible
for the inhibition of biosynthesis of LCPUFAs(93).
In addition, hepatic desaturases play an important role in the decline of PUFAs
and progression of NAFLD. Animal studies have demonstrated an increase in
desaturases transcription in mice with type II diabetes and, occasionally, associated
with NAFLD(107, 202, 203). Wang et al have studied the regulation of desaturases
and elongases in different models of metabolic diseases, including diabetes, obesity
and NAFLD(93). Streptozotocin‐induced diabetes (a model of type I diabete)
showed decline in SCD1 mRNA abundance, but does not affect D5D and D6D
expression. Consistently, PUFA levels were not altered in this model. High fat diet
induced obesity and NAFLD model correlates with decreased C20:4, n‐6 synthesis,
but does not affect D5D or D6D expression. In leptin deficiency induced obesity and
NAFLD, PUFA content (C18:2, n‐6, C20:4, n‐6 and C22:6 n‐3) was significantly
decreased; major desaturases (D5D, D6D and D9D) and elongases (ELOVL‐5 and
ELOVL6) expression were significantly elevated. These studies directly
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demonstrated that alterations in liver fatty acid composition due to changed
desaturase and elongase activity greatly contribute to the development of NAFLD.
1.2.2.3.2.2.

Dietary PUFAs supplementation improves

NAFLD
Dietary LCPUFAs can improve NAFLD(57). Delarue et al. have reported that the
ingestion of fish oil rich in n‐3 LCPUFAs (1.1 g of EPA + 0.7 g of DHA daily) for 3
weeks stimulated an increase of almost 35% in fatty acid oxidation(204). Moreover,
Capanni et al. observed significant improvements in hepatic steatosis and
inflammatory parameters in patients treated with EPA plus DHA (1 g, 0.9/1.5
EPA/DHA ratio) daily during 12 months(205). Spadaro el al. also demonstrated that
LCPUFAs (1g capsule twice a day) during a 6‐month period reduced liver fat content
and inflammatory markers and improved IR in NAFLD patients(206).
The possible explanations for the benefits of PUFAs in NAFLD contain both
genomic and non‐genomic mechanisms(207). For non‐genomic mechanisms,
incorporation of LCPUFAs into biological membranes increases membrane
fluidity(198, 208). An adequately fluid membrane affects the activity of
transmembrane enzymes(209, 210) and improves the function of cell surface
receptors and signals transduction(211). Accordingly, LCPUFAs increase the
number of insulin receptors in the cell membrane in a fluidity dependent
manner(212), and enhance the translocation of glucose transporter type 4 (GLUT4)
to the cell surface(213‐215).
Through genomic mechanisms, PUFAs function as feed‐forward activators of
fatty acid oxidation through PPARα and feedback inhibitors of DNL through SREBP‐
1c and ChREBP. This regulatory pattern not only reduces overall hepatic lipid
content and VLDL secretion by inhibiting lipogenic genes, but also eliminates
excessive very long chain PUFA that may cause oxidative stress or impair membrane
integrity by enhancing their oxidation.
The PUFA mediated suppression of SREBP‐1c occurs at three different levels
(Figure 1.2‐6)(79‐82). First, PUFAs decrease the transcription of SREBP‐1c by
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antagonizing ligand‐dependent activation of the LXR, a positive regulator of SREBP‐
1 gene(216); second, LCPUFAs reduce the transcriptionally active nuclear form of
SREBP‐1c by preventing proteolytic processing; third, LCPUFAs reduce SREBP‐1c
mRNA stability. Similarly, LCPUFAs inhibit ChREBP by promoting ChREBP mRNA
decay and decreasing the nuclear active form of ChREBP(217). Known as potent
endogenous ligands for PPARα, LCPUFAs directly bind and activate PPARα, leading
to increased rate of hepatic β‐oxidation of fatty acids(218).

Figure 1.2‐6. (n‐3) PUFA suppress nSREBP‐1c by different mechanisms (207)
(n‐3) PUFA suppress SREBP‐1c gene transcription and proteolytic processing. It also
enhance mRNA SREBP‐1c decay and nSREBP‐1c degradation in the proteasome. A
decline in nSREBP‐1c results in reduced DNL, fatty acid desaturation and elongation,
and elevated expression of MTP and PEPCK.
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1.2.3. Lipid storage in adipose tissue
TAGs stored in fat cells come from two major routes: lipids synthesized in the
liver by DNL and delivered by VLDL and dietary lipids absorbed by small intestine
and delivered by chylomicrons (CM) through lymph prior to entering the systemic
circulation.
When VLDL and CM travel to adipose tissue capillaries, lipoprotein lipase (LPL)
located on luminal face of the capillary endothelium hydrolyzes TAGs and releases
NEFA(3). The NEFA then diffuse through endothelial lining to the adipocytes(3).
NEFA enter cells through fatty acid transporters: fatty acid transport protein
(FATP), CD36 or diffusion. Once inside, NEFA are rapidly converted to fatty acyl CoA
by FATP(219) or fatty acyl CoA synthetases to trap NEFA inside of cells and also
maintain concentration gradient for diffusion(220). NEFA and fatty acyl CoA are
bound to fatty acid binding protein (FABP) and acyl CoA binding protein (ACBP),
proteins that transport fatty acids among intracellular compartments for
metabolism(221) or to the nucleus to interact with transcription factors(222). These
binding proteins and pathways keep intracellular NEFA and fatty acyl CoA very
low(207).
NEFA are highly toxic to cells. Therefore they are esterified to TAGs and
packaged into lipid droplets to protect fat cells from the detrimental effects of NEFA
(Figure 1.2‐7). The lipid droplet is coated with protein such as perilipins to protect
esterified FA from lipases(223).
1.2.4. Lipid mobilization and utilization
1.2.4.1.

Lipid mobilization from adipose tissue

1.2.4.1.1.

Adipose tissue lipolysis

TAGs can be hydrolyzed in a stepwise fashion to diacylglycerol (224) and
monoacylglycerol (MAG) (Figure 1.2‐7). Complete break down of 1 mole of TAG
produces 3 mole of NEFA and 1 mole glycerol.
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Figure 1.2‐7. Synthesis and lipolysis pathway of DAG and TAG
MGL, monoacylglycerol lipase; MOGAT, monoacylglycerol acyltransferase; HSL,
hormone‐sensitive lipase; DGATs, diacylglycerol acyltransferase; ATGL, adipose
triglyceride lipase.

Lipolysis in adipose tissue is through three major lipases: adipose triglyceride
lipase (ATGL), hormone‐sensitive lipase (HSL) and monoacylglycerol lipase (MGL)
(Figure 1.2‐8).

Figure 1.2‐8. Regulation of adipocyte lipolysis
Figure is adapted from (225)
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HSL can hydrolyze both TAG and DAG, however, its activity for DAG is 10‐fold
greater than the activity for TAG in vitro(226‐229). HSL activity is modulated by
cAMP levels, catecholamines and insulin through phosphorylation (Figure 1.2‐ 8 &
9). In the resting (i.e., unstimulated) state, HSL is dispersed in the cytoplasm,
whereas perilipin coats the lipid droplets and binds to 〈/β‐hydrolase domain‐
containing protein 5 (ABHD5 also known as CGI‐58), a key co‐activator of ATGL.
Catecholamines promote cAMP production while natriuretic peptides stimulate
cGMP production. cAMP activates PKA while cGMP activates PKG (cGK‐I), both
leading to phosphorylation of perilipin and HSL. In the activated state, perilipin
phosphorylation induces a physical alteration of the lipid droplet surface, which
facilitates the action of phosphorylated HSL on TAG hydrolysis.
ATGL is another TAG hydrolase discovered in 2004. It was discovered because
lipolysis was not completely abolished in HSL‐deficient mice. ATGL shows 10‐fold
higher affinity for TAG than DAG(230). However, HSL has higher capacity to break
down TAG than ATGL in vitro(231). ABHD5 is the co‐activator of ATGL and essential
for ATGL activity. ABHD5 is tightly bound with perilipin A in the basal state. When
lipolysis is stimulated, perilipin A is phosphorylated by PKA, ABHD5 disassociates
from perilipin A, translocates to the cytosol, and activates ATGL by directly
interacting with ATGL(232‐234) (Figure 1.2‐9). An inhibitor of ATGL, named as G0S2
(G0/G1 switch gene 2), has been recently identified by Liu et al(235). G0S2 is co‐
localized with ATGL in hela cells and inhibits ATGL activity by directly interacting
with the patatin‐like domain of ATGL.
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Figure 1.2‐9. Activation of ATGL and HSL
Figure is from (3). ATGL, adipose triglyceride lipase; ABHD5, α/β‐hydrolase
domain‐containing protein 5; GC, guanylyl cyclase; HSL, hormone‐sensitive lipase;
MGL, monoacylglycerol lipase; NEFA, nonesterified fatty acid; NPR‐A, natriuretic
peptide receptor‐A;

MGL is required for the last step of TAG hydrolysis. MGL hydrolyzes the 1or 2‐
monoacylglycerols with the same specificity, but has no activity on TAG, DAG or
cholesteryl esters hydrolysis(236). Concomitant enhancement of ATGL, HSL and
MGL activities is necessary for full hydrolysis of TAG and release of NEFAs and
glycerol.
1.2.4.1.2.

Regulation of lipolysis

Fasting stimulates lipolysis in adipose tissue to release NEFAs and provide fuel
that can be oxidized to generate energy in other metabolic tissues. The most potent
lipolysis activator is catecholamines. Catecholamines bind with β‐AR (β‐adrenergic
receptors) in adipocytes, which are coupled to the G‐α subunit of the Gs protein. The
activated Gs protein stimulates adenylyl cyclase to produce cAMP, and activate PKA.
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HSL and perilipin are then phosphorylated by PKA to induce lipolysis(237‐239)
(Figure 1.2‐8 & 9).
Conversely, lipolysis is inhibited during the fed state by insulin, the most
important inhibitor of lipolysis. When insulin binds with insulin receptor (IR)
(Figure 1.2‐8), it causes tyrosine phosphorylation of IR, and activates PI3‐K
(phosphatidylinositol kinase‐3)‐ PKB/Akt‐ PDE3B (phosphodiesterase 3B) cascade.
PDE3B can degrade cAMP (cyclic AMP) to 5’AMP, terminate cAMP dependent
activation of PKA. This results in reduced phosphorylation of HSL and perilipins,
and thus decreased lipolysis.
Lipolysis can also be stimulated by inflammatory cytokines secreted from
dysfunctional adipose tissue, including IL‐6 (interleukin 6) and TNFα (tumor
necrosis factor by a paracrine/autocrine mechanism. IL‐6 and TNFα production are
increased in adipocyte from obese patients and may contribute to increase lipolysis
in obesity. IL‐6 stimulates lipolysis in human adipocytes and exerts anti‐insulin
actions(240). TNFα stimulates lipolysis and inhibits insulin‐induced glucose
transport(225, 241, 242). By binding with TNFα receptor 1, TNFα activates MAP
kinases p44/42 and JNK (Jun kinase), which in turn decreases PDE3B, increases
phosphorylation of perilipin and induces lipolysis. TNFα also reduces the effect of
insulin by inactivating IRS‐1 through p42/44(243).
Insulin resistance is closely related to NAFLD(244‐250). Studies have been
conducted to identify which insulin‐resistance tissues are most critical for the
development of this disease. It was logical to assume that insulin resistance in liver
plays a major role in the development of NAFLD since this is a liver disease;
however, liver‐specific insulin receptor knockout (LIRKO) does not cause NAFLD in
mice(251). It has now been clearly shown that insulin resistance in adipose tissue is
the major contributor for development of NAFLD(244, 250, 252). Failure of insulin to
inhibit lipolysis releases excess amounts of NEFA, which overloads the capacity of
liver to handle and eventually leads to lipid accumulation.
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1.2.4.1.3.

Selective mobilization of fatty acids

The hydrophobic NEFA generated by lipolysis must be trafficked from the site of
lipolysis (lipid droplet) to the plasma membrane. This process is mainly mediated
by FABP4 (fatty acid binding protein 4)(253). A variety of saturated and unsaturated
NEFA binds FABP4 at 1:1 ratio with affinities that range from 0.1 to 5.0 µM(254).
FABP4 is associated with phosphorylated, activated hormone‐sensitive lipase (HSL)
on the surface of lipid droplet. The FABP4‐FA‐HSL complex then translocates to
plasma membrane. In FABP4 deficient mice, there is a ~35% reduction in the level
of glycerol released from isoproterenol‐stimulate lipolysis and a nearly 3‐fold
increase in NEFA content of adipocytes compared to wild‐type mice(255).
The selectivity of fatty acids mobilized from adipose tissue has been studied
during fasting in vivo(256, 257) and during stimulated lipolysis in isolated
adipocytes(258, 259). The relative mobilization rate for essential fatty acids
decreased in the following order: C20:5, n‐3>C20:4, n‐6>C18:3, n‐3>C18:2, n‐
6>C22:6, n‐3. Interestingly, C20:5, n‐3 and C20:4, n‐6, which are respectively
precursors of the 3‐ and 2‐series of prostaglandins, were preferentially mobilized.
As a rule, the relative mobilization decreases with increasing chain length for a
given degree of unsaturation and increases with increasing desaturation for a given
chain length.(3)
1.2.4.2.

Lipid oxidation

Most fatty acyl‐CoAs are metabolized through β‐oxidation, which occurs mainly
in mitochondria, but also in peroxisomes. A third of fatty acyl CoAs are metabolized
by ω‐oxidation by cytochrome P450 in microsomes. In higher eukaryotes, including
humans, rats and mice, both mitochondria and peroxisomes are capable of fatty acid
β‐oxidation, whereas in lower eukaryotic organisms, including yeasts and plants,
fatty acid β‐oxidation is confined to peroxisomes(260).
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1.2.4.2.1.

Fatty acid β‐oxidation

Mitochondrial and peroxisomal β‐oxidation share common mechanism
comprised of four steps: dehydrogenation, hydration, dehydrogenation again and
finally thiolytic cleavage. Although similar in mechanism, mitochondrial and
peroxisomal β‐oxidation differ in substrate, function and enzymatic machinery
(Figure 1.2‐10).

Figure 1.2‐10. Comparison of peroxisomal β‐oxidation to mitochondrial β‐
oxidation(261)
NEFAs are transported into the peroxisome via the ABC transporters (ABCD), by
contrast, they enter the mitochondria in a carnitine‐dependent manner catalyzed by
carnitine palmitoyltransferase (CPT). The electrons in the first reaction of
peroxisomal β‐oxidation are transferred by acyl‐CoA oxidases (ACOXs) to molecular
oxygen, whereas in the mitochondria the acyl‐CoA dehydrogenases reduce FAD to
FADH2, which is regenerated in the respiratory chain (RC). The subsequent
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reactions are similar in both compartments; they are catalysed by different enzymes
with distinct substrate specificities.

Short‐chain (<C8), medium‐chain (C8‐12), and long‐chain (C12‐20) fatty acids
are oxidized in mitochondria. In mitochondria, β−oxidation is tightly coupled to the
production of ATP. The resulting NADH and FADH2 and the following oxidation of
acetyl‐CoA in the citric acid cycle, are used for ATP production in the respiratory
chain(262).
Very long chain saturated and polyunsaturated fatty acids (>C20) and branched
chain fatty acids are firstly metabolized in peroxisomes, chain shortened, and then
imported to mitochondria for further oxidation(263). Other peroxisomal
metabolism substrates are: 1) pristanic acid (2,4,6,19‐tetramethylpentadecanoic
acid, which is converted by α‐oxidation; 2) di‐ and trihydroxycholestanoic acid; 3)
long chain dicarboxylic acids; 4) certain LCPUFAs, including C24:6, which undergoes
one cycle of β‐oxidation in peroxisomes to produce C22:6 and 5) prostaglandins and
leukotrienes(264‐266).
The oxidation rate of specific substrates is partially controlled by the rate of
entry into oxidative compartments. The entry of substrates across membranes of
mitochondria and peroxisome is mediated by different mechanisms. Long‐chain
fatty acids enter mitochondria by the CPT cycle. Short‐ and medium‐ chain fatty
acids enter mitochondria directly in their protonated form. Entry of fatty acyl‐CoAs
into peroxisomes is mediated by ABCD transporters (ATP‐binding cassette, D
subfamily) (D1‐D4)(260). In the peroxisomal membrane, two specific acyl‐CoA
synthetases were identified that are responsible for the esterification of fatty
acids(267).
The first reaction in mitochondria β‐oxidation is the dehydrogenation of the
acyl‐CoA ester by a family of four chain length‐specific straight‐chain acyl‐CoA
dehydrogenases. These include very long chain, long chain, medium chain and short
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chain enzymes. The electrons of this reaction are transferred to FAD and are used in
the respiratory chain for ATP production.
In the second reaction, the enzyme enoyl‐CoA hydratase adds water to trans‐
delta2‐enoyl‐CoA. The production 3‐L‐hydroxyacyl‐CoA is then oxidized by
dehydrogenase, which transfer two electrons to NAD+. In the last step, the acyl‐
thioester is hydrolyzed and shortens the chain by two carbon atoms. The resulting
n‐2 fatty acyl‐CoA can be further degraded by another β‐oxidation cycle and the
generated acetyl‐CoA can be metabolized in the citric acid cycle(262).
Similarly, peroxisomal‐oxidation system consists of four steps with each
metabolic reaction carried out by at least two different enzymes. In the first step,
fatty acyl‐CoA is dehydrated to produce trans‐2‐enoyl‐CoA. This reaction is
catalyzed by specific peroxisomal acyl‐CoA oxidase (ACOX) isoforms. In rats and
mice, three acyl‐CoA oxidases isoforms have been identified. In humans, two acyl‐
CoA oxidases have been identified: ACOX1 is specific for the CoA esters of straight‐
chain fatty acids. Whereas ACOX2 can react with both straight‐chain and 2‐methyl
branched‐chain fatty acids, including pristanoyl‐CoA and di‐ and
trihydroxycholestanoyl‐CoA(268). This FAD‐containing oxidase transfers the
generated electrons directly to oxygen, leading to the formation of hydrogen
peroxide (H2O2). Catalase then converts hydrogen peroxide into water and oxygen
to reduce oxidative stress generated in this step. This reaction is unique to
peroxisomes.
The second and third steps: hydration and dehydrogenation of enoyl‐CoA esters
to 3‐ketoacyl‐CoA are catalyzed by a single enzyme, enoyl‐CoA hydratase/L‐3‐
hydroxyacyl‐CoA dehydrogenase (L‐bi/multifunctional enzyme, L‐PBE/MFP1).
In the fourth reaction of β‐oxidation, 3‐ketoacyl‐CoAs are thiolytically cleaved to
yield acetyl‐CoA and n‐2 acyl‐CoAs(269). This reaction is catalyzed by 3‐ketoacyl‐
CoA thiolases. The two human peroxisomal thiolases comprise (1) peroxisomal 3‐
ketoacyl‐CoA thiolases 2, better known as sterol carrier protein X (SCPX), which
catalyzes the thiolytic cleavage of the 3‐ketoacyl‐CoA esters of both straight‐chain
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and branched‐chain FAs, and (2) peroxisomal 3‐ketoacyl‐CoA thiolases 1 (pTH1),
which resembles the clofibrate‐inducible thiolases and is only reactive with the 3‐
ketoacyl‐CoA esters of straight‐chain FAs(270).
The shortened acyl‐CoA reenters the β‐oxidation cycle, and this process repeats
until the appropriately chain‐shortened acyl‐CoAs that can be oxidized in
mitochondria are generated. The products of peroxisomal β‐oxidation are exported
from the peroxisome as carnitine esters and acyl moiety.
1.2.4.2.2.

Anabolic aspects of peroxisomal fatty acid β‐oxidation

As discussed in section 1.2.2.2, peroxisomal β‐oxidation is also involved in
biosynthesis of ether lipids and the last step of 22:6, n‐3 and 22:5, n‐6 synthesis(72).
Tissue 22:6, n‐3 was decreased in peroxisomal disorders that affect β‐oxidation
pathway(271). Human skin fibroblast with deficiency of either straight‐chain ACOX
or MFP1 showed reduction in 22:6, n‐3 synthesis, although it is not completely
abolished(272, 273). The same results were also observed in ACOX‐/‐ mice(274).
These data demonstrated an essential role of peroxisomal β‐oxidation in the
biosynthesis of n‐3 LCPUFAs.
1.2.4.2.3.

Fatty acid β‐oxidation and NAFLD

Impairments in mitochondrial or peroxisomal oxidation pathway would
contribute to the progression of NAFLD. Medium‐chain acyl‐CoA dehydrogenase
deficiency is the most common inherited disorder of mitochondrial fatty acid
oxidation in humans(10). Mice with disrupted medium‐chain and very‐long‐chain
acyl‐CoA dehydrogenase genes showed defects in fatty acid oxidation and developed
micro‐ and macrovascular hepatic steatosis(275).
Essentiality of peroxisomal β‐oxidation was demonstrated by studies of
disorders related to peroxisomal β ‐oxidation. Today, more than 25 proteins are
known to be involved in peroxisomal β ‐oxidation, but only six disorders with a
single protein deficiency have been clearly diagnosed(276). The best characterized,
also the most common peroxisomal β‐oxidation disease, is X‐linked
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adrenoleukodystrophy (X‐ALD). Others include ACOX1, MFP2, AMACR and SCPX
deficiencies. ACOX‐/‐ mice have high levels of very long chain fatty acids (>C22) in
serum, growth retardation, severe hepatic steatosis and steatohepatitis(277).
1.3. Peroxisomes
1.3.1. ABCD transporters
The entry of substrates into peroxisomes is dependent on the D class of
peroxisomal ABC tranporters. ABC transporters constitute one of the largest
families of proteins, with 48 members identified so far in humans(260). ABC
transporters are membrane proteins that can transport variety of substrates
ranging from ions to proteins. Most eukaryotic ABC transporters are full
transporters comprised of two homologous halves. Each half is made up of a
hydrophobic transmembrane domain containing multiple alpha helices and a
hydrophilic nucleotide‐binding fold with Walker A and B consensus motifs. ABC
transporters also exit as half transporters, which only contain a single hydrophobic
and hydrophilic domain and function as homo‐ or heterodimers. All peroxisomal
ABC transporters are half transporters(270).
There are three currently known peroxisomal transporters in mammalian:
ABCD1 (adrenoleukodystrophy protein, ALDP), ABCD2 (adrenoleukodystrophy
related protein ALDRP) and ABCD3 (peroxisomal membrane protein, PMP70). A
fourth half transporter, ABCD4 (70‐kDa peroxisomal membrane protein related
protein, P70R), initially reported as peroxisomal was recently shown to be localized
to the ER(278). The four members of the D‐subfamily share high sequence homology.
D2 shares 66%, D3 shares 60%, and D4 shares 46% of homology of D1(279‐281).
ABCD transporters are half transporters that are only functional as hetero‐or
homodimers. However, it is still controversial whether the different half ABCD
transporters actually form homo‐ or heterodimers. On one hand, in vitro methods
(yeast two‐hybrid and immunoprecipitation experiments) showed that ABCD1 (D1)
could form homodimers as well as heterodimers with PMP70 and D2(282, 283). On
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the other hand, most physiological approaches suggest that D1 and D3 would form
homodimers in vivo(284, 285).
The relative mRNA expression levels of ABCD transporters in tissues are very
different. The expression profile of ABCD mRNA in human and mice tissue was
summarized by Ronald J.A. et al (Table 1.3‐1)(260). D1 mRNA was abundant in the
heart, testis, lung, and intestine, whereas D2 mRNA was enriched in the brain and
skeletal muscle. D3 was most abundant in the liver and kidney, where as D4 was
abundant in the lung and testis.
In addition to mRNA expression, Troffer Charlier et al. also examined the protein
abundance of D1 and D2 in different mouse tissues. This study revealed the mirror
expression pattern of D1 and D2 within the same tissue (Table 1.3‐2)(260, 286).
This study suggested that D1 and D2 might perform similar functions in different
cells. It also provided evidence that D1 and D2 are unlikely to function as a
heterodimer. A similar expression pattern of D1 and D2 was also found in adrenal
gland. In this organ, D1 in mainly expressed in the adrenal cortex whereas D2
expression is found in the medulla(287).
Table 1.3‐1. Comparison of mRNA expression profiles in different mouse and
human tissues
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Table 1.3‐2. Results of immunohistochemical studies in different mouse
tissues

So far, the only known human disease associated with peroxisomal ABCD
transporters is X‐ALD. X‐ALD presents as a severe neurodegenerative disease with
widely varying clinical phenotypes ranging from childhood cerebral ALD to
adrenomyeloneuropathy (AMN) Currently, 1058 mutations of ABCD1 have been
reported, 519 of which are unique (see www.X‐ald.nl)(288). Biochemically, X‐ALD is
characterized by the accumulation of saturated VLCFAs, in plasma and tissues.
Oxidation of the VLCFA C26:0 and C24:0 is impaired in X‐ALD fibroblasts, suggesting
that ABCD1 is involved in the import of VLCFAs into the peroxisome for
degradation(289).
1.3.2. ABCD2
1.3.2.1.

Function of D2

Overexpression of D2 in human X‐ALD fibroblasts and mouse D1‐/‐ cells
increased the oxidation of C24:0 and C26:0 and normalized the VLCFAs levels(287,
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290, 291). This indicates that D1 and D2 are functionally redundant and likely have
overlapping substrate specificities. Overexpression of D2 in vivo compensated for
the loss of D1, prevented VLCFAs accumulation and several neurodegenerative
features in mice, further demonstrating the functional redundancy between D1 and
D2. Therefore, expression of the D2 gene constitutes a potential therapeutic target
for X‐ALD in a strategy aimed at inducing their expression through pharmacological
treatments.
However, D2 has preferred substrates despite overlapping functions with D1. By
modifying D2 expression in hepatoma cells, Genin EC et. al, demonstrated that D2 is
involved in the β‐oxidation of C24:0, C26:0 and C22:6, n‐3 (198, 292). Wanders RJ et.
al, used yesast S. cerevisiae as a model system to study D2 substrate specificity, since
peroxisomes are the only organelles in which β‐oxidation of fatty acids take
place(293). By transforming human D1 and/or D2 cDNA in yeast, which has its own
peroxisomal ABC transporters (Pxa1p and Pxa2p) mutated, they demonstrated that
D2 is largely responsible for facilitating the β‐oxidation of C22:0 and exclusively
responsible for oxidation of unsaturated VLCFAs including C24:6, n‐3 and especially
C22:6, n‐3. In contrast, D1 is responsible for the import of C24:0 and C26:0.
Pujol et al, analyzed the fatty acid profile in tissues from D2‐/‐ mice(101).
Consistent with in vitro studies, they observed impaired β‐oxidation of C24:6, n‐3
and C26:0, and impaired synthesis of C22:6, n‐3 and C22:5, n‐6. In addition to that,
they also observed the accumulation of C20:0, C20:1, n‐9 and C22:1, n‐9 in adrenal
gland and sciatic nerve. C20:0 and C22:1, n‐9 levels in serum were also elevated in
D2‐/‐ mice fasted for 48 hours. Accumulation of C20:0 and C22:0 in liver reaches
statistical significance at 12 months in D2‐/‐ mice. These data indicated that D2 plays
a role in the degradation of long‐chain saturated and n‐9 monounsaturated fatty
acids, as well as degradation and synthesis of DHA.
D2‐/‐ mice exhibit a late onset cerebellar and sensory ataxia, loss of cerebellar
Purkinje cells, and dorsal root ganglia cell degeneration together with oxidative
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damage in adrenal gland(294, 295). To date, human D2 deficiency has not been
reported.
1.3.2.2.

Regulation of D2 expression

Regulation of D2 gene expression in rodents and humans has been intensively
investigated because of the potential therapeutic effect of D2 in X‐ALD. D2
expression is regulated by various transcriptional factors (PPARα, SREBP and LXR),
thyroid hormone, energy status (fasting and refeeding), and nutrients such as
cholesterol and PUFAs. D2 can also be induced by the pro‐drug 4‐phenylbutyrate, a
histone deacetylase (HDAC) inhibitor.
PPARα agonists, such as fenofibrate, can strongly induce ABCD2 mRNA levels in
liver and intestine (but not brain) of rats and mice(296‐299). Another PPARα
agonist: GW7647 can also upregulate D2 expression in mouse liver and adrenals,
but not brain and testis(300). The induction of D2 by fibrates was abolished in
PPARα knockout mice. PPARα is a nuclear receptor that activates transcription of
genes participating in lipid metabolism, including peroxisomal β‐oxidation of fatty
acids. No functional PPRE can be identified in the human or rodent D2 promoter,
suggesting that the effect of PPARα‐agonist on D2 expression might be indirect(296,
298, 300). Since SREBP2 was induced by fenofibrate through PPARα, it was
assumed then that SREBP2 mediated the indirect induction of D2 by
PPARα agonist(300).
Later, by using reporter gene studies, site directed mutagenesis and gel shift
assays, a functional sterol regulatory element (SRE) has been identified in the
human D2 promoter region, thus providing a link between peroxisomes, cholesterol
and fatty acid metabolism(301, 302). Activated SREBP1c directly binds with the SRE
and induces D2 expression(302).
Interestingly, the SRE motif in the promoter region of human D2 overlaps with a
direct repeat (DR4) element by 5 bp, which is capable of binding a retinoid X
receptor a (RXR), thyroid hormone receptor (TR) α and β heterodimer and
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LXRα (Figure 1.3‐1) (302). LXRα is a negative modulator of D2 gene expression. In
cultured cells, ligand‐activated LXRα can directly bind the DR4 element in the
promoter of D2, antagonize the access of SREBP1c to the SRE, and therefore
suppress the SREBP‐1c‐mediated induction of D2.

Figure 1.3‐1. The SRE and DR‐4 motifs of the human ABCD2 promoter
Figure is from (302). An SRE is located at nucleotide position ‐401 to ‐391 with
respect to the translation start site of the human ABCD2 gene. The SRE sequence
overlaps by 5 bp with a direct repeat hexameric sequence of the DR‐4 type (in the
opposite orientation) that serves as binding site for both TRβ/RXRα and
LXRα/RXRα heterodimers.

T3 induces D2 expression in murine D1‐/‐ fibroblasts (but not in primary rat
astrocytes), and in the liver but not in the brain of rats(303, 304). The upregulation
of D2 in response to T3 is TRα dependent and requires intact SRE/DR‐4 motifs(304).
In contrast, unliganded TRβ represses D2 expression without binding with D2
promoter. This effect was relieved by hormone binding, especially in the context of
SREBP‐activated D2 expression.
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mRNA levels of D2 in mouse adipose tissue and liver are sensitive to fasting and
refeeding(302). In white adipose tissue (WAT), response of D2 mRNA to energy
status correlates with SREBP‐1c target genes (Figure 1.3‐2). D2 expression in WAT
was downregulated following a 24 hour fast and restored by refeeding of a high
carbohydrate/low fat diet for 12 hours. Liver D2 mRNA levels exhibit the opposite
pattern in the same experiment. D2 expression in liver was induced during fasting
stage and suppressed during refeeding stage, which is due to the concurrent
activation of LXRα and SREBP‐1c.
A

B

Figure 1.3‐2. ABCD2 mRNA expression in liver and white adipose tissue is
sensitive to fasting‐refeeding.
Fasting‐refeeding of mice reveals that Abcd2 expression in the liver is regulated by
PPARα, whereas Abcd2 mRNA levels in white adipose tissue correlate with
SREBP1c‐stimulated genes. Wild type C57BL/6 mice were fasted for 24 h and then
refed a high carbohydrate/low fat diet for 12 h. Total RNA was isolated from
adipose tissue and liver and Abcd2 mRNA levels were evaluated by (a, b) QRT‐PCR
performed in triplicate wells and normalized to the number of hydroxy‐
phosphoribosyl transferase mRNA copies (results are shown as mean ± S.E. with the
number of treated mice in parentheses and statistically significant differences by
Student's t test are indicated by asterisks (p < 0.05))

D2 expression can be induced under cholesterol deprivation condition in
cultured human and murine monocytes as well as in human primary fibroblasts.
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Cholesterol‐lowering compounds such as lovastatin also induce D2 expression(301).
Dietary cholesterol regulates D2 expression in liver(302). Feeding of a high
cholesterol diet (2% cholesterol) for 1 week results in the activation of LXRα and
SREBP‐1c, but significant suppression of liver D2 expression.
D2 is also regulated by dietary PUFAs. Leclercq S et. al, reported that when rats
are fed with α‐linolenic acid, 18:3, n‐3 deficient diet, D2 expression in liver was
found to be significantly higher than it the rats fed with α‐linolenic acid containing
diet or the DHA supplemented diets(305).

1.4. Erucic acid
C22:1, n‐9, also known as erucic acid, accumulates in the serum and liver of D2‐/‐
mice, indicating that it is a substrate for D2. We therefore used this fatty acid to
explore D2 mediated peroxisomal oxidation of unusual fatty acids. Erucic acid is
naturally enriched in rapeseed and mustard oil. Erucic acid was associated with
transient cardiac lipidosis when fed to rats(306). In isolated liver cells, both the rate
of esterification and mitochondrial oxidation of erucic acid is distinctly slower,
which is calculated to be about 1/3 of the rate of palmitic acid(307‐310). In perfused
heart, erucic acid is esterified as rapidly as palmitic acid, whereas the rate of
mitochondrial oxidation of erucic acid is comparable to its rate in liver(307, 311,
312). In liver and heart, erucic acid is shortened to C18:1, n‐9, and smaller amounts
of C20:1, n‐9 and C16:, n‐9 fatty acids, by peroxisomal β‐oxidation.
In adipocytes isolated from rat epididymal fat, erucic acid can either be
incorporated into triglycerides, diacylglycerol and phospholipids or be
oxidized(313). The rate of esterification of erucic acid in TAG, DAG or phospholipids
occurred at 1/3 of the rate with pamitic acid as substrate. The incorporation in DAG
was 10% and the incorporation in the phospholipids was 1% of the rate of
esterification in TAG. The rate of oxidation of erucic acid to CO2 and acid‐soluble
intermediates was about 1/3 of the rate of palmitic acid. However, no significant
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chain‐shortening of erucic acid to shorter monounsaturated fatty acid was identified
in the isolate adipocytes.
In rats, long term feeding of erucic acid enriched diet (5 month) results in a
significant elevation of liver triglyceride levels(314). However, mice are resistant to
the lipotoxicity of erucic aicd.

1.5. Summary
Peroxisomes are sites of both n‐3 PUFAs synthesis and degradation, therefore,
peroxisomes play an important role in maintaining proper levels of PUFAs in TAG,
CE and phospholipids and regulating energy homeostasis. Among the four members
of ABCD transport, D2 is uniquely regulated by key transcriptional factors that
control lipogenesis, sterol metabolism and β‐oxidation, which allows D2 to serve as
an important regulator of peroxisomal lipid metabolism by importing very‐long‐
chain MUFA and PUFA into peroxisomes. However, the physiological role of D2
remains unclear.

Copyright © Jingjing Liu 2011
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2. Chapter 2: The role of ABCD2 in adipogenesis and metabolism of VLCFA
C22:1
2.1. INTRODUCTION
Peroxisomes play essential roles in the metabolism of both dietary and
endogenously synthesized lipids (315, 316). The synthesis of etherphospholipids
(platelet activating factor and plasmalogens), partial β‐oxidation of very long chain
fatty acids (VLCFA, C>22), and the α‐oxidation of phytanic acid occur within this
organelle. A comprehensive integrative map of peroxisomal metabolic pathways can
be found in http:www.peroxisomedb.org (317). The importance of the organelle is
best exemplified by the occurrence of peroxisome biogenesis disorders and single
enzyme deficiencies that result in severe metabolic diseases which are often lethal
in early childhood. X‐linked Adrenoleukodystrophy (X‐ALD) is the most common
peroxisomal disorder and is characterized by the accumulation of VLCFA in tissues,
progressive demyelination and adrenocortical dysfunction (318). X‐ALD is caused
by mutations in ABCD1 (D1), an ATP binding cassette (ABC) half transporter that
presumably mediates the transport of very long chain acyl‐CoAs into peroxisomes
(319). D1 is the founding member of a quartet of ABC half‐transporters that contain
peroxisomal targeting sequences and form heterodimers in vitro (282). However,
homodimers appear to be preferred in vivo and each subfamily member has a
unique tissue distribution (320, 321).
The closest paralogue to D1 is D2, which shares 66% amino acid identity and is
expressed in the adrenal, brain and liver (322). Expression of a D2 transgene in D1
deficient mice partially corrected the phenotype in this mouse model of X‐ALD
indicating that these two transporters have some degree of overlapping substrate
specificity (323, 324).
In liver, D2 mRNA levels are typically less than 10‐20% of those observed in
brain or adrenal (322, 325). However its expression is induced by fasting, feeding
fibrates and statin treatment, while expression levels in brain remain constant (302,

50

326‐329). More recently, D2 mRNA was shown to be expressed in adipose tissue
where its mRNA levels are highest in the fed state, decline in the fasted state and
return during re‐feeding (302). The promoter of D2 contains a functional sterol
response element that interacts with both SREBP‐1a and ‐1c, suggesting it is a
component of the lipogenic program (302, 330, 331).
Mice deficient in D2 (D2‐/‐) are characterized by late‐onset cerebellar and
sensory ataxia, degeneration of dorsal root ganglia (DRG), and accumulation of
VLCFA in DRG (332). They show evidence of disrupted mitochondrial membranes,
consistent with increased oxidative stress. In addition, the adrenal gland of D2‐/‐
mice shows morphological signs of oxidative stress and has increased expression of
manganese superoxide dismutase (SOD2) (295). Collectively, the data suggest that
D2 opposes the accumulation of VLCFA and oxidative stress in adrenal and brain. A
recent report suggests that D2 may play a role in fatty acid metabolism in adipose
tissue since VLCFA increased in plasma following a 48 hr fast in mice lacking D2 but
not in wild‐type controls (333). However, the role of D2 in adipocytes and adipose
tissue remains unexplored. In the present study we determined the relative
abundance of D2 protein in adipose tissue, its role in adipogeneis and the clearance
of dietary erucic acid in adipose tissue. Our results indicate that D2 expression is
robust in adipose tissue and upregulated during adipogenesis, but is not essential
for adipogenesis or lipid storage in vitro. Conversely, erucic acid accumulated in the
adipose tissue of mice challenged with a diet enriched in this fatty acid in a gene‐
dosage dependent manner, suggesting that the role of D2 in fat is to facilitate the
clearance of this, and presumably other, dietary VLCFA that are generally very low
or absent in adipose tissue but present in significant quantities in the diet.

2.2. MATERIALS AND METHODS
2.2.1. Development of ABCD2 antibody
The cDNA encoding the cytoplasmic domain c‐terminal of the ATP binding
cassette of murine D2 (amino acids 366‐711) was fused to the large T‐antigen of
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tetanus toxin and a six‐histidine tag and cloned into pET28a (+) bacterial expression
vector. Expression in the BL21 strain of E. coli cells was induced by IPTG and the 6‐
His fusion protein isolated under denaturing conditions using NiNTA agarose beads.
The purified peptide was dialyzed against phosphate buffered 4M urea and
quantified. The immunization of rabbits was outsourced to ProSci (Poway, CA).
Antiserum was screened for immunoreactivity to D2 by immunoblotting of the
antigen. Its utility immunoblotting and immunofluroescence applications was
determined in CHO‐K1 cells transfected with plasmid harboring cDNA encoding full
length murine ABCD2 and total membrane preparations from adipose tissue of wild‐
type and D2 deficient mice (Figure 2.4‐1).
2.2.2. Animal husbandry
Mice lacking Abcd2 and their wild‐type littermates maintained on the C57BL/6J
background were examined at 8 weeks of age. Genotyping experiments to
differentiate Abcd2 knockouts from herozygotes and wild types was done as
described(332). Animals were housed in a temperature‐controlled room with 12:12
light:dark cycle (6:00 am to 6:00 pm). All mice were maintained on standard rodent
chow (Harlan Teklad 2014S). The erucic acid enriched diet was made by mixing 50g
(37oC) of erucic acid with 1000g of powdered diet (Tables 2.4‐3 and 2.4‐4; #D1001,
Research Diets, New Brunswick, NJ) in a standard mixer equipped with a wire wisk.
The diet was vacuum packaged after preparation and stored at 4oC to prevent
oxidation.
Body composition of mice was measured using Echo MRI. Following a 4 hr fast
beginning shortly after lights‐on, mice were killed by exsanguination under
ketamine/xylazine anesthesia. Blood was collected from the right ventricle with a 1
cc syringe fitted with a 20ga hypodermic needle. Serum was separated by
centrifugation and stored at ‐20oC until analysis. Tissues were excised, rinsed with
PBS to remove blood and snap frozen in liquid nitrogen. Tissue samples were
stored at ‐80oC until analyzed.
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2.2.3. Blood analysis
Blood glucose levels were measured using a standard glucometer from a drop of
blood obtained by tail‐vein prick following a 4 hr fast beginning at lights‐on. Total
serum cholesterol and triglyceride concentrations were determined by colorimetric‐
enzymatic assays (Wako Chemicals, Richmond, VA.)
2.2.4. Lipid analysis
Total fatty acids in adipose tissue were extracted by chloroform‐BHT (50mg/ml)
and C17:0 was added after extraction as internal standard. The total fatty acids were
methyl esterified with BF3/Methanol (10%, Supelco, Bellefonte, PA) by incubating
the mixture at 60°C for 16 hours. The fatty acid esters were extracted with
chloroform. The BF3 and methanol was removed by 3X water wash and the samples
were ready for GC‐MS analysis. Serum fatty acid was extracted by Folch reagent
after adding C17:0 as an internal standard. The lipids were esterified following the
same procedure as adipose tissue lipid extraction. 1µl of the sample was injected
onto a gas chromatography system (Agilent 6890 GC G2579A system, Palo Alto, CA)
equipped with an OMEGAWAXTM 250 capillary column (Supelco, Bellefonte, PA)
and a FID detector. Agilent 5973 network mass selective detector (Agilent, Palo Alto,
CA) was used to identify target peaks. The GC program was: Injector: 1µl at 10:1
spilit, 250°C; Detector: FID, 260°C; oven: 160°C (5min) to 220°C at 4C/min; Carrier:
helium, 1.2 ml/min.
2.2.5. Cell culture
3T3‐L1 cells were propagated as fibroblasts in sub‐confluent cultures. Two days
post‐confluence, the cells were differentiated into adipocytes using a standard
protocol (1.7 µM insulin, 0.5 µM dexamethasone, 0.5 mM isobutylmethylxanthine,
and 1 µM Rosiglitizone). Mouse embryonic fibroblasts (MEF) were isolated from
Day 13.5 embryos and differentiated exactly as 3T3‐L1 cells at between passage 0
and 3.
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2.2.6. Protein and RNA analysis
Membrane proteins were prepared and analyzed by SDS‐PAGE and immunoblot
analysis as previously described(334). The isolation of total RNA and the
determination of relative transcript abundance by quantitative Real‐Time PCR
(qRT‐PCR) for both tissues and cells was conducted as previously described(334).
2.2.7. Statistical analysis
Data were analyzed by ANOVA. Bonferroni posts tests were employed where
indicated. All statistical analyses were conducted using GraphPad Prism statistical
analysis software.

2.3. RESULTS
Previous reports indicated that D2 mRNA is present in adipose tissue and is
regulated by fasting and re‐feeding in mice; however, the presence and relative
abundance of D2 protein in adipose tissue is unknown (302). In order to determine
the relative abundance of D2 protein in fat with respect to other tissues, we
developed a polyclonal antibody to mouse ABCD2 (Figure 2.4‐1). We then prepared
total membranes from tissue homogenates and compared the relative levels of
immunoreactive D2 by immunoblot analysis (Figure 2.4‐2).
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Figure 2.3‐1 Validation of D2 antibody
(A) Immunofluorescence microscopy and immunoblot analysis of D2 protein in
cultured cells. Cells were transfected with a plasmid containing a cDNA encoding
mouse D2. Cells were processed for indirect immunofluorescence microscopy using
a polyclonal D2 antibody. Inset: lysates from cells transfected with control plasmid
(V) and D2 were analyzed by immunoblotting using a polyclonal antibody directed
against D2. Results from cells infected with adenovirus encoding D2 were
essentially identical. (B) Total membranes were prepared from wild‐type and D2‐/‐
mice and analyzed by immunoblotting with the D2 antibody.
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Figure 2.3‐2 D2 protein expression among different tissues
Relative expression of immunoreactive D2 in selected mouse tissues. Total
membrane proteins were prepared from tissues of male C57Bl6/J mice. Equal
amounts of proteins were pooled from each mouse and analyzed by immunoblotting
using the antibody directed against D2. Specifi city of the immunoreactive D2 bands
was confirmed using tissues from D2‐deficient mice (D2‐/‐) mice. Epi., epididymal;
NSB, nonspecific band.

Total membrane preparations were pooled from four male C57BL6/J mice.
Epididymal fat from a D2 deficient mouse (D2‐/‐) was used as a negative control. The
antibody detected a 75kDa band in brain, skeletal muscle, lung, liver, testis, brown
fat and epididymal fat. With longer exposures, D2 was also detected in adrenal (not
shown). Our antibody also cross‐reacted with a 65 kDa band present in several
tissues that was most prominent in lung, liver, kidney, testis and brown fat. This
band was judged to be non‐specific (251) based on its persistence in blots in each of
these tissues in D2‐/‐ mice (not shown).
The 75 kDa band was most prominent in adipose tissue. In addition, much of the
immunoreactive D2 migrated as a prominent “smear” in our SDS‐PAGE gels ranging
from 120 kDa to greater than 220 kDa, the largest of our molecular weight markers.
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We initially presumed these forms to represent protein aggregates of D2 since a
number of ABC transporters are prone to aggregation upon boiling in SDS. However,
efforts to resolve this material using gentle heating in urea buffer or increasing the
relative amount of SDS and β‐ME to membrane proteins failed to resolve this
protein into a single 75kDa band (Figure 2.4‐3).

Figure 2.3‐3 High molecular weight signal of D2 protein
(A) To increase the SDS/protein ratio, adipose membrane proteins were diluted in a
common volume of Laemmli Buffer (3% SDS final) and 50, 20 and 10 mg of total
protein were loaded on an SDS‐PAGE gel and analyzed by western blotting. (B)
Signal intensities were analyzed by densitometry. The sum intensity of the high
molecular weight (HMW) signal was divided by the total sum intensity of the lane
and expressed as percent. These results indicate that increasing the relative amount
of detergent did not denature the HMW forms to D2 monomers. (C) Many ABC
transporters aggregate upon boiling in SDS. To determine if gentle heating in urea
buffer (37ºC for 60 min) would resolve the HMW forms of D2, we compared this
method with our standard procedure. ABCA1 was used as a positive control for
protein aggregation in boiling SDS. These results indicate that the HMW forms of D2
are unlikely to be protein aggregates.
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Given the prominent signal observed for D2 in adipose tissue, we next
determined the relative abundance of D2 among mouse fat depots by qRT‐PCR and
immunoblotting (Figure 2.4‐4). Whereas the mRNAs for D2 were similar among the
epididymal, inguinal and retroperitoneal fat pads, the expression was low in
mesenteric and brown fat (Figure 2.4‐4A). For comparative purposes, we evaluated
the expression of the related family member, D1. Whereas D1 was similar among
each of the white fat pads, its expression was approximately 4 fold greater in brown
adipose tissue when compared to epididymal fat. It should be noted that the
relative abundance of D1 mRNA among the white fat depots was similar to that of
liver. Conversely, the abundance of D2 mRNA in liver was less than 5% of
epididymal fat (not shown).
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Figure 2.3‐4 Relative expression of D2 mRNA and protein among selected
mouse fat depots
(A) The relative levels of D2 and D1 mRNA among fat pads were measured by qRT‐
PCR and normalized to cyclophilin and epididymal fat using the CT method. (B)
Total membrane proteins were prepared from epididymal (Epi.), inguinal,
retroperitoneal, mesenteric, and brown fat pads and analyzed by immunoblotting.
Epididymal and brown fat pads from D2‐/‐ mice were also analyzed to ensure specifi
city of immunoreactive proteins.

Immunoblotting results were consistent with mRNA data indicating abundant
expression of D2 in epididymal, inguinal and retroperitoneal fat pads and much less
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expression in mesenteric and brown fat (Figure 2.4‐4B). As in Figure 2.4‐2,
visualization of immunoreactive D2 in membrane preparations from mesenteric and
brown adipose tissue resulted in over‐exposure of films for epididymal and other fat
pads.
Although the adipocyte is the predominant cell type present in adipose tissue,
other cell types are also present and could be the source of immunoreactive D2 in
fat. To test the hypothesis that D2 was present in adipocytes within adipose tissue,
we compared the expression between adipocytes and the stromal vascular fraction
that contains a mixture of pre‐adipocytes, fibroblasts, macrophages, endothelial
cells, and others. Following collagenase digestion of adipose tissue, adipocytes were
separated from stromal vascular cells by low‐speed centrifugation. Whole adipose,
adipocytes and stromal vascular cells were evaluated for abundance of D2 by
quantitative PCR and immunoblotting (Figure 2.4‐5). The relative abundance of
adipocyte markers (fatty acid synthase, FAS; acetyl CoA carboxylase, ACC),
macrophages (CD68) and endothelial cells (CD31) were used as controls in this
experiment. Whereas mRNAs for FAS and ACC are enriched in adipocytes, CD68 and
CD31 are enriched in the stromal vascular fraction (Figure 2.4‐5A). D2 and D1 were
enriched in the adipocyte and stromal vascular fractions, respectively. These results
were confirmed by immunoblotting (Figure 2.4‐5B), which show that virtually all of
the immunoreactive D2 was confined to the adipocyte fraction within adipose tissue.
CD36, a protein expressed in adipocytes, macrophages and endothelial cells were
used as a loading control, although it is slightly enriched in adipocytes.
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Figure 2.3‐5 Relative expression of D2 mRNA and protein among adipose
tissue fractions
(A) Adipocytes were separated from stromal vascular (SV) cells by collagenase
digestion and low‐speed centrifugation. The mRNA levels of D2 were measured by
qRT‐PCR as described in methods section. FAS and ACC were used as positive
controls for adipocytes. Macrophage (CD68) and endothelial cells (CD31) were used
as controls for separation of stromal vascular cells from adipocytes. (B) Total
membranes were prepared and analyzed by immunoblotting. CD36 was used as a
control, although it is somewhat enriched in adipocytes.
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Next we determined if D2 was upregulated during adipogenesis. For these
experiments, we utilized murine NIH3T3‐L1 cells (Figure 2.4‐6). Cells were
cultured to confluence (Day 0) and treated with differentiation cocktail beginning
on Day 2 (see methods). Neutral lipids were stained with Oil‐Red O on even days of
the differentiation protocol (Figure 2.4‐6A). Neutral lipid is detectible by Day 4,
accumulates in a linear fashion until Day 8 and remains constant through Day 10
(not shown). The expression of aP2 was used to assess expression of adipocyte
markers (Figure 2.4‐6B). Although not nearly as robust as the upregulation of fatty
acid binding protein 4 (aP2), D2 mRNA increased four‐fold between Day 2 and Day
4 and remained elevated throughout the differentiation protocol. In contrast, the
expression of D1 declined between days 0 and 2 and never returned to pre‐
differentiation levels. We also evaluated immunoreactive levels of D2 in cell lysates
on even days of the differentiation protocol. Similar to other tissues, a non‐specific
band was observed for D2 in NIH3T3‐L1 cells. Immunoreactive D2 was first visible
on Day 4 and accumulated throughout the differentiation protocol. The high
molecular weight forms of D2 were only observed with long exposure in these
immunoblots, indicating that they are either poorly soluble in our lysis buffer or are
far less abundant in 3T3‐L1 adipocytes compared to adipocytes in vivo.
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Figure 2.3‐6 Expression of D2 mRNA and protein during adipogenesis in 3T3‐
L1 cells
(A) 3T3‐L1 cells were differentiated to adipocytes and stained with Oil‐Red O. (B)
D2 mRNA levels were determined on even days of differentiation by qRT‐PCR. Fatty
acid binding protein 4 (aP2) was examined as positive control for differentiation. D1
was examined as negative control. (C) D2 protein expression during differentiation
was analyzed by immunoblotting. Actin was blotted as loading control. Asterisk
denotes the nonspecific band.

Next, we evaluated mice (n=10) deficient in D2 for adipose‐related phenotypes.
Male wild‐type and D2 deficient mice were weaned at 3 weeks of age and
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maintained on standard rodent chow. Mice were evaluated at 8 weeks of age for
differences in body weight, adiposity, blood lipids and glucose, and adipocyte
diameter (Table 2.4‐1). We observed no statistically significant differences due to
genotype in these parameters although there was a tendency for increased adiposity
in D2‐/‐ mice. We also evaluated a smaller cohort of female mice and obtained
similar results (not shown).

Table 2.3‐1 Parameters of wild‐type and D2‐/‐ mice at 8 weeks
Parameter

Wild‐type

D2‐/‐

Body Weight (g)

25.6 ± 0.74

25.9 ± 0.99

Adiposity (%)

4.3 ± 0.62

5.4 ± 0.45

Adipocyte diameter (mM)

44. 1 ± 13.6

48.6 ± 14.5

Fasting Glucose (mg/dl)

109 ± 8

114 ± 9

Total Cholesterol (mg/dl)

110.1 ± 16.7

113.6 ± 7.6

Triglycerides

78.61 ± 20.52

69.43 ± 6.02

GC‐MS analysis of adipose tissue revealed significant differences in the fatty acid
profiles of these mice (Table 2.4‐2). We observed an accumulation of C20 and C22
fatty acids in adipose tissue, but not C24 or C26. These results are largely consistent
with those observed in neural tissues of D2 deficient mice (332) and suggest that
although D2 is a target of SREBP‐1a/c and upregulated during adipogenesis, it is not
essential to adipogenesis or lipid accumulation in mice maintained on standard
rodent chow.
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Table 2.3‐2 Fatty acid profile in adipose tissue of wild‐type and D2‐/‐ mice
Fatty Acid

Wild Type

D2-/-

C16:0

0.1347 ± 0.0196

0.1271 ± 0.0183

C16:1

0.0297 ± 0.0015

0.0226 ± 0.0055

C18:0

0.0192 ± 0.0037

0.0224 ± 0.0023

C18:1

0.1594 ± 0.0255

0.1780 ± 0.0128

C18:2

0.2293 ± 0.0285

0.2329 ± 0.0185

18:3, n-6

0.0034 ± 0.0008

0.0038 ± 0.0010

18:3, n-3

0.0193 ± 0.0026

0.0147 ± 0.0030

C20:0

0.0021 ± 0.0008

0.0033 ± 0.0005 *

C20:1

0.0027 ± 0.0024

0.0118 ± 0.0011 *

C22:1

nd

0.0054 ± 0.0011 *

One potential explanation for this result is that adipose tissue is not the
predominant lipogenic organ in vivo and that the absence of D2 in adipose tissue is
compensated by other mechanisms, perhaps the presence of the related family
member D1, in the liver where the majority of endogenous lipids are synthesized.
To test the hypothesis that D2 expression is critical for adipogenesis in cultured
adipocytes, we isolated Day 13.5 mouse embryonic fibroblasts (MEF) from wild‐
type and D2‐/‐ mice and differentiated them to adipocytes. Total lipid accumulation
was measured by oil‐red‐O staining (Figure 2.4‐7). Consistent with our in vivo
observations, the absence of D2 did not prevent adipogenesis or suppress lipid
accumulation in adipocytes. In fact, there was a significant increase in lipid
accumulation in MEF cells from D2‐/‐ mice compared to cells from wild‐type controls.
These results indicate that although D2 is upregulated during adipogenesis and is
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regulated by SREBP, it is not essential for adipocyte differentiation or lipid
accumulation in vitro or in vivo.
A

B

wild-type

D2-/-

Figure 2.3‐7 Lipid accumulation in wild‐type and D2‐/‐ MEF cells
(A) Mouse embryonic fibroblasts were isolate from wild‐type and D2‐/‐ mice
(Day13.5) and differentiated into adipocytes. Neutral lipids were stained with Oil‐
Red‐O. Stained adipocytes were imaged in bright field. (B) Oil‐Red‐O was extracted
with isopropanol throughout the differentiation protocol and the amount of lipid
accumulation was quantified by absorbance (560 nM). Data were analyzed by two‐
way ANOVA (genotype x time). Main effects of genotype and time were detected (p
< 0.05). Interaction not significant.

These findings suggest that the role of D2 in adipose is not to facilitate bulk lipid
storage, but rather to mediate the clearance of fatty acids not typically found in the
triglyceride storage droplets of adipocytes, but may be present in the diet. To
determine if D2 mediated the clearance of such fatty acids in adipose, we evaluated
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the effect of a diet enriched in erucic acid (C22:1, n‐9; Table 2.4‐3 & 4). Although it
is unlikely that the substrates of D2 are limited to erucic acid, this fatty acid was
selected as a model lipid since it accumulates to the greatest extent in adipose and
neural tissues of mice maintained on standard rodent chow.
Table 2.3‐3 Composition of erucic acid enriched diet
D10001 (AIN‐76‐A)

Erucic Enriched D10001

gm%

kcal%

gm%

kcal%

20.3

20.8

19.3

18.7

Carbohydrate

66

67.7

62

59.7

Fat

5

11.5

9.5

21.6

Protein

Table 2.3‐4 Fatty acid profile of erucic acid enriched diet
Fatty Acid

D10001 (AIN-76-A)

Erucic Enriched D10001

% by label

% by GC

16:0

11.1

4.2

18:0

2.0

0.7

18:1

25.2

12.7

18:2

60.7

22.1

22:1

* nd

55.6
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Wild‐type, heterozygous and D2‐/‐ mice were challenged with a diet containing
50% erucic acid for 4 weeks. The fatty acid profile of serum and adipose tissue was
examined by GC‐MS. Our results indicate that in adipose tissue, the deficiency of D2
has a gene‐dosage dependent effect on the accumulation of erucic acid (Figure 2.4‐
8A). The increase in erucic acid occurred at the expense of 18:1 and 18:2. In D2
deficient mice, the relative abundance of erucic acid among adipose tissue fatty
acids mirrored that of the diet, suggesting that there is neither preferential
metabolism nor storage in the absence of D2.
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Figure 2.3‐8 Fatty acid profile in adipose tissue and serum from wild‐type and
D2‐/‐ fed with an erucic acid enriched diet
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(A) Total lipids were extracted from adipose and analyzed by GC‐MS‐FID. Fatty acid
abundance was normalized to C17 internal standard and expressed
milligram/milligram of white adipose tissue mass (WAT). (B) Fatty acid profi le of
serum from mice maintained on an erucic acid diet and fasted for 24 h. Total serum
lipids were extracted with Folch reagent and prepared for GC‐MS‐FID as described
for adipose tissue. Inset: total free fatty acid in serum following a 24 h fast. Asterisks
denote significant differences from the wild type ( P < 0.05).

Consistent with the observations in adipose tissue, erucic acid accumulated to a
greater extent in serum from D2+/‐ and D2‐/‐ compared to wild‐type (D2+/+) mice
after 24 hours fasting (Figure 2.4‐8B). However, erucic acid was not detected in
serum from mice fasted for 4 hours (not shown). These data suggest that in the
absence of D2, erucic acid is efficiently stored in adipose tissue and is mobilized
from TG stores during fasting. Interestingly, total free fatty acids were greater in
fasted D2 deficient mice compared to wild‐type controls (Figure 2.4‐8B inset). The
significance of this observation awaits further investigation.

2.4. DISCUSSION
The major findings of this study are: 1) expression of ABCD2 protein is much
more abundant in adipose tissue than in other tissues in which it is expressed. 2)
Consistent with previous reports of its regulation by SREBP, it is upregulated during
adipogenesis. 3) Although D2 is a component of the adipogenic program, its
expression is not required for adipogenesis or lipid storage in vitro or in vivo. 4)
Erucic acid accumulates in adipose of D2‐/‐ and D2+/‐, when mice were challenged
with an erucic acid enriched diet suggesting that D2 facilitates metabolism of this
dietary fatty acid in adipose tissue. To the best of our knowledge, this is the first
report that establishes a role for D2 in VLCFA metabolism in non‐neuronal tissues.
In addition, our results suggest a novel role for peroxisomes within adipose tissue in
the clearance of “atypical” dietary lipids.
The majority of lipids stored in adipose tissue triglycerides is comprised of the
fatty acids palmitate, oleate and linoleate (16:0, 18:1 & 18:2, respectively). However,
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dietary lipids can contain many “atypical” fatty acids which may require remodeling
to one of these forms prior to storage. The term “atypical” is used to describe fatty
acids that are not generally stored in triglyceride pools. To the best of our
knowledge, a role for peroxisomal metabolism of dietary fatty acids in adipose
tissue has not been described. However, peroxisomes harbor a unique set of
enzymes that are capable of both α‐ and β‐oxidation of fatty acids, removing double
bonds from unsaturated fatty acids, and metabolizing 2‐hydroxy fatty acids
(reviewed in (335)). Therefore, peroxisomes may play a significant role in this
putative remodeling process by allowing for incomplete oxidation of fatty acyl CoA
esters and the release of chain‐shortened, saturated fatty acids.
Unlike storage, the role of peroxisomal metabolism in the utilization of fatty
acids for energy has been extensively studied. Generally, fatty acyl‐CoA esters are
transported into mitochondria through CPT for complete oxidation to provide
energy. However, acyl‐CoA esters containing atypical fatty acids are not the
substrates for CPT (336). These include VLCFA, branched chain fatty acids, highly
unsaturated fatty acids (HUFA), some polyunsaturated fatty acids, each of which
have been shown to be metabolized in peroxisomes (336‐338).
Peroxisomal oxidation of fatty acids yields acetyl‐CoA and chain‐shortened fatty
acids (C8‐C20). To exit peroxisomes, medium and long chain fatty acids require
esterification to carnitine by one of two peroxisomal acyl‐carnitine transferase
(335). Acyl‐carnitine esters can be transported into mitochondria independently of
carnitine palmitoyltransferases, effectively bypassing the rate‐limiting step in
mitochondrial oxidation of fatty acids (335). Alternatively, removal of the carnitine
moiety allows for re‐activation of fatty acids which can then be elongated and
desaturated to generate the more common species stored in triglycerides.
Consequently, the transport of atypical fatty acyl‐CoAs into adipose tissue
peroxisomes would allow for “remodeling” of dietary fatty acids and facilitate
energy storage. A limitation of the present study is that the fate of dietary erucic
acid in wild‐type mice is not known. While it may have been “remodeled” and
stored in adipose tissue, this has not formally been demonstrated and will require
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additional studies. In addition, the present study cannot exclude a role for D2 in
non‐adipose tissues in this process.
The entry of atypical fatty acyl CoAs into peroxisomes is thought to be
dependent upon the transporters on the peroxisomal membrane, principally ABCD
transporters. Unlike other classes of transport proteins, ABC transporters generally
mediate the transmembrane movement of a variety of substrates. Consequently, D2
may facilitate the metabolism of a number of fatty acyl CoAs. The type and number
of atypical lipids dependent upon D2 for adipose tissue metabolism and the
consequences of allowing atypical lipid accumulation within the adipose triglyceride
storage pool awaits further investigation.

Copyright © Jingjing Liu 2011
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3. Chapter 3: The role of D2 in opposing dietary C22:1 induced metabolic
diseases
3.1. INTRODUCTION
Peroxisomes are essential organelles that play critical roles in lipid metabolism,
biosynthesis of ether phospholipids and bile acids and detoxification of hydrogen
peroxide. Peroxisomes contain enzymatic machinery for β‐oxidation of VLCFAs and
branched chain fatty acids. However, peroxisomal β‐oxidation is incomplete and
produces C16~C18 acyl‐CoA, which are then shuttled into mitochondria for further
oxidation or ER for de novo lipid synthesis. Peroxisomal β‐oxidation is also involved
in the last step of polyunsaturated fatty acids (PUFA) synthesis such as
docosapentaenoic acid (4,7,10,14,16‐C22:5, n‐6) and docosahexaenoic acid (DHA,
4,7,10,13,16,19‐C22:6, n‐3). Due to the limited types of desaturase that exist in
mammals (delta 5, 6 and 9 desaturase), biosynthesis of C22:5 and C22:6 begins with
the essential fatty acids linoleate (9,12‐C18:2) and linolenate (9,12,15‐C18:3).
Linoleate and linolenate undergo a series of elongation and desaturation steps in
the ER to generate 6,9,12,15,18,21‐C24:6 (n‐3) and 6,9,12,15,18‐C24:5 (n‐6)
respectively, but must be transported into peroxisomes and chain shortened to yield
22 carbon HUFAs via β‐oxidation.
The entry of fatty acids into peroxisome is dependent on ABCD transporters.
There are four members in this subfamily: D1 (ALDP), D2 (ALDRP,
adrenoleukodystrophy‐related protein), D3 (PMP70, peroxisomal membrane
protein 70KDa) and D4 (PMP69). ABCD transporters are half transporters that
function as homodimers in vivo. However, when these proteins are overexpressed in
vitro, heterodimers can be formed and are functional. The only known human
disease associated with this class of transporters is X‐linked adrenoleukodystrophy
(X‐ALD), a demyelinating disorder of the central nervous system that is caused by
mutations in the D1 gene. X‐ALD patients accumulate very long chain fatty acids
(VLCFA) in plasma, adrenal cortex and the nervous system, presumably due to the
lack transport into peroxisomes. The closet paralog of D1 is D2, which share 66%
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amino acid sequence similarity and some overlapping function. Studies have shown
that the overexpression of D2 is able to compensate for the loss of D1 and correct
VLCFA accumulation in D1‐/‐ mice and X‐ALD fibroblast.
D2 mRNA has been detected in brain, liver, lung, and adipose tissue. mRNA levels
of D2 in liver and adipose tissue respond differently to fasting and refeeding. In
adipose tissue, D2 mRNA level significantly declines during fasting and restores
when mice are refed with a high carbohydrate/low fat diet, which shows the same
regulation pattern as other SREBP‐1c target genes, indicating the possible role of D2
in lipid synthesis and storage in adipose tissue. However, the opposite pattern of D2
mRNA regulation was seen in liver, where expression induced by fasting but
suppressed during refeeding. This pattern resembles the one of PPARα target gene
acyl‐CoA oxidase, which suggests that D2 might play a role in lipid degradation in
the liver in energy depleted states. Moreover, active SREBP‐1c can turn on D2
transcription by binding with SRE in D2 promoter, but LXR can block the binding of
SREBP‐1 with the SRE through a overlapping response element. The significance of
this unique regulation pattern remains unexplored.
It has been previously shown in section 2.4 that D2 protein is most abundant in
white adipose tissue (~50 fold compare to its level in liver). Among different fat
depots, D2 is enriched in epididymal, inguinal and retroperitoneal fat. Unlike other
srebp‐1 target genes, D2 is not essential for lipid storage or adipogenesis in vitro
and in vivo. We have shown that D2 is a major player in the metabolism of very long
chain fatty acids (VLCFA), especially erucic acid (EA, C22:1, n‐9). The absence of D2
leads to accumulation of erucic acid in both differentiated 3T3‐L1 cells in vivo and in
mice fed with an EA enriched diet.
Erucic acid is naturally enriched in rapeseed and mustard seed. It is well
characterized that erucic acid can cause transient triglyceride accumulation
(lipidosis) and dyslipedimia when fed to rats. However, mice are resistant to this
effect. Due to health concerns in humans, EA was virtually eliminated from rapeseed
oil in the development of canola oil. However, EA is used therapeutically as a
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component of lorenzo’s oil for treatment of X‐ALD due to its inhibition of fatty acid
elongation(341).
Our studies use erucic acid as a tool to understand the role of D2 in the clearance
of very long chain fatty acid and its effect on lipotoxicity. We showed that deficiency
of D2 sensitizes mice to the effect of erucic acid. We established a novel protective
role of D2 against the EA induced obesity, dyslipidemia and hepatic steatosis.

3.2. MATERIALS AND METHODS
3.2.1. Animal husbandry
Mice harboring the mutant Abcd2 allele are maintained on the C57BL/6J
background as heterozygotes. Strain refreshing is conducted every five generations
using C57BL6/J females obtained from The Jackson Laboratory (Bar Harbor, ME).
Genotyping experiments to differentiate Abcd2‐deficient (D2‐/‐) from herozygous
and wild‐type (WT) mice was conducted as previously described(332). Animals were
housed in a temperature‐controlled room with 12:12 light:dark cycle (6:00 am to
6:00 pm). All mice were maintained on standard rodent chow (Harlan Teklad
2014S). The erucic acid enriched diet was custom made by by adding 50g/kg of
purified erucic acid to standard rodent chow (#D1001, Research Diets, New
Brunswick, NJ, Tables 2.4‐3 and 2.4‐4). The diet was provided in pelleted form and
stored at 4oC. The diet was provided ad libitum and was replaced twice weekly
Body composition of mice was measured using Echo MRI. Mice were killed by
exsanguination under ketamine/xylazine anesthesia following a 4 hr fast beginning
shortly after lights‐on. Blood was collected from the right ventricle with a 1 cc
syringe fitted with a 20ga hypodermic needle. Serum was separated by
centrifugation and stored at ‐20oC until analysis. Tissues were excised, rinsed with
PBS to remove blood and snap frozen in liquid nitrogen. Tissue samples were stored
at ‐80oC until analyzed.
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3.2.1. Blood analysis
Blood glucose levels were measured using a standard glucometer from a drop of
blood obtained by tail‐vein prick following a 4 hr fast beginning at lights‐on. For
glucose tolerance test, mice were intraperitoneally injected with sterilized 20% glucose
solution (10 µl/ gram of body weight), blood glucose levels were measured prior to and
30, 60, 90 and 120 min time following glucose injection. Total serum cholesterol and
triglyceride concentrations were determined by colorimetric‐enzymatic assays
(Wako Chemicals, Richmond, VA.) Plasma adipokine concentrations were
determined using a mouse adipokine lincoPlex multiplex immunoassay kit, insulin
levels was measured using ELISA.
3.2.2. Tissue histological analysis
Small pieces of liver and epididymal adipose tissue were excised and fixed
overnight in 4% (w/v) paraformaldehyde (PFA) in PBS, pH7.4 and stored in 70%
ethanol at 4°C until further use. Tissue was processed in a dehydrating ethanol
gradient, followed by xylene incubation and paraffin embedding. Paraffin blocks of
tissue were cut into sections of 1‐3 µm thickness. Haematoxylin and eosin (H&E)
stain of tissue sections was performed by COBRE facility.
Small pieces of tissue were directly embedded into a cryo‐preservative solution
(Optimal Cutting Temperature, OCT) in freezing molds and placed on dry ice. The
OCT‐embedded tissue was stored at ‐80°C prior to use. Frozen tissue were cut at
10µm thickness and subjected to Oil‐Red‐O staining.
3.2.3. Lipid analyses
Total lipids from individual mice were extracted by chloroform‐BHT (50mg/ml)
and fractionated into cholesteryl esters, triglycerides, and phospholipids using 500‐
mg silica columns (varian, 1211‐3036) as previous described(110). C17:0 was
added after extraction as internal standard. After methyl esterification with
BF3/Methanol (10%, Supelco, Bellefonte, PA) by incubating the mixture at 60°C for
16 hours (110, 131, 339), the fatty acid methyl esters were extracted by chloroform.
Fatty acid composition was analyzed by GC‐MS as described in section 2.3.4.
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3.2.4. Fatty acid elongation assay
Fatty acid elongase activity was conducted as previously published(110).
Microsomes were prepared from wild‐type and D2‐/‐ mice fed with erucic acid
enriched diet. Microsomal proteins (30 µg) were incubated with a reaction mixture
containing 150 µM [14C] malonyl‐CoA (American Radiolabeled Chemicals, Inc., St.
Louis, MO) and 20 µM of the indicated fatty acids in the presence of 100 µM CoA,
1mM ATP, and 1 mM NADPH at 37°C for 10 min. Fatty acids were extracted from the
reaction mixture and the total incorporation of [14C] malonyl‐CoA to fatty acid
substrates was measured.
3.2.5. Protein and RNA analysis
Proteins were prepared and analyzed by SDS‐PAGE and immunoblot analysis as
previously described (334). The isolation of total RNA and the determination of
relative transcript abundance by quantitative Real‐Time PCR (qRT‐PCR) for both
tissues and cells was conducted as previously described (334).
3.2.6. Statistical analysis
Data were analyzed by ANOVA. Bonferroni posts tests were employed where
indicated. All statistical analyses were conducted using GraphPad Prism statistical
analysis software.
3.3. RESULTS
We previously published that WT and D2‐/‐ mice were indistinguishable with
respect to body weight, adiposity and plasma lipids at 8 weeks of age(340).
Similarly, we observed no discernable differences between genotypes at the
initiation of EA feeding (Figure 3.4‐1a, week 1). Following 8 weeks of a diet enriched
in EA feeding, we observed increased body weight in D2‐/‐ mice as compare to WT
controls. Body composition analysis by MRI indicated a significant increase in fat
mass in D2‐/‐ mice, but not WT controls. Following EA feeding, lean mass was lower
in D2‐/‐ mice compared to WT controls, but due to the lack of an increase in D2‐/‐
mice as opposed to a decline. The accumulation of excess adipose tissue occurred
primarily in epididymal and retroperitoneal depots, with a tendency towards an
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increase in the inguinal fat pad. (Figure 3.4‐1b). The expansion of adipose in the
absence of an increase in lean mass produced a substantial increase in adiposity in
D2‐/‐ mice (Figure 3.4‐1c). H&E staining of adipose tissue revealed that the
expansion of adipose tissue was associated with the enlargement of adipocytes in
D2‐/‐ mice (Figure 3.4‐1d). Analysis of fasting levels of serum lipids showed an
elevation in cholesterol, but no change in triglycerides (Figure 3.4‐2a). Fasting
glucose levels were increased by 75% in D2‐/‐ mice (Figure 3.4‐2b). A glucose
tolerance test revealed a decrease in glucose disposal (Figure 3.4‐2c, d).

Figure 3.3‐1 EA feeding induces obesity in the absence of D2
(A) Body composition was measured by Echo MRI at the beginning and end of study
(n=7). (B) Different fat pads were dissected and weighted at the end of study (n=4).
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(C) Adiposity was calculated by ratio of fat mass/ body weight (n=4). (D) H&E
staining of paraffin embedded epididymal fat. * p < 0.05, **p < 0.01, ***p < 0.001.
Two way ANOVA
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Figure 3.3‐2 Dyslipidemia and glucose intolerance in D2‐/‐ mice fed with EA
diet
(A) Serum was collected at the end of study, total cholesterol (TC) and triglycerides
(TG) level in serum were measured. (B) Fasting glucose levels measured following 8
weeks of EA diet. (C) Glucose tolerance test was performed at week 8. Both real
value and percentage value (D) Area under the curve of GTT were calculated. Data
are shown as mean ± SD (n=7 unless indicated otherwise). * p < 0.05, **p < 0.01,
***p < 0.001, t test
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The expansion of adipose and the loss of glycemic control is generally associated
with inflammation of the adipose tissue. We measured serum levels of
adipocytokines using a LINCOplex panel (Tabel 3.4‐1). Consistent with the
expansion of adipose tissue, leptin levels were elevated in D2‐/‐ mice. However, we
failed to detect any differences in other adipocytokines typically associated with
inflammation including adiponectin, Il‐6 and TNF‐α. We also stained adipose tissue
sections for CD68 and did not observe an accumulation of crown macrophages or
the presence of crown‐like structures (data not shown). These data suggest the
absence of inflammation in D2‐/‐ adipose tissue following EA feeding despite the
increase in adipose mass, adipocyte hypertrophy loss of glycemic control.
Table 3.3‐1 Adipokine and insulin levels mice fed with EA diet
Erucic acid enriched Diet (22% kCal fat)
Wild‐type

D2‐/‐

Leptin (ng/mL)

2.704 ± 1.18

20.236 ± 6.53 *

IL‐6 (pg/mL)

7.998 ± 0.89

10.30 ± 2.31

Resistin (pg/mL)

2991 ± 187

2570 ± 245

TNF‐α (pg/mL)

3104 ± 276

2806 ± 348

PAI‐1(pg/mL)

3104 ± 276

2806 ± 348

Insulin (ng/ml)

0.30 ± 0.06

0.299 ± 0.13

GC‐MS analysis of the fatty acid profile of epididymal adipose tissue showed that
the relative abundance of EA was similar in WT and D2‐/‐ mice and comprised less
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than 7% of the total fatty acids within adipose tissue (Figure 3.4‐3a). The relative
abundance of C18 and C20 monounsaturated fatty acids (MUFA) was lower in D2‐
deficient mice, which was offset by an increase in C14 and C16 saturated fatty acids
(SFA). The reduction in 20:1 and 18:1 in D2‐/‐ mice is consistent with a reduction in
β‐oxidation and shortening of dietary EA prior to storage in adipose tissue TAGs.
However, it should be noted that given the increase in adipose tissue mass, the total
amount of all fatty acids is greater in D2‐/‐ compared to WT mice. On the whole,
there was an increase in SFA and decrease in MUFA in adipose tissue, while the
levels of polyunsaturated fatty acids were unaffected (Figure 3.4‐3b).
To explore potential mechanism for increased adiposity as well as alterations in
the lipid profile in adipose tissue, we analyzed the mRNA levels of several key genes
involved in the regulation of adipose function and lipid and carbohydrate
metabolism. Although the mRNA level of the lipogenic transcription factor, SREBP‐1,
was not altered, several SREBP‐1 target genes were selectively downregulated in
adipose tissue of D2‐/‐ mice fed EA, including ACC1, FAS and SCD‐1 (Figure 3.4‐3c).
In addition, transcription factors that regulate cholesterol, fatty acid and glucose
homeostasis were also downregulated in D2‐/‐ mice (LXR, ChREBP). Consistent with
the development of obesity and insulin resistance, Insig‐1was also significantly
suppressed in D2‐/‐ mice. Consequently, it is difficult to discern if the alterations in
gene expression in adipose tissue of D2‐/‐ mice are causative or secondary to obesity
and impaired insulin signaling.
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Figure 3.3‐3 Adipose tissue lipid profile and gene expression
(A) Lipid was extracted and methyl esterified, then analyzed using GC‐MS for fatty
acids profile. Fatty acid levels were normalized to internal standard C17 and
expressed as percentage of total fatty acids. (B) Lipids are classified by degree of
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saturation. (C) mRNA levels of lipogenic genes in adipose tissue were measured by
qRT‐PCR. Data are shown as mean ± SD (n=7 unless indicated otherwise) . * p < 0.05,
**p < 0.01, ***p < 0.001, t test
The development of obesity is often associated with ectopic accumulation of
lipids. Therefore, we measured total lipids in liver. Indeed, there was an
accumulation of both cholesterol and triglycerides (Figure 3.4‐4a). H&E staining of
liver sections revealed vacuolar structures in liver sections that stained positively
with Oil‐Red‐O in D2‐/‐ mice (Figure 3.4‐4b). Whereas the alteration in the fatty acid
profile in adipose tissue was limited to a few specific fatty acids, the hepatic fatty
acid profile revealed significant differences for many fatty acid species (Figure 3.4‐
4c). There is dramatic shift from wild‐type to D2‐/‐ mice toward more MUFA (C18‐
22) and less PUFA (C18‐22) (Figure 3.4‐4c and inset). Levels of C22:6 and C20:4, as
well as intermediates of PUFA synthesis such as C18:2 and C20:3, were significantly
lower in D2‐/‐ mice. Unlike adipose tissue, the absence of D2 leads to greater
accumulation of C22:1 as well as C20:1 in liver, indicating the important role of D2
the clearance of dietary C22:1. Another significant change is the dramatic increase in
the level of C18:1 in D2‐/‐ mice which constitutes nearly 50% of the total fatty acid
pool in liver as compared to 30% in wild‐type controls
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Figure 3.3‐4 Liver histology and lipid profile
(A) Paraffin embedded liver sections from wild‐type and D2‐/‐ mice were stained
with H&E. Cryo‐sections of liver are stained with Oil‐Red‐O. (B) TC and TG levels in
total hepatic lipid extraction were measured. (C) Fatty acid profile of total hepatic
lipid were measured by GC‐MS. Fatty acid levels were normalized to internal
standard C17 and expressed as percentage of total fatty acids. Data are shown as
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mean ± SD (n=7 unless indicated otherwise). Insert showed the summary of lipid
profile by degree of saturation. * p < 0.05, **p < 0.01, ***p < 0.001, t test

EA is used to treat X‐ALD patient due to its ability to inhibit elongase
activity(341). Moreover, deficiency of elongase, especially ELOVL5, which is
essential for PUFA biosynthesis is associated with hepatic steatosis(110). Therefore,
we hypothesized that the reduction of PUFA synthesis could be due to inhibition of
elongase activity by EA. Assays for measuring elongase activity were conducted. The
results showed that the elongation of PUFA precursors were elevated in D2‐/‐ mice

Malonyl-CoA Incorporation (nmoles)

compare to wild‐type mice (Figure 3.4‐5).

Figure 3.3‐5 Elongase activity in liver microsomes from mice fed with EA diet
Elongase activity is measured as the incorporation of [14C] malonyl‐CoA to fatty acid
substrates. Each bar represents the mean ± SE of the values (n=4 unless indicated
otherwise). * p < 0.05, ***p < 0.001, t test.
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To explore other potential mechanisms for reduced PUFA levels. We measured
expression of genes involved in PUFA and MUFA synthesis in liver. The results
showed significant upregulation of SCD‐1, D6D and SREBP‐1(Figure 3.4‐6a). SCD‐1
is a important desaturase that introduces a double bond at the n‐9 position of C16
and C18 to generate C16:1 and C18:1, respectively. The selective upregulation of
SCD‐1 among other SREBP‐1 target genes reflected the increase in MUFA, in this
case C18:1 in hepatic lipid profile (30% in wild‐type vs 50% in D2‐/‐ mice). The ratio
of C18:1/C18 was a standard method used to estimate SCD‐1 activity. By using this
method, we detected a 123% increase in SCD‐1 activity in D2‐/‐ mice compare to
wild‐type mice. (Figure 3.4‐6b).
It has also been reported that endogenously synthesized C18:1 is the preferred
substrate for acyl‐CoA: cholesterol acyltransferase 1 (SOAT1), which catalyze the
esterification of fatty acid acyl‐CoA and free cholesterol. To understand if the
accumulation of C18:1 in D2‐/‐ mice liver contributed to the increase in hepatic
cholesterol ester, total hepatic lipid extraction was separated into cholesterol ester
(CE), triglycerides (TG), unesterified fatty acid (NEFA) and phospholipid (PL) by
silica column(58). The fatty acid profile of CE but not TG showed significant
elevation of C18:1 and reduction in C18 in D2‐/‐ mice (Figure 3.4‐6c&d). In addition,
free cholesterol detected in unesterified fatty acid fractions from D2‐/‐ mice were
significantly decreased, indicating that more free cholesterol had been actively
esterified to C18:1 cholesterol esters because of the excessive availability of C18:1 in
D2‐/‐ mice liver (Table 3.4‐2). The elevation in MUFA content in total hepatic lipid
extract was only reflected in CE lipid pool, which also suggested that the
accumulation of C18:1 is driving cholesterol esterification in liver.
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Figure 3.3‐6 liver gene expression and lipid profile
(A) mRNA levels of liver lipogenic genes were measured by qRT‐PCR. (B)
Desaturase index calculated by ratio of product/precursor of specific desaturase
(∆9: C16:1/C16:0, ∆9: C18:1/C18:0, ∆6: C18:3/C18:2, ∆5: C20:4/C20:3). (C) Hepatic
lipid isolated from mice was separated into different lipid pools, lipid profile of each
fraction were analyzed using GC‐MS (n=3). Ratio of saturated/ monounsaturated
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fatty acids was calculated for each lipid fraction. (E) Lipid profile of hepatic
cholesterol ester pool. * p < 0.05, **p < 0.01, ***p < 0.001, t test
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Table 3.3‐2 Lipid profile of major hepatic lipid classes

3.4. DISCUSSION
It has been shown in the previous chapter that D2 promotes the clearance of
dietary EA after short term feeding the EA enriched diet (4 weeks). In this chapter,
our studies demonstrated that D2 protects mice from EA induced metabolic
syndrome following long term feeding.
EA causes transient lipidosis and dilated cardiomyopathy in mice and other
species. EA is also associated with an elevation in liver triglycerides after long term
feeding of rats(306). However, mice are resistant to the deleterious effects of EA. In
the absence of D2, the phenotype is revealed in mice and is no longer transient. This
suggests that mice have sufficient D2 present at all times or can upregulate D2 very
rapidly to compensate for the presence of dietary EAs. Interestingly, D2 expression
is highly regulated during 3T3‐L1 adipogenesis as described in aim I, whether this
provides mice with protection against EA toxicity is still unknown. Unlike the rat
phenotype, we did not observe evidence of dilated cardiomyopathy. While the
species difference is interesting, it is beyond the scope of these studies.
EA leads to obesity and insulin resistance in the absence of D2. However, the
expanded adipose tissue does not show signs of inflammation, which implies that
the obesity phenotype is not cause of insulin resistance (IR) but secondary.
Although D2 opposes the transient accumulation of EA in adipose tissue, EA
levels in wild‐type and D2‐/‐ adipose tissue reach the same amount after long term
feeding. The level of EA detected in adipose tissue (around 5 %) is much lower than
its level in the diet (50%), suggesting that EA is not a good substrate for
esterification and storage as TAG. Indeed, its rate of esterification to TG is about 1/3
of the rate of palmitic acid in rat liver and epididymal fat (307‐310), (313). Failure of
the proper storing of EA in the form of TAG increases the demand for β‐oxidation in
peroxisomes in order to eliminate its toxic effects. In the absence of D2, import of EA
into peroxisomes for β‐oxidation in liver and adipose tissue is compromised,
therefore exposing liver to more EA. Consistently, EA level is higher in liver of D2‐/‐
mice compare to wild‐type mice. However, the immediate β‐oxidation products of
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EA: C20:1 and C18:1 levels are also higher in D2‐/‐ mice, indicating that there is
compensatory pathway responsible for β‐oxidation of EA in the liver in the absence
of D2. ABCD1 expression in liver is higher than D2. Substrate specificity studies of
D1 and D2 showed that C22 are good substrate for both D1 and D2 facilitated
peroxisomal import (198, 289). Therefore, it is possible that D1 is compensating the
loss of D2 and promoting the oxidation of EA in liver.
In addition, EA disrupted the ratio of MUFA to PUFA in liver of D2 deficient mice.
Low PUFA bioavailability is associated with increased SREBP1 activity and SREBP‐1
dependent gene expression. Indeed, we observed increased SREBP and elevated
expression of some target genes, but not others. However, liver tissues from these
mice are collected during the fasting stage, when SREBP1 pathway is suppressed. So
the results could under‐represent the true gene expression levels. This suggests that
in the absence of D2, EA bypassed the regulatory machinery to detect lipid overload
in liver, resulting in accumulation of C18:1, either from endogenous synthesis or
shortening of EA via ABCD1.
The precise biochemical mechanism by which EA disrupts lipid metabolism
remains unresolved. We hypothesized that it may be related to inhibition of
elongase activity, but in fact, the opposite phenotype was observed. This results
were consistent with other literature, which reports increased elongase activity in
fibroblasts from X‐ALD patients. Further studies are needed to measure the
desaturase activity, which might explain the increased MUFA/MUFA ratio.

Copyright © Jingjing Liu 2011
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4. Chapter 4: Determine the subcellular localization of D2 in adipose tissue
4.1. INTRODUCTION
Peroxisomes are ubiquitous subcellular organelles present in most eukaryotic
cells. General biochemical functions of peroxisomes include β‐oxidation of fatty
acids, biosynthesis of plasmalogens (ether lipids) and bile acids, and the
detoxification of hydrogen peroxide by catalase (315, 316). Peroxisomes, often
described as multipurpose organelles, exhibit significant functional differences not
only between species but between different tissues within single organisms. This
functional diversity is achieved by modulating their protein composition(342).
Peroxisomes are best characterized in liver due to their high abundance and
induction by peroxisome proliferators. In addition to peroxisomal fatty acid β‐
oxidation, liver peroxisomes contain unique enzymatic machinery for bile acid
synthesis. Bile acid intermediates DHCA (dihydroxycholestanoic acid) and THCA
(trihydroxycholestanoic acid) are synthesized from cholesterol and imported into
peroxisomes, where their side chains are shortened by the enzymatic machinery
required for degradation of methyl‐branched fatty acids. Peroxisomal modified bile
acids are subsequent conjugated to taurine or glycine(343). Since conversion of
cholesterol into bile acids is the predominant route for its removal from the human
body, peroxisomes have been regarded as important for maintenance of cholesterol
hemeostasis.
Peroxisomes isolated from different tissues including kidney, intestine, heart,
lung, brain and testis are heterogeneous and contribute to varying pathways in each
tissue. For example, testicular peroxisomes are enriched in leydig cells, proliferate
in response to luteinizing hormone (LH), and are associated with free cholesterol
staining(224, 344). However, the exact physiological role of peroxisomes in testis is
sill unknown. In contrast, peroxisome abundance in sertoli cells are very low.
AB. Novikoff et. al, have reported the presence of microperoxisomes in
differentiating 3T3‐L1 cells(345, 346). These microperoxisomes lack nucleoids, are
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small (ranging from 0.05 to 0.25 µm in length and are ~0.1 µm wide) and may be
contiguous with the ER. These organelles are more numerous in differentiating 3T3‐
L1 cells than in any other cell types studied at that time. These studies imply that
peroxisomes could play important role in lipid synthesis during adipogenesis.
Indeed, up to 40% of glycerolphosphate backbone synthesis for TAG synthesis in
3T3‐L1 cells is thought to occur in the alternative pathway from peroxisomal acyl‐
DHAP (acyl dihydroxyacetone phosphate)(347).
Import of fatty acyl‐CoAs into peroxisomes is dependent on ABC transporters.
All peroxisomal ABC transporters are half‐transporters and belong to D subclass of
the ABC protein family. There are four members in this family: D1 (ALDP,
adrenoleukodystrophy protein), D2 (ALDRP, adrenoleukodystrophy‐related
protein), D3 (PMP70, peroxisomal membrane protein 70KDa) and D4 (PMP69). The
primary structure of D2 contains a peroxisomal targeting signal (PTS) and is
thought to be a peroxisomal membrane protein like D1 and PMP70, whereas D4 has
recently been reassigned to the ER(278). D2 has been reported as peroxisomal
membrane protein in transiently transfected CHO cells in vitro(348). However, the
localization of D2 to peroxisomes has not been formally demonstrated.
Expressions of ABCD transporters among different tissues are also distinct. D1
and D2 mRNA and protein expression levels display a mirror pattern in most mouse
tissues. In adrenal gland, D1 in mainly expressed in the adrenal cortex whereas D2
expression is found in the adrenal medulla(287). In testis, D1 highly expressed in
Sertoli cells, whereas D2 shows highest concentrations in Leydig cells(224). In our
studies, we have demonstrated that within adipose tissue, D1 is enriched in stromal
vascular fraction and D2 is exclusively expressed in adipocytes(340). However,
subclass of peroxisome within cell‐type has not been reported.
D2 mRNA has been detected in brain, liver, lung, and is highly abundant in
adipose tissue. Similar to other SREBP‐1 target genes, D2 mRNA in adipose tissue is
suppressed during fasting and restored when mice are refed with a high
carbohydrate/low fat diet, indicating the possible role of D2 in lipid synthesis and
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storage in adipose tissue. However, peroxisomes are not major component of
adipocytes and the abundance and role of peroxisomes in adipose tissue has never
been carefully characterized. To explore the role of D2 and peroxisome, we
examined the subcellular localization of D2 in adipose tissue of mouse using a
variety of peroxisomal markers with morphological and biochemical approaches.

4.2. MATERIALS AND METHODS
4.2.1. Isolation of peroxisome
A protocol was adapted from published methods for perixsome isolation from
liver(349‐351). Adipose tissue was dissected from mice, placed in ice‐cold SEM
buffer (250 mM sucrose, 1 mM EDTA, 50 mM MOPS, pH7.4) and minced into small
pieces using scissors. The tissue was homogenized using Potter‐Elvehjem
homogenizer for 5 strokes at 500 rev./min at 4°C. The homogenate was centrifuged
at 750 x g, 4°C for 10 min to generate post‐nuclear supernatant (named nuclear
supernatant, NS). The NS fraction was then centrifuged at 8500 xg for 10 min to
generate mitochondria enriched pellet (named heavy mitochondria pellet, HM). The
resulting supernatant (named heavy mitochondria supernatant, HMS) was then
centrifuged at 27,000 xg for 20 min to generate peroxisome enriched pellet (named
light mitochondria pellet, LM). The resulting supernatant (light mitochondria
supernatant, LMS) was centrifuged at 100,000 xg, for 45 min to precipitate all the
membrane proteins. All the pellet fractions generated were resuspended in 1X
protein sample buffer. Protein concentration of each fraction was determined.
4.2.2. Immunofluorescence:
CHO‐K1 cells were transiently transfected with plasmids containing myc‐tagged
D2. Cells are fixed in methanol (‐20°C) for 5 min, blocked in 0.1% BSA in PBS for 1
hour and then incubated with primary antibody in blocking solution overnight at
4°C with gentle rocking. Following wash with PBS, samples incubated with
fluorescent conjugated secondary antibody for 1 hour. After being washed with PBS
for 3 times, the cells are mounted on #1.0 borosilicate coverglass, covered with
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~150 µl of Vectashield mounting medium and imaged under fluorescence
microscope.
4.2.3. Fixation and EM
Biochemically generated fractions (HMP or LMP) from adipose tissue were fixed
in 4% paraformaldehyde and washed 3 times for 5 min with 0.1 M cacodylate buffer.
Samples were dehydrated in a series of graded ethanol (70% to absolute) and
embedded in Epoxy resin. Ultrathin sections were inspected after contrasting with
electron microscope.
4.2.4. Immunoelectron microscopy
Wild‐type and D2‐/‐ mice were anaesthetized by intraperitoneal injection and
perfused via the left ventricle with a mixture of 4% paraformaldehyde, 2%
glutaraldehyde in 0.01M cacodylate buffer (pH7.4). After fixation, adipose tissue
were dissected, cut in slices with razor blades, post‐fixed in 2% glutaraldehyde in
cacodylate buffer (pH7.4) for 45 min, and washed 3 times for 5 min with 0.1 M
cacodylate buffer. Fixed adipose tissue were embedded into LR White resin
(medium grade). LR White‐filled gelatin capsules were polymerized at 50°C for
three days. After preparation of semithin sections blocks, ultrathin sections of 80nm
were cub, collected on 100 mesh nickel grids and therefore coated on the back side
with a 1% formvar film. The grids were dried at 37°C overnight prior to
immunostaining. The sections were incubated with blocking solution (1% BSA in
TBST) for 30 min at room temperature. Incubation with the primary antibodies was
performed on droplets with antibodies (anti‐D2 and anti‐pex19) in 0.5% BSA in
TBST overnight at room temperature. Thereafter the sections were incubated with a
secondary antibodies conjugated with gold particles (12nm particles conjugated
with anti‐rabbit antibody and 6nm particles conjugated wit anti‐mouse antibody)in
0.5% BSA in TBST for 1 hour at room temperature. Negative controls were
processed in parallel. The grids were rinsed on droplets of TBST and subsequently
contrasted with uranyl acetate for 2 min and lead citrate for 45 sec. The sections
were examined using electron microscope.
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4.3. RESULTS
We first examined the subcellular localization of D2 in CHO‐K1 cells transfected
with plasmid harboring a cDNA encoding full length murine ABCD2 engineered with
a COOH terminal myc tag. Cells transfected with G5‐myc containing plasmid were
used as negative control.
CHO‐K1 cells were immunostained with anti‐myc and anti‐pex19 antibodies, and
imaged using fluorescent microscopy. D2‐myc protein showed a punctuate staining
pattern consistent with peroxisomal proteins (Figure 4.4‐1). A similar pattern was
seen in the pex19 signals. However, the D2 signals do not overlap with pex19 signals
in the merged image.
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Figure 4.3‐1 Localization of D2 and Pex19 in transfected CHO‐K1 cells
CHO‐K1 cells are transfected with a plasmid containing a cDNA encoding mouse D2
and myc tag. Cells were processed for indirect immunofluorescence microscopy
using monoclonal myc antibody and polyclonal pex19 antibody.
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Another peroxisomal marker PMP70 was used to confirm our finding. In the
merged image, yellow signals are visible, representing the overlapping of D2 (red
signals) and PMP70 (green signals) (Figure 4.4‐2). Stacks of images were taken
using a confocal microscope. A 3D cut view of stacked images is shown in the boxes
located on the top and right side of main image (Figure 4.4‐3). Red and green signals
are clearly identifiable and do not co‐localize with each other. This suggests that the
yellow signals seen in the 2D images were artifactual. Our studies suggested that
although D2 protein displays classical punctuate pattern of peroxisomes, it does not
co‐localize with pex19 or PMP70 in transfected CHO‐K1 cells.
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Figure 4.3‐2 Localization of D2 and PMP70 in transfected CHO‐K1 cells
CHO‐K1 cells are transfected with a plasmid containing a cDNA encoding mouse D2
and myc tag. Cells were processed for indirect immunofluorescence microscopy
using monoclonal myc antibody and polyclonal PMP70 antibody.

98

!"#$%&'()*+(
!,'(-)**.(

!"#$%&'()*+(
!,'(-)**.(

Figure 4.3‐3 Confocal imaging of D2 and PMP70 in transfected CHO‐K1 cells

99

Images were taken under confocal microscope at apotome mode. Cut view images
were generated using Zeiss AxioVision software.

To confirm the results in vivo, adipose tissue was fractionated using a protocol
adapted from liver that generates a peroxisome enriched fraction that also contains
light mitochondria (LM). A flowchart of the protocol and designation for each
fraction is shown in Figure 4.4‐4. To confirm the successful isolation of peroxisomes,
LM fractions from liver and adipose tissue were fixed and imaged using electron
microscope (Figure 4.4‐5). Hepatic peroxisomes are clearly identifiable as single
membrane organelle with dense matrix. However, peroxisomes found in adipose
tissue (0.2 ~ 0.25 µm in diameter) are smaller compare to the ones found in liver.
This finding is consistent with the microperoxisomes reported in differentiating
3T3‐L1 cells. HM fractions that contain heavy mitochondria as also imaged as
control. In these HM images, the mitochondria are recognizable by their cristae and
outer tripartite membrane. Our results confirmed the enrichment of peroxisomes in
LM fraction in both liver and adipose tissue.
Homogenate

Nuclear Pellet Nuclear Supernatant
(NS)
(NP, 750 x g)

Heavy Mito
(HM, 8500 x g)

Mitochondria Sup
(HMS)

Light Mito
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Light Mito
(LMS)

Light Membranes
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Cytosol
(C)
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Figure 4.3‐4 Flowchart of method used to isolate peroxisomes from adipose
tissue
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Adipose LMP

Adipose HMP

Figure 4.3‐5 EM imaging of mitochondria and peroxisomes isolated from liver
and adipose tissue
HM and LM pellet isolated from liver and adipose tissue of wild‐type mice (n=4)
were fixed using 4% paraformaldehyde and processed for EM imaging.

To determine the subcellular localization of D2 in adipose tissue, 2.3% of each
fraction was loaded on an SDS‐PAGE gel and immunoblotted for D2 (Figure 4.4‐6).
As we expected, D2 is abundant in the LM fraction. To our surprise, other
peroxisomal markers including pex19, D3 (PMP70) and catalase were absent in LM
fraction, but present in the LM supernatant. However, another peroxisomal marker
pex14 was present in the LM fraction, which indicates that D2 resides in a distinct
compartment that does not contain catalase, pex19 or PMP70. However, the LM
fraction contained pex14, suggesting that D2 is in a distinct subclass of peroxisome,
rather than other organelle.
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Figure 4.3‐6 Abundance of D2 and other peroxisomal markers in
biochemically generated fractions from adipose tissue
2.3% of each fraction generated from adipose tissue was loaded onto SDS‐PAGE.
Abundance of D2 and other peroxisomal markers were examined (n=4).

To determine the localization of D2 within adipose tissue, LM fractions were
isolated from adipose tissue of wild‐type and D2‐/‐ mice, immunolabeled with D2
antibody and imaged with an electron microscope. Results demonstrated that D2
protein is specifically associated with organelles that are similar to
microperoxisomes observed in the LM fractions from adipose tissue in figure 4.4‐5
(Figure 4.4‐7). The absence of D2 signals in the LM fraction from D2‐/‐ mice
demonstrated the specificity of D2 antibody used in this experiment.
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WT LMP

D2-/- LMP

Figure 4.3‐7 Immunogold labeling of peroxisomes isolated from wild‐type and
D2‐/‐ adipose tissue
Peroxisomes were isolated from adipose tissue of wild‐type and D2‐/‐ mice (n=4).
The resulting pellet were fixed and immunostained using a D2 antibody. Pellet were
then embedded and imaged under electron microscope.

In addition to biochemically generated fractions, we also examined the
localization of D2 in whole adipose tissue. Adipose tissue was immunostained with
D2 and pex19 antibody and processed for EM imaging (Figure 4.4‐8). Pex19
antibody was labeled with secondary antibody conjugated with 12 nm gold particles
(as indicated by red arrows). D2 antibody was recognized by secondary antibody
conjugated with 6 nm gold particles (as indicated by black arrows). Results clearly
show that D2 dose not co‐localize with pex19 in adipose tissue. However, we could
not use pex14 antibody to confirm the co‐localization of D2 with pex14 because
both antibodies are generated in rabbit.
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Figure 4.3‐8 Locolization of D2 and pex19 in adipose tissue
Mice were perfused with a mixture of 4% paraformaldehyde, 2% glutaraldehyde in
0.01M cacodylate buffer (pH7.4). After fixation, epididymal fat were dissected and
embedded. The embedded samples are cut into ultrathin sections of 80nm and
immunostained with D2 and pex19 antibody.

4.4. DISCUSSION
Our studies demonstrate the subcellular localization of D2 in a compartment
consistent with peroxisomes within adipose tissue. However, D2 resides in a distinct
subclass of peroxisomes that dose not contain classical peroxisomal markers such as
catalase, pex19 or PMP70. Catalase is a peroxisomal matrix protein. The absence of
catalase in LM fraction could not fully exclude the existence of catalase in D2
containing peroxisomes if the integrity of peroxisomes is destroyed in the
preparation and peroxisomal matrix proteins have been released. Therefore, it is
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necessary to determine the abundance of catalase in whole adipose tissue using
Immunoelectron microscopy.
D2 containing peroxisomes in adipose tissue has not been reported previously.
The physiological role of D2 in adipose tissue is still not completely understood.
Peroxisomes are heterogenous organelle that can modulate their protein
composition to meet the specific metabolic needs of particular tissue. To investigate
the role of D2 containing peroxisomes in adipose tissue, protein composition of this
organelle needs to be identified. Peroxisomal isolation methods that allow for
purification of the D2 containing compartment without losing the structural or
functional integrity of the complex will be critical for the purpose of proteomic
analysis. Generally, peroxisomes are purified by combining the classical differential
centrifugation and density gradient centrifugation. These fractions still contain
other contaminating organelles such as mitochondria. By using a specific antibody
against peroxisomal membrane protein D3, Miki Kikuchi et, al. were able to
immunoisolate peroxisomes and perform proteomic analysis(352). We have
adapted this method and successfully immunoisolated D2 containing compartment
in CHO‐K1 cells transfected with D2‐myc plasmid (Figure 2.4‐1c). In future
experiments, D2 containing peroxisomes will be immunoisolated from adipose
tissue and analyzed by proteomics, which will reveal the function of this unique
organelle and D2 in adipose tissue. This experiment may also provide us with
information about how D2 is distinguished from some classic peroxisomal markers
such D3 and targeted to this unique subclass of peroxisomes.
In addition, our data suggest that the peroxisomes found in adipose tissue are
consistent with the microperoxisomes found in differentiating 3T3‐L1 cells.
Interestingly, D2 is also highly upregulated in differentiating 3T3‐L1 cells, indicating
that this novel organelle plays a role in adipogenesis. However, we have
demonstrated in aim I that D2 is not required for either adipocytes differentiation or
lipid storage. The role of this D2 containing compartment needs further
investigation.
Moreover, the function of classic peroxisomes (D3 containing) in adipose tissue
is also a mystery. Therefore, immunoisolation of D3 containing peroxisomes and
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analysis of its protein composition is necessary. These future experiments would
greatly increase our knowledge on peroxisomes in adipose tissue.

Copyright © Jingjing Liu 2011
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5. Chapter 5: General Discussion
The goal of my studies was to determine the role of D2 in adipose tissue with
regards to adipocyte differentiation, lipid accumulation, promoting metabolism of
VLCFA, the subcellular localization of D2 within adipose tissue, and the role of
peroxisome in adipose tissue.
First, we determined the abundance of D2 in adipose tissue. Our studies showed
that the expression of ABCD2 protein is much more abundant in adipose tissue than
in other tissues in which it is expressed. D2 is exclusively enriched in adipocytes
within adipose tissue. This is the first report on the relative high abundance of D2 in
adipose tissue. We also observed a high molecular weight immuno‐reactive form of
D2 in adipose tissue. Although the nature of this D2 protein is still unknown, it is the
major form of D2 in adipose tissue. We also demonstrated that D2 is upregulated
during adipogenesis. Although D2 is a component of the adipogenic program, its
expression is not required for adipogenesis or lipid storage in vitro or in vivo. This
finding is unusual for a SREBP target gene. However, the regulation of D2 by both
LXR and SREBP in an opposite direction represents a novel regulation pattern which
distinguishs D2 from classical lipogenic genes regulated by SREBP.
Next, we studied the effect of D2 on the clearance of the atypical fatty acid C22:1.
The majority of lipids stored in adipose tissue triglycerides is comprised of the fatty
acids palmitate, oleate and linoleate (16:0, 18:1 & 18:2, respectively). However,
dietary lipids can contain many “atypical” fatty acids that may require remodeling to
one of these forms prior to storage. The term “atypical” is used to describe fatty
acids that are not generally stored in triglyceride pools. Peroxisomes harbor a
unique set of enzymes that are capable of β‐oxidation of very long chain,
polyunsaturated and branched chain fatty acids. The entry of atypical fatty acyl CoAs
into peroxisomes is thought to be dependent upon the transporters on the
peroxisomal membrane, principally ABCD transporters. Unlike other classes of
transport proteins, ABC transporters generally mediate the transmembrane
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movement of a variety of substrates. As the most abundant peroxisomal ABC
transporter in adipose tissue, we hypothesized that D2 could facilitate the import of
its substrates such as very long chain fatty acyl‐CoA into peroxisomes for clearance.
Our preliminary data revealed the accumulation of erucic acid in adipose tissue of
D2‐/‐ mice. Therefore we tested erucic acid as a potential substrate of D2. Erucic acid
accumulates in adipose of D2‐/‐ and D2+/‐ when mice were acutely challenged with
an erucic acid enriched diet, suggesting that D2 facilitates metabolism of this dietary
fatty acid in adipose tissue. To the best of our knowledge, this is the first report that
establishes a role for D2 in VLCFA metabolism in non‐neuronal tissues. In addition,
our results suggest a novel role for peroxisomes within adipose tissue in the
clearance of “atypical” dietary lipids. The type and number of atypical lipids
dependent upon D2 for adipose tissue metabolism awaits further investigation.
In the second part of my studies, we examined the consequences of allowing
atypical lipid accumulation within the adipose triglycerides. EA causes transient
lipidosis and dilated cardiomyopathy in rats and other species. EA is also associated
with elevation in liver triglycerides after long term feeding of rat(306). However,
mice are resistant to the deleterious effects of EA. In the absence of D2, mice are
sensitized to the deleterious effects of EA and the phenotypes are no longer
transient.
EA leads to obesity and insulin resistance in the absence of D2. However, the
expanded adipose tissue does not show signs of inflammation, which implies that
the obesity phenotype is not cause of insulin resistance but secondary to expanded
adipose tissue. Although D2 opposes the transient accumulation of EA in adipose
tissue, EA levels in wild‐type and D2‐/‐ adipose tissue reach the same amount after
long term feeding. The level of EA detected in adipose tissue (around 5 %) is much
lower than its level in the diet (50%), suggesting that EA is not a good substrate for
esterification. Fat absorbed from diet is first delivered to adipose tissue by
chylomicrons for storage in TAGs before it reaches liver. If a fatty acid is not a good
substrate for esterification, the fatty acids will not be efficiently packaged into TAGs
and stored in adipose tissue. Indeed, its rate of esterification to TAG is about 1/3 of
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the rate of palmitic acid in rat liver and epididymal fat (307‐310), (313). Failure of
the proper storing of EA in TAGs exposes both adipose tissue and liver to EA and
increases the demand for its clearance through peroxisomal β‐oxidation in order to
eliminate its toxic effects. In the absence of D2, import of EA into peroxisomes for β‐
oxidation is compromised, therefore exposing liver to more EA, which is the major
organ for lipid metabolism. Consistently, EA level is higher in liver of D2‐/‐ mice
compare to wild‐type controls. However, the immediate β‐oxidation products of EA:
C20:1 and C18:1 levels are also higher in D2‐/‐ mice, indicating that there are
compensatory pathway responsible for β‐oxidation of EA in the absence of D2. The
abundance of D1 in liver is higher compare to D2, therefore D1 could be responsible
for the oxidation of EA. So the question remains: what does D2 do with EA in
adipose tissue?
In addition, EA disrupted the ratio of MUFA to PUFA in liver of D2 deficient mice.
Low PUFA bioavailability is associated with increased SREBP1 activity and SREBP‐1
dependent gene expression. Indeed, we observed increased SREBP and elevated
expression of some target genes (SCD1 and D6D), but not others. We also observed
an elevation in C18:1 in liver that is associated with increased C18:1‐cholesterol
esters. Consistent with other reports on C18:1 being a driver of cholesterol
esterification, the increased MUFA contributes to this unique CE enriched hepatic
steatosis phenotype. These results suggested a novel role for peroxisomes in the
maintenance of MUFA/PUFA ratios in liver, which is known to be essential to avoid
steatosis.
Peroxisomes are poorly understood organelle outside of the liver and perhaps
the brain. Previous studies showed the presence of microperoxisomes in 3T3‐L1
cells. However, no study has been conducted to determine the role of
microperoxisomes in adipocyte differentiation. Interestingly, D2 protein is highly
regulated during 3T3‐L1 differentiation, whether D2 is associated with the
microperoxisomes needs further investigation.
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D2 contains a peroxisomal targeting signal (PTS) in its primary structure and is
thought to be a peroxisomal membrane protein like D1 and D3. However, its
localization to peroxisomes has not been formally demonstrated. Since only sparse
information is available on D2 or peroxisomes in the adipose tissue, we have
characterized the subcellular localization of D2 in adipose tissue of mouse using a
variety of peroxisomal markers with morphological, biochemical techniques.
Our studies have clearly demonstrated the subcellular localization of D2 in a
compartment consistent with peroxisomes within adipose tissue. However, D2
resides in a distinct subclass of peroxisomes that dose not contain classical
peroxisomal markers such as catalase, pex19 or PMP70. Our results revealed a novel
subpopulation of D2 containing peroxisomes in adipose tissue has never been
reported before. The physiological role of D2 containing peroxisome in adipose
tissue needs further investigation.
In conclusion, this research demonstrated a novel role of D2 and peroxisomes in
opposing the accumulation of erucic acid and protecting mice from the deleterious
effects associated with this atypical fatty acids. The studies also revealed a novel
subclass of peroxisomes that contains D2, but not classical peroxisomal markers.
Further studies are required to identify the protein composition of this organelle
and provide deeper insight into its role in adipose tissue.

Copyright © Jingjing Liu 2011
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6. Chapter 6: Future Directions
Peroxisomes are heterogenous organelles that can modulate their protein
composition to meet the specific metabolic needs of particular tissue. To investigate
the role of D2 containing peroxisomes in adipose tissue, protein composition of this
organelle needs to be identified. Proper peroxisomal isolation method that allows
purification of this D2 containing compartment without losing the structural or
functional integrity of the complex is critical for the purpose of proteomic analysis.
Generally, peroxisomes are purified by combining the classical differential
centrifugation and density gradient centrifugation. These fractions still contain
other contaminating organelles such as mitochondria. By using a specific antibody
against peroxisomal membrane protein D3, Miki Kikuchi et, al. was able to
immunoisolating peroxisomes and perform proteomic analysis(352). We have
adapted this method and successfully immunoisolated D2 containing compartment
in CHO‐K1 cells transfected with D2‐myc plasmid (Figure 2.4‐1c). In the future
experiment, D2 containing peroxisomes will be immunoisolated from adipose tissue
and analyzed by proteomic, which will provide information for the function of this
unique organelle and D2 in adipose tissue.
Moreover, peroxisomal protein content is distinct within cell‐types. How this
diversity is achieved is poorly understood. How is D2 get separated from other
peroxisomal proteins and incorporated into this distinct subclass of peroxisomes is
still a myth. Understanding the protein targeting of D2, and identify possible novel
regulator for peroxisomal protein targeting by proteomic of D2 containing
peroxisomes will benefit such studies.

Copyright © Jingjing Liu 2011
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7. Appendices
Appendix I: Buffers and solutions
Table 0‐1 Solutions, buffers and medium used in this dissertation

50X TAE Buffer
4X Laemmli Buffer
Lower Tris Buffer
Upper Tris Buffer
10X Running Buffer
10X Transfer Buffer
10X TBS
TBST (Wash Buffer)
Blotting Buffer
Stripping Buffer
Triton Lysis Buffer
Membrane Protein
Buffer
Homogenization
Buffer for Tissue
Fractions (SEM
Buffer)
SDS‐PAGE
Solutions:
10% resolving gel
for 2 SDS‐PAGE gels
4% stacking gel for
2 SDS‐PAGE gels

Solutinos for Biochemistry
121.1g of Tris‐base, 28ml of Glacial acetic acid,
50ml of 0.5M EDTA, adjust pH to 8.0, qs to 500ml
with H2O
120 mM Tris base, 40 mM EDTA, 20% glycerol,
0.025% bromophenol blue, pH 6.8
1.5 M Tris base, 0.4% w/v SDS, pH 8.8
0.5 M Tris base, 0.4% w/v SDS, pH 6.8
250 mM Tris base, 1.92 M Glycine, 1% w/v SDS
250 mM Tris base, 1.92 M Glycine
200 mM Tris‐base, 1.37 M NaCl , pH 7.6
0.2% Tween 20, 1X TBS
5% Carnation dry milk, 0.2% Tween 20, 1X TBS
62.5 mM Tris‐base, 2.0 % SDS, 100 mM β‐
mercaptoethanol, pH 6.7
80 mM NaCl, 50 mM Tris (pH 8.0), 2 mM CaCl2, 1%
Triton, supplemented with 10% Protease
Inhibitors
20 mM Tris‐Cl (pH7.5), 2 mM MgCl2, 0.25 M
sucrose, pH 7.5, qs to 500 ml
250 mM Sucrose, 1 mM EDTA, 50 mM MOPS,
supplemented with 10% Protease Inhibitors,
pH7.4

4.5 ml of lower tris, 4.5 ml of 40% Acyl‐bis, 9 ml of
ddH2O, 180 ml of 10% aps, 20 ml of Temed
1.5 ml of upper tris, 600 µl of 40% Acyl‐bis, 3.9 ml
of ddH2O, 60 µl of 10% APS, 20 µl of Temed
Solutinos for Histology

Fixation Solution
(for Paraffin
Embedding)

4% (w/v) Paraformaldehyde in 1X PBS, pH 7.4
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Fixation Solution
(for Electron
Microscope)

4% depolymerized Paraformaldehyde, 0.1‐2%
Glutaraldehyde in 0.1 M Sorensen's phosphate
buffer (pH 7.4).
4.03 g potassium phosphate (KH2PO4), 18.87 g
sodium phosphate heptahydrate (Na2HPO4 7H2O),
qs to 500ml, pH 7.2

0.2M Sorensen's
phosphate buffer
IF Blocking Solution
(Buffer A)
IF Washing Solution
(Buffer B)
Hematoxyling and
Eosin Staining
Oil Red O Stock
Solution
Oil Red O Working
Solution

1% BSA in 1X PBS
0.1% BSA in 1X PBS
Xylene, 100%, 96%, 80%, 70%, and aqua dest,
10% Mayer's Hematoxyling, 1% Acetic Acid Eosin
0.5% Oil red O stock solution in 100% Isopropanol
0.3% Oil red O stock solution (30 ml stock and 20
ml distilled water)

Solutinos for Molecular Biology
2% agarose gel, 50
ml
Folch/BHT Reagent
2X MTSP/OG
(100ml)
Fatty acid
separation solvents
Cholesteryl Ester
solvent (Solvent I)
Triglycerides
Solvent (Solvent III)
Phospholipid
Solvent (Solvent IV)
Ammonium Acetate
Free Cholesterol
(Solvent II)
Fatty Acid (Solvent
VI)
Column
Acidification
(Solvent V)

1 g of Agarose, 50 ml of 1X TAE, 1 ml of Ethidium
Bromide (10 mg/ml)
Solutinos for Lipid Extraction
Chloroform: Methanol (2:1), BHT (to 100ug/ml)
0.97 g of MES (pH 6.4), 1.75 g of NaCl, 2 ml of Triton
X‐100, 3.51 g of Octylglucopyrannosid, qs to 100 ml
with ddH2O, supplemented with 10% Protease
Inhibitors

Hexane/MTBE (Methyl‐tert‐butyl ether) (200:3)
Hexane/MTBE (96:4)
MTBE/Methanol/Ammonium Acetate (pH 8.6)
(5:8:2)
0.001 M Ammonium Hydroxide/0.001 M Acetic
Acid (2:1)
MTBE/Glacial Acetic Acid (500:1)
Hexane/MTBE/Acetic Acid (100:2:0.2)
Hexane/Acetic Acid (100:0.2)
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Solutinos for Cell Culture
3T3 Cell Culture
medium
3T3 medium (1 L)
3T3 Adipocyte
medium (1 L)
Initiation medium
Progression
medium
CHO‐K1 medium

13.4 g of D‐MEM powder, 3.7 g of sodium
bicarbonate, qs to 1 L with ddH2O, pH to 7.3. Filter
to sterilize. Supplement with 10% NCS and 1% P/S
13.4 g of D‐MEM powder, 3.7 g of sodium
bicarbonate, qs to 1 L with ddH2O, pH to 7.3. Filter
to sterilize. Supplement with 10% FBS and 1% P/S
3T3 Adipocyte Medium supplement with 100 nM
Insulin, 500 μM IBMX, 250 nM Dexamethasone, 1
μM Rosiglitizone
3T3 Adipocyte Medium supplement with 1 µg/mL
Insulin
13.4 g of D‐MEM/F12 powder, 3.7 g of sodium
bicarbonate, qs to 1 L with ddH2O, pH to 7.3. Filter
to sterilize. Supplement with 10% FBS and 1% P/S

Appendix II: Reagents
Table 0‐1 Primary antibodies used in this dissertation
Host

Primary Antibodies

Dilution

Rabbit

ABCA1

WB 1:1000

Rabbit

ABCD2

WB 1:1000

Goat

AP2/ FABP4

WB 1:250

Mouse

β‐actin

WB 1:1000

Rabbit

Calnexin

WB 1:5000
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Supplier
Gift from Dr.
Mason Freeman
(Harvard Medical
School, Boston,
MA, USA)
Made in our lab
Abcam Inc.,
Cambridge, MA
02139, USA Cat.
No: ab23693
Sigma, St Louis,
MO 63103, USA
Cat. No: A1978
Stressgen,
Victoria, BC
Canada Cat. No:
SPA‐860

Rabbit

Catalas

WB 1:5000

Rat

CD36

WB 1:500

Mouse

MTCO1

WB 1: 18000

Rabbit

myc (polyclonal)

WB 1:500

Rabbit

Pex 14

WB 1:500

Chicken

Pex 19

WB 1:500 IF
1:600

Rabbit

WB 1:500 IF
1:600

PMP 70

Abcam Inc.,
Cambridge, MA
02139, USA Cat.
No: ab1877
Gift from Dr.
Nancy Webb,
Nutritional
Sciences,
Lexington, KY, USA
Abcam Inc.,
Cambridge, MA
02139, USA Cat.
No: ab14705
Upstate, Lake
Placid, NY 12946,
USA Cat. No: 06‐
549
Gift from Dr.
Myriam Baes
Abcam Inc.,
Cambridge, MA
02139, USA Cat.
No: ab14065
Abcam Inc.,
Cambridge, MA
02139, USA Cat.
No: ab3421

Table 0‐2 Primers sequence for gene expression RT‐PCR
Abrevia
tion
ABCD1

ABCD2

ACC1

Also
Gene Name known
as
ATP‐binding
cassette,
sub‐family D

ALDP

Accession
Numb.

Forward/reverse primers
For
CATCGACCCTCCCTATGGAAGTAC
NM_007435.1
Rev
CGCTGCTTCTCTTCAGTCAGGC

ATP‐binding
cassette,
NM_011994.2
For TTACACCAGCGGGCGAAGTG
ALDR;
sub‐family D
ALDL1
(ALD),
member 2
Rev GGCCACAGCCCGCTTAAGAT
acetyl‐coa
For
Acaca NM_133360.2
carboxylase
TGGACAGACTGATCGCAGAGAAA
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AP2

fatty acid
binding
protein 4,
adipocyte

carbohydrat
ChREB
e response
element
P
binding
protein
delta‐5 fatty
D5D
acid
desaturase
delta‐6 fatty
D6D
acid
desaturase
elongation
of long
ELOVL2
chain fatty
acids 2
elongation
of long
ELOVL4
chain fatty
acids 4
ELOVL5

elongation
of long
chain fatty
acids 5

ELOVL6

elongation
of long
chain fatty
acids 6

FAS

fatty acid
synthase

GAPDH

glyceraldeh
yde‐3‐
phosphate
dehydrogen
ase

G
Rev TGGAGAGCCCCACACACA
For
CACCATCCGGTCAGAGAGTACTT
FABP4 NM_024406.1 Rev
CGGTGATTTCATCGAATTCCA
For CCTTCGCCAACTCAGCACTT
NM_021455.3
Rev TGGCTTGCTCAGGCACAA
NM_146094.1

For CACCCTTTGGATCTTTGGAA

Rev GTGCCCAAAGTCATGCTGTA
For
NM_019699.1 ACCGTGTCATCGGACACTATT
Rev AAGAACTTGCCCACGAAGTC
For
TCAATGCTTTCTTGGACAACATG
NM_019423.1
Rev
GGTAAGAGTCCAGCAGGAACCA
NM_148941.1

For CAATGAGCCGAAGCAGTCAA
Rev TCACGCCGTTCGATGAGATA

For
ATGGACACCTTTTTCTTCATCCT
NM_134255.2 T
Rev
ATGGTAGCGTGGTGGTAGACATG
For
TGTACGCTGCCTTTATCTTTGG
NM_130450.2
Rev GCGGCTTCCGAAGTTCAA
For
GCTGCGGAAACTTCAGGAAAT
NM_007988.3
Rev
AGAGACGTGTCACTCCTGGACTT
For TGTGTCCGTCGTGGATCTGA
XR_035503.1
Rev CCGCTTCACCACCTTCTTGAT
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Insig‐1

insulin
induced
gene 1

LXR‐a

Liver X
receptor
alpha

SCD‐1

SCD‐2

SREBP‐
1

SREBP‐
2

stearoyl‐
Coenzyme A
desaturase
1
stearoyl‐
Coenzyme A
desaturase
2
Sterol
regulatory
element‐
binding
proteins 1
sterol
regulatory
element
binding
factor 2

NM_010570.3

For GCGGGCTGACTCCAAGAAC

Rev GCTATCCGCGGCAATGG
For
TCTGGAGACGTCACGGAGGTA
NM_013839.3
Rev
CCCGGTTGTAACTGAAGTCCTT
For CCGGAGACCCCTTAGATCGA
NM_009127.3 Rev
TAGCCTGTAAAAGATTTCTGCAA
ACC
For
CCACCCAGATGCTAAAATGATG
NM_009128.1
Rev
TTCCGATTTTTGTCCGTTTTACA
For GCCGAGATGTGCGAACT
NM_011480.2

Rev
TTGTTGATGAGCTGGAGCATGT
For GCGTTCTGGAGACCATGGA

NM_033218.1

Rev
ACAAAGTTGCTCTGAAAACAAAT
CA

Appendix III: Protocols
7.1.1. Protein analysis
7.1.1.1.
•
•
•
•
•
•
•
•

Membrane protein preparation

Weigh out tissue (pulverized) 0.2 g for everything except fat (for fat use 0.4
g) into 14 ml Falcon tubes containing 1.2 ml of membrane buffer.
Homogenize approx. 1 min and put on ice (Tekmar SDT‐25 Homogenizer,
probe SDT‐080 EN)
Centrifuge for 10 min., 3500 rpm at 4 °C (~2000 xg)
Remove 1 ml of supernatant. Do not take any of the pellet or fat/junk that
may be on top of supernatant.
Place in centrifuge tube for either 100.2 (1.5 ml) or 120.2 (3ml) rotor.
Centrifuge at 100,000 x g (55000 rpm), 45 min, 4°C.
Decant supernatant. Leave tube upside down to drain for 1 min.
Suspend pellet in 1X sample buffer (100 µl ‐ 250 µl).
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7.1.1.2.
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Wash glass spacers and combs in EtOH, and assemble plates.
Pour resolving gel to 0.5 cm below comb.
Overlay with water saturated isobutanol and allow to polymerize.
Rinse top of gel with distilled H2O. Remove remaining water with filter paper.
Insert comb and pour stacking gel.
Allow to polymerize and submerge in 1X Running Buffer until use.
Heat samples to 95°C for 5 min. and quick spin. While samples are heating,
remove comb and rinse wells with running buffer.
Run at 50 mAmps (constant current)
Transfer to nitrocellulose membrane for western blot
Remove stacking gel and soak in 1X Transfer Buffer for 5 min.
Cut two pieces of filter paper and 1 piece of nitrocellulose membrane for
each gel.
Wet in 1X Transfer Buffer for 5 min.
Build sandwich in cold (4°C) Transfer Buffer, and run at 200 mAmps
(constant current) for 2hrs.
After transfer, trim excess membrane and do not allow nitrocellulose to dry

7.1.1.3.
•
•
•
•
•
•
•
•
•
•

SDS‐PAGE

Western blotting

Block membrane with Blotting Buffer for 30 min at room temp.
Pour off Blotting Buffer and incubate with 1o antibody for 1 hr at room temp.,
or 4°C overnight.
Remove 1o antibody and wash 15 min at room temp. Change Wash Buffer
every 5 min.
Incubate with 2o antibody for 30 min at room temp.
Remove 2o antibody and wash 15 min at room temp. Change Wash Buffer
every 5 min.
Wash with TBS for 5 min.
Develop with ECL reagent
Immediately prior to use combine 3 ml of reagent A with 3 ml reagent B for
each membrane and vortex.
Place membrane in a clean dish, add ECl reagent and incubate for 5 min. at
room temp.
Wrap membrane in food service film and immediately expose to film
(typically 30 s, 60 s, 3 min. and 5 min.; however, some reactions may take
longer to develop).
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7.1.1.4. Immunoprecipitation

•

•
•

•

•

•

•
•

Isolate and weight 5 g of adipose tissue and place it in a chilled beaker
containing 10 ml of ice‐cold SEM buffer (Add protease inhibitors before
experiment)
Decant the medium and finely mince the liver using scissors
Suspend the minced tissue in 20 ml SEM buffer and transfer half of this
suspension of to the glass vessel of the Potter‐Elvehjem homogenizer. (ice
cold)
The motor should be mounted either to a wall, via a G‐clamp to the bench, or
in a floor‐standing cradle. Attachment to a free‐standing retort stand is not
adequate.
Attach the cold pestle to the electric motor and homogenize the adipose
tissue mince using 4 to 5‐up‐ and‐down strokes of the pestle, rotating at
~500 rpm.
Decant the homogenate into a beaker on ice, and after rinsing the
homogenizer with medium and wiping the pestle to remove any connective
tissue that may be adhering, repeat steps 5 and 6 with the other half of the
mince and combine the homogenates.
Centrifuge the homogenate 10 min at 750 xg, 0 to 4 °C, in the low‐speed
centrifuge.
Decant and retain the post nuclear supernatant (PNF)

Prebind protein A‐agrose beads with PI serum
•
•
•

Add 20 µl of protein A–agrose beads to 200 µl of PI (pre‐immu) serum and
incubate for 20 minutes at 4°C
Centrifuge beads 2000 rpm on microfuge for 0.5 min and retain beads
Wash the beads 2 times with 1 ml of SEM buffer and resuspend beads in 1 ml
of SEM buffer

Pre‐clear of PNF
•
•
•

Add beads to PNF and rotate at room temperature for 30 min ( while waiting,
prepare the binding of magnetic beads with D2 antibody)
Centrifuge beads at 2000 rpm for 0.5 min
Transfer supernatant to a new tube.

Pre‐bind magnetic beads with D2 antibody
•

•
•

200 µl of the Magna TM bind beads are washed with 1 ml of SEM buffer for 3
times. Between each wash, perform magnetic separation. Resuspend the
beads in 200 ml of SEM buffer.
The beads are incubated with 5 µl of D2 antibody for 20 min at 4°C
Magnetically separate the beads/antibody complex and wash 3 times with 1
ml SEM buffer and resuspended in 1 ml of SEM buffer.
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Immuno‐isolation of D2 containing compartments
•

•
•

The PNF will be added to the beads/antibody complex and incubated for
overnight at 4°C, agitating the suspension every 10 min to promote
attachment
The beads will be magnetically separated for 10 min
The magnetic pellet as well as the supernatant will be collected and store at ‐
20 °C for later assay.

7.1.2. Cell biology
7.1.2.1.
•
•

•
•
•
•
•

Dissect adipose tissue, minced with fine scissors.
The minced tissue (2.5 g of brown adipose tissue/ liver and 4~5 g of white
adipose tissue) is transferred to 10ml homogenize buffer and homogenized
with two or three strokes in a Potter_Elvehjem glass‐Teflon homogenizer to
prepare homogenate
The homogenate is filtered through gauze, and diluted to a final volume of 20
ml with SEM buffer
The homogenates are centrifuged at 750 xg, 4°C for 10 min to remove
nuclear pellet
Record the volume of post‐nuclear supernatant (PNS). The PNS is centrifuged
at 4°C, 8500 g for 10 min to remove the heavy mitochondria pellet (HMP)
The heavy mitochondria supernatant (HMS) is centrifuged at 27,000 g for 20
min at 4°C, to obtain the light mitochondria pellet (LMP).
Pellets are suspended using 1X protein sample buffer (PSB), supernatants
are diluted using 4X PSB. Equal amount of protein (50 µg) from each fraction
was loaded to SDS‐PAGE to examine the enrichment of interested protein in
different fractions. While equal percentage of each fraction (2%) was loaded
on SDS‐PAGE to examine the distribution of interested protein in each
fraction.

7.1.2.2.
•
•
•
•
•

Mitochondria and peroxisome isolation

Immunofluorescence

Cells are cultured on the coverslips placed in 6‐well plate
After transfection, coverslips are rinsed 2 x with PBS (4°C) quickly
Add 2 ml MeOH (‐20°C) and incubate at –20°C for 10 min
Rinse cells 3 ‐ 5 min in PBS (4°C)
Block in 2 ml PBS contain 1% BSA (Buffer A) for 30 min (4°C)
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•
•
•
•
•
•
•
•
•
•
•
•
•
•

Blot edge of coverslip on a paper towel to remove excess Buffer and place in
a humidified chamber
Quickly add 150 µl of primary antibody diluted in Buffer A
Incubate at room temp for 1 hr
Transfer coverslips to 6‐well plates containing 3 ml of PBS containing 0.1%
BSA (Buffer B)
Rinse 3 ‐ 5 min in 3 ml of Buffer B (RT)
Transfer coverslips to a humidified chamber
Quickly add 150‐200 µl of secondary antibody diluted in Buffer A
Incubate at room temp for 1 hr
Transfer coverslips to 6‐well plates containing 3 ml of Buffer B
Rinse 3 ‐ 5 min in 3 ml of Buffer B (RT)
Rinse 2 x quickly with PBS
Rinse 2 x quickly in water
Blot edge of coverslip on a paper towel and mount on glass slides using 40 µl
(for 24 mm2 coverslips) of mounting medium
Allow mounting medium to set at least 30 min and seal coverslip to slides
with nail polish

7.1.2.3.
•
•
•
•

Biochemically generated fractions (HMP or LMP) from adipose tissue was
fixed in 4% paraformaldehyde for 45 min
After fixation, the pellets were washed 3 times for 10 min with 0.1 M
Sorenson’s buffer
Samples were dehydrated in a series of graded ethanol (70% to absolute)
and embedded in Epoxy resin
Ultrathin sections were inspected after contrasting with electron microscope

7.1.2.4.
•

•
•
•
•

Electron microscope

Immunoelectron microscopy

Wild‐type and D2‐/‐ mice were anaesthetized by intraperitoneal injection and
perfused via the left ventricle with a mixture of 4% paraformaldehyde, 2%
glutaraldehyde in 0.1M Sorenson’s buffer (pH7.4)
Adipose tissue were dissected, cut in slices with razor blades and post‐fixed
in 2% glutaraldehyde in Sorenson’s buffer (pH7.4) for 45 min
Samples were washed 3 times for 10 min with 0.1 M Sorenson’s buffer
Fixed adipose tissue was dehydrated in a graded series of alcohols (50% and
70% ethanol) and embedded into LR White resin (medium grade)
LR White‐filled gelatin capsules were polymerized at 50°C for 24 hours
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•

•
•
•

•
•

•
•
•
•

After preparation of semithin sections blocks, ultrathin sections of 80nm
were cut, collected on 100 mesh nickel grids and therefore coated on the
back side with a 1% formvar film
The grids were dried at 37°C overnight prior to immunostaining
The sections were incubated with blocking solution (1% BSA in 0.1M
phosphate buffer, pH7.4) for 30 min at room temperature
Incubation with the primary antibodies was performed on droplets with
antibodies (anti‐D2 and anti‐pex19) in 1% BSA in 0.1M phosphate buffer, pH
7.4 overnight at 4°C.
Sections were rinsed in 0.1 M phosphate buffer containing 10 mg/ 20 ml of
polyetheylene glycol 3 times and rinsed in phosphate buffer
Sections were then incubated in colloidal gold secondary antibody (12nm
particles conjugated with anti‐rabbit antibody and 6nm particles conjugated
wit anti‐mouse antibody) in 1% BSA in 0.1 M phosphate buffer, pH 7.4 for 1‐2
hours. Negative controls were processed in parallel.
The grids were rinsed on droplets of 0.1 M phosphate buffer containing 10
mg/ 20 ml of polyetheylene glycol 3 times and rinsed in phosphate buffer
Sections were fixed in 1% glutaraldehyde in 0.1 M phosphate buffer for 5 min
Sections were rinsed in 0.1 M phosphate buffer
Sections were subsequently contrasted with uranyl acetate for 2 min and
lead citrate for 45 sec. The sections were examined using electron
microscope.

7.1.3. Molecular biology
7.1.3.1.
•
•
•
•
•
•
•
•
•
•
•

RNA isolation

Weight 40mg tissue and put the tissue into the tube containing 0.8 ml RNA
STAT‐60TM Reagent
Homogenize tissue with homogenizer machine.
Store the homogenate for 5 min at room temperature
Add 160 µl of chloroform to each tube, and Vortex 15 sec
Let the samples stay at room temperature for 2 min
Centrifuge the homogenate at 12,000g (353) for 15 minutes at 4oC
Transfer the aqueous phase (about 455µl) to a new tube
Prepare labeled spin column
Add 245 µl 100% EtOH, pipette immediately to mix
Transfer 750 µl of liquid into spin column, centrifuge for 30 S at 12,000 rpm.
Discard the flow‐through
Add 700 μl Buffer RW1 and centrifuge for 30 S at 12,000 rpm. Discard the
flow‐through
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•
•
•
•
•
•

Add 500 μl Buffer RPE and centrifuge for 30 S at 12,000 rpm. Discard the
flow‐through
Add 500 μl Buffer RPE and centrifuge for 2 min at 12,000 rpm.
Place the RNeasy spin column in a new 2 ml collection tube, and centrifuge at
full speed for 1 min
Place the RNeasy spin column in a new 1.5 ml collection tube (supplied).
Add 40 μl RNase‐free water directly to the spin column membrane.
Centrifuge for 1min at 12,000 rpm to elute the RNA

7.1.3.2.

RT‐PCR

7.1.3.2.1.
•

•

•

Investigator provides 500‐1500 bp of sequence, preferably covering at least
one intron‐exon boundary within the target gene/cDNA or spanning a region
in the 3’‐untranslated sequence.
Primer Express oligonucleotide prediction program is used to determine
possible primer pairs. The primers are designed around a probe that is
noted but not ordered. All parameters have been preset within the software.
Four pairs are chosen for synthesis.
Primers are stored at stock concentration of 100μM and working
concentration of 2.5μM at ‐20°C.
7.1.3.2.2.

•

Primer Design

Reverse Trasncriptation

Isolated RNA is also unstable and must be stored at ‐80°C in RNAse free
water or as a precipitate in 70% ethanol; freeze thaw cycles should be kept to
a minimum. In order to analyze levels of mRNAs in samples, we first convert
(reverse transcribe) them to cDNAs since these are much more stable. The
following is an example using iScript cDNA Synthesis Kit. Once synthesized,
cDNAs should be stored at ‐20°C.

Each RT cocktail:
Component
5x Iscript reaction mix
Iscript reverse transcriptase
Nuclease‐free water
RNA template (200ng to 10000ng total
RNA)
Total volume
Reaction protocol
Step 1: 5 minutes at 25°C
Step 2: 30 minutes at 42°C
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Volume per reaction
4 µl
1 µl
X µl
Y µl
20 µl

Step 3: 5 minutes at 85°C
Step4: Hold at 4°C

7.1.3.2.3.

RT‐PCR reaction

•
•
•

Program the robotic pipettor according to specific experiment plate design
Pipette a 1:10 serial dilution of target gene cDNA in 0.5 ml tubes.
Dissolve primers in Nuclease Free Water (5 mM stock)

•

Determine PCR conditions for each reaction

Components
2x SYBR Green PCR Master Mix
Nuclease‐free water
Forward Primer (100 nM final)
Reverse Primer(100 nM final)
*cDNA template
Total volume
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Volume
(1 Reaction)
10 µl
4.2 µl
0.4 µl
0.4 µl
*5 µl
20 µl

•
•
A
1
2
3
4
5
6
7
8
9
10
11
12
13

Prepare each gene specific Sub‐Master
The table below shows our calculations. Additional volumes are present to
allow for the robotic pipettor to operate properly.
B
Number of samples
cDNAs
replicates
Gene specific Submaster
2X SYBRGreen (354)
Nuclease Free water
Forward primer ( 5µM stock; 100
nM final)
Reverse primer ( 5µM stock; 100
nM final)
Mr Neo Pipettes
cDNA
Gene‐spefic Submaster

•
•
•
•

C

Note

5
3

Total=5*3=15 Rxns

165
69.3

C6=10* 15 Rxns *1.1
C7=4.2* 15 Rxns *1.1

6.6

C8=0.4* 15 Rxns *1.1

6.6

C9=0.4* 15 Rxns *1.1

5

There should be at least
20‐25µl solution left in
each tube after the robot
pipettes.

15

Run the program
After finishing, seal the plate thoroughly to prevent evaporation
Centrifuge for 3 min at 1,200 x g
Program 7900HT, specify the samples, target genes detectors and run rt‐PCR

Reaction protocol
Step 1: 2 minutes at 50°C
Step 2: 10 minutes at 95°C
Step 3: 15 seconds at 95°C followed by 1 minute at 60°C (40 cycles)

7.1.3.2.4.
•
•
•

Results analysis

Calculate ∆Ct: Ct of target gene subtract corresponding points of GAPDH
Calculate slope with dilution point and ΔCt
Choose relative standard curve method if the slope is > 0.1. If the slope is ≤
0.1, choose comparative Ct (ΔΔCt) method.
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7.1.3.3.
•
•

•
•

•
•

•
•

•
•

Transfection

Allow FuGENE HD transfection reagent, DNA, and medium to warm up at
room temperature. Vortex for one second.
Dilute DNA with serum‐free medium to a concentration of 2μg plasmid
DNA/100μl SF medium
Tube I (labeled as Control): 12μg plasmid DNA (β‐Gal) + 600μl of SF
medium
Tube II (labeled as D2): 12μg plasmid DNA (D2) + 600μl of SF medium
Form the transfection complex (FuGENE HD : cDNA = 6 µl : 2 µg)
Pipet the FuGENE HD transfection reagent 30μl directly into the medium
containing the diluted DNA without allowing contact with the walls of the
plastic tubes
Mix and incubate the transfection complex
Vigorously tap the tube or vortex for one to two seconds to mix the contents.
Incubate the transfection reagent:DNA complex for 15 minutes at room
temperature.
Add the transfection complex to cells
Remove the old medium. Add the transfection complex 500μl to the cells in a
drop‐wise manner. Swirl the wells to ensure distribution over the entire
plate surface. Use of a rotating platform shaker for 30 seconds at low speed
to shake.
Incubate the transfected cells for 3 hours and add serum‐containing medium
and return the cells back to incubator.
Incubate the cells for 24 hours before determing the transfection efficiency
7.1.4. Cell culture
7.1.4.1.

•
•
•
•
•

•
•
•

CHO/ HEK culture

Thawing and freezing protocol are the same as described below for 3T3 cell
culture
Cells are ready for passage when they are between 80‐95% confluent. Cells
that are 100% confluent will have lower viability.
Pre‐warm CHO medium to 37oC
Aspirate medium and wash cells with 2 ml Trypsin‐EDTA.
Add 1 ml of Trypsin‐EDTA and incubate at room temperature until cells
dissociate from dish and from one another (1‐3 min). Tap the side of the dish
repeatedly to release cells; verify single cell suspension by microscope.
Bring volume up to 10 ml with culture medium, run cell suspension up and
down 10 ml, pipette 3‐5 times to assure single cell suspension.
Remove a small amount of suspended cells and place in the hemocytometer
Count the number of cells in 1‐4 of the four, 4x4 grids and use the following
formula to determine the cell density:
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Cells/ml =

Total number of cells x 104
# of 4x4 grids counted

•
•

Seed two, 10 cm dishes of cells at 2.5 and 5 x 105 cells/dish in 10 ml of CHO
medium in order to maintain the line.
Seed cells at the desired density for experiments. The table below is only a
guide.
Dish (Volume)

Cells/dish

~D1 Confluence

10 cm (10 ml)

6

1 x 10

50%

60 mm (4 ml)

5 x 105

50%

35 mm (3 ml)

2 x 105

50%

7.1.4.2.

3T3‐L1 and MEF cells differentiation

Thawing:
•
•
•
•
•
•

Pre‐warm 3T3 Medium to 37oC
Remove vial from nitrogen storage tank and thaw rapidly by holding in a
37oC water bath (Do not drop the vial into the bath)
Once the cells have thawed, rinse the vial with 70% ethanol and decant the
cells into a 10 cm dish.
Add 10 ml 3T3 Medium, drop‐wise, over a 1‐2 min period (this improves
viability by allowing the cells to equilibrate to the DMSO free medium).
Culture the cells in a humidified incubator (5% CO2) for 12‐16h.
Aspirate medium and feed 10 ml of 3T3 medium. Do not allow the cells to
reach greater than 90% confluence prior to passage.

Passage: Cells are ready for passage when they are between 70‐90% confluent.
Do not allow the cells to reach confluence. They will not differentiate into
adipocytes with subsequent passage.
•
•
•

•
•
•

Pre‐warm 3T3 Medium to 37oC
Aspirate medium and wash cells with 2 ml Trypsin‐EDTA.
Add 2 ml of Trypsin‐EDTA and incubate at room temperature until cells
dissociate from dish and from one another (1‐3 min). Tap the side of the dish
repeatedly to release cells; verify single cell suspension by microscope.
Bring volume up to 10 ml with culture medium, run cell suspension up and
down 10 ml pipette 3‐5 times to assure single cell suspension.
Remove a small amount of suspended cells and place in the hemocytometer
Count the number of cells in 1‐4 of the four, 4 x 4 grids and use the following
formula to determine the cell density:
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•
•
•

Cells/ml = Total number of cells x 104
# of 4 x 4 grids counted
Seed two, 10 cm dishes of cells at 2.5 and 5 x 105 cells/dish in 10 ml of 3T3
medium in order to maintain the line.

Freezing: Cells should be frozen when they are actively dividing in order to
optimize viability (70‐90% confluence)
•
•
•

•
•
•
•

•
•
•

Pre‐warm 3T3 Medium to 37oC
Aspirate medium and wash cells with 2 ml Trypsin‐EDTA.
Add 2 ml of Trypsin‐EDTA and incubate at room temperature until cells
dissociate from dish and from one another (1‐3 min). Tap the side of the dish
repeatedly to release cells; verify single cell suspension by microscope.
Bring volume up to 10 ml with culture medium, run cell suspension up and
down 10 ml pipette 3‐5 times to assure single cell suspension.
Remove a small amount of suspended cells and count on hemocytometer
Centrifuge cells at 500 x g for 5 min (22oC)
Add 90% of the calculated volume of 3T3 Medium to achieve a final
suspension of 5 x 106 cells/ml and suspend the cells by gently pipetting up
and down 3‐5 times.
Slowly add DMSO, drop‐wise, to a final concentration of 10%.
Aliquot the 1 ml of cells into an appropriately labeled cryo‐vial and place in a
room temperature Mr. Frosty® freezing container that contains isopropanol.
Place in the ‐80oC freezer overnight and transfer into the liquid nitrogen
container the following day. Do not forget to enter the vials into Cell Culture
Database

Differentiation into Adipocytes:
•

•

•

•

Day ‐X
o Trypsinize sub‐confluent cells and count on hemocytometer.
o Centrifuge cells at 500 x g for 5 min (22oC)
o Suspend cells (1 x 104/ml) in 3T3 Medium
o Aliquot 2 ml/well in a 24‐well plate (seed at 2 x 104 in 2 ml 3T3
Medium)
o Allow cells to grow until confluent, aspirate and feed 2 ml of 3T3
medium, and define as Day 0
Day 2
o Aspirate medium from confluent cells
o Add 2 ml of Initiation Medium to each well
Day 4
o Aspirate medium from cells
o Add 2 ml of Progression Medium to each well
Day 6
o Aspirate medium from cells
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•

o Add 2 ml of 3T3 Adipocyte Medium to each well
Day 8‐14
o Feed cells 2 ml of 3T3 Adipocyte Medium every 48h.
o Cells should contain lipid droplets and are suitable for lypolysis
assays from Days 8‐14.

Isolation of Mouse Embryonic Fibroblasts (MEF)
•

Timed Pregnancy
o Place male with female and monitor female for appearance of vaginal
plug shortly after lights‐on the following and subsequent mornings.
The presence of a plug is defined as Day 1.
o Separate and weigh the female on Day 1
o Weigh the female on Day 14.5. If pregnant with a sizeable litter, she
should gain 2.5‐3g.

•

Isolation of embryonic fibroblasts (MEFs)
o Administer a lethal dose of ketamine/xylazine to the pregnant female
o Carefully lift the abdominal wall away from the body. Cut the skin and
peritoneum at the midline just proximal to the hind legs. Cut along
the midline to the sternum. Make two lateral incisions away from the
midline at the proximal and distal end of the first incision.
o Lift the uterus containing the pups away from the abdomen and cut
near the cervix. Place the uterus into a 10 cm dish and transport to
the tissue culture hood for immediate dissection.
o Cut along the surface of the uterus and release the pups into the dish.
Carefully dissent the pups away from the placenta and transfer them
to a new dish.
o Remove the head and abdominal organs of each pup. Transfer the
rest of the pup to a new dish.
o Once all the pups have been dissected, finely mince the tissue with a
sterile razor.
o Digest the tissue in 10 ml of Trypsin‐EDTA (0.5%). for up to 30 min at
37oC.
o Pipette the cells, trypsin and tissue clumps up and down 2‐3X every 3‐
5 min. (solution will be viscous).
o Seed the MEFs in 10 ml of DMEM (10% FBS, 1% P/S, 1% Fungizone)
at a density of 1 pup/dish.
o Culture overnight in a humidified CO2 (5%) incubator.
o Remove unattached cells by aspiration.
o Cells are generally very near confluence the following morning. They
can be passed and propagated or frozen for future use.
o Differentiation of MEF cells follows similar protocol for 3T3‐L1 cells
differentiation with few differences described below.
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o Plate MEF cells on Day 1 in 10 cm dish to reach 50~60% confluence
on next day.
o Digest cells and plate the cells into 1 well of 6‐well plate to reach high
density of cells.
o Start differentiation on Day 3 by adding Initiation medium to cells
o Maintain cells in Initiation medium for 4 days, change medium every
other day
o Swith to progression medium and follow the 3T3‐L1 cells protocol
7.1.4.3.
•

•
•
•
•
•

•
•
•
•

•
•

•

FA containing medium preparation

Make the FA solution of required concentration (eg., 100 µM) using serum
free medium supplemented with 0.2% essential fatty acid free‐ bovine serum
albumin (FAF‐BSA).
Depending on the number of culture plates, prepare required amount of fatty
acid‐enriched medium.
Take out stock solution from the freezer, open cap, pass nitrogen gas through
it for 10 sec.
Take out about 0.5 ml of stock FA solution using a pasteur pipette
(previously cleaned with chloroform:methanol).
Pass N2 gas through the flask containing stock FA for 10 sec again, recap it
and put it back in freezer immediately.
Calculate how much of stock is needed to make 100 µM conc. Measure the
amount of stock and add it to a glass tube. Cover the mouth of the tube to
prevent oxidation.
Calculate the amount of 5N NaOH needed. Add NaOH to FA, mix thoroughly‐
vortex.
Pass N2 gas through the tube until the solution dries up into a salt of FA.
Boil distilled water in a small beaker.
Add about 1 ml of hot water into dried down FA + NaOH, and mix well. Dip
the tube in boiling water for a few minutes so that all the FA + NaOH goes
into solution.
Add the fatty acid solution to required amount of medium (5%) and adjust
the pH with 2N HCl.
Filter the fatty acid containing media through a 0.45 µm filter into a 50 ml
falcon tube under hood.
FAs solution preparation:
o The pure fatty acids are purchased from NuCheck (http://www.nu‐
chekprep.com/home.htm).
o First make the solution in Hexane. Record the weight of fatty acid and
the molecular weight. Make a 5 ml solution in graduated flask and
then calculate the final concentration: N1
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X mg × 1000
5 ml × MW
o Result is in unit as mM.
o Fill with gas N2 and carefully sealed with parafilm.
•

FA Media preparation:
o For 10ml plate, if the final conc. of fatty acid is 20mM, we need to
calculate how much fatty acid solution in hexane we need. V1
o 1: stock solution, 2: experimental solution.
V1N1=V2N2
X×N1 =10×0.02
10×0.02
X=

N1

o X is in the unit of ml.
o For 12 plates, we will need 120ml media. Always prepare extra 5 ml
as later we will need to filter the media and lost some volume.
o Fatty acid will be prepared in serum free medium enriched with 0.2%
(v/v) FAF‐BSA. The ratio of free fatty acids to albumin should not
exceed 3 to 1, otherwise fatty acid is toxic to cells.
•

NaOH 30 times exceed of FA concentration.
o Volume of 5 N NaOH: V3
FA conc.×30× V2
5
o Put NaOH (V3) in a culture glass tube, then add FA (V1).
o Carefully blow in the gas N2 for 15 min to 30 min until it totally dried
(white powder).
o Wash out FA from glass tubes into the media (V2)
o Adjust pH of the media to 7.4 with HCl.
7.1.5. Lipid analysis
7.1.5.1.

Lipid extraction

7.1.5.1.1.
•
•
•
•

Lipid extraction from cells

Rinse plates 2X with 3 mL PBS (4oC).
Scrape dishes in 3 mL of PBS and transfer to a 12x75mm glass tube.
Vortex and take a 100 µL aliquot for protein determination.
Centrifuge at 1000 xg for 5 min. (4oC), and aspirate PBS.
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•
•
•
•
•
•
•
•
•
•
•

Add 2 mL 3:2 hexane:isopropanol. Vortex.
Incubate and for 10 min. (20oC).
Centrifuge at 1000 xg for 5 min. (4oC), and transfer supernatant to a fresh
12x75 mm tube
To pellet, add 2 mL 3:2 hexane:isopropanol. Vortex.
Incubate and for 10 min. (20oC).
Centrifuge at 1000 xg for 5 min. (4oC), and transfer supernatant to 12x75 mm
tube (7).
Evaporate to dryness under N2(g).
Solubilize the extracted lipids in a suitable solvent.
For Storage: Suspend in 500 µL of CHCl3, flush with N2(g) and store at ‐20oC
For TLC: Suspend in 200 µL of 1:1 CHCl3:CH3OH (must be used immediately)
For Enzymatic Cholesterol Assays: Suspend in 2 mL 1% Triton in CHCl3.
Solution can be stored at ‐20oC.

7.1.5.1.2.
•
•
•
•

•

•
•
•
•
•

Lipid extraction from tissue

Cut 100 mg of tissue (0.1 g) and put in dounce test tube. Homogenize using
dounce pestle.
After three/four ups and downs, insert 1 ml of MTSP/OG and homogenize a
little more. Put the dounce test tube in ice and wait 30 min for extraction.
Add 50 µl of C17:0 standard (5 mg/ml in CHCl3) in another test tube. Then
move the liver soln to the test tube by using a glass pipette.
Add 2 ml of Folch/BHT reagent(355). Vortex for 3 x 10 sec (vortex all
samples once, then twice, then three times. Leave 5 min. waiting time
between each vortex).
Soln should look like floating milky‐powders right now. Centrifuge at 2000
rpm for 10 min at RT. (RPM = 2000, RCF = 850, Rotor (the big wheel and its
name) = S‐5.1, Time = 10 min, Temp = 20ºC) After centrifuge, soln should
have three phases (methanol phase, protein & nucleic acid phase, then
chloroform and FA phase at bottom).
Move majority of lower phase to reaction tube with glass pipette, dry under
N2 to about 50 µl.
Add 1 ml BF3/methanol, cap, 55 ºC for overnight.
Move to a glass tube, + 2 ml chloroform, mix well, + 2 ml water, vortex
vigorously for 3x 10 sec.
Remove upper phase. + 2 ml water, vortex vigorously for 3x 10 sec.
Move majority of lower phase to sample vial, inject 1ul at 1:10 to 1:100 to
GC‐MS analysis.
Folch, J., M. Lees, et al. (1957). "A simple method for the isolation and purification of
total lipides from animal tissues." J Biol Chem 226(1): 497-509.
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7.1.5.1.3.
•

•
•
•
•
•

In a glass tube, + 50 µl of serum + 1 ml Folch/BHT + 5 µl of C17:0 standard,
vertex vigorously, + 1 ml of water, vertex vigorously for 3x 10 sec. stand for 5
min until two phase separated.
Remove upper phase, + 1 ml of water, vertex vigorously for 3x 10 sec.
Centrifuge at 2000 rpm for 5 min at room temperature
Move majority of lower phase to a reaction vial, dry under N2 to about 50 µl.
Add 1 ml BF3/methanol, cap, 55ºC for overnight (16h).
Follow the rest steps descried in tissue lipid extraction.

7.1.5.2.
•
•
•
•

•
•
•
•

•

•

•
•

•
•

Lipid extraction from serum

Lipid fractionation

Take approximate 400 mg of liver and place in a fatty acid tube containing 20
ml Folch/BHT reagent.
Homogenize liver and filter into a new fatty acid tube using a No. 2 Whatman
Filter.
Rinse fatty acid tube with 20 ml folch and pour through same filter.
Remove 2 ml and place in screw top glass tube for total fatty acid
determination. Evaporate under nitrogen and proceed with methyl‐
esterification protocol.
Evaporate the remaining folch under nitrogen.
Set up silica columns (one for each sample) with collection tubes in vacuum
apparatus.
Equilibrate silica column with 1 column full (approx. 10 ml) of cholesteryl
ester solvent (solvent I).
Resuspend dried samples with 2 ml of cholesteryl ester solvent by vortexing
and transfer each to its own silica column. Let solvent go completely through
column by slow dripping (vacuum applied).
Add additional 8 ml of cholesteryl ester solvent to the fatty acid tube and
vortex to ensure complete removal from fatty acid tube. Transfer solvent to
the appropriate silica column and collect flow through in test tube and
transfer to new fatty acid tube. MUST use vacuum for each of the remaining
steps.
Rinse column again with 1 column full of cholesteryl ester solvent and collect
flow‐thorough. Combine with previous flow‐through (contains cholesteryl
esters) and evaporate under nitrogen in fatty acid tube.
Change collection test tubes in rack and fill column with triglyceride solvent
(solvent III) and collect flow‐through in a new fatty acid tube/
Fill column a second time with triglyceride solvent and collect flow‐through
and combine with first TG flow (contains triglycerides). Dry samples down
under nitrogen.
Fill column with 10 ml acidification solvent (solvent V) and 10 ml again.
Discard the flow‐through.
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•
•
•
•

•

Fill column with 10 ml of fatty acid solvent (solvent VI) and collect flow‐
through.
Repeat last step and combine the two flow‐through.
Fill column with phospholipid solvent (solvent IV) and collect flow‐through
to a new collection test tube. Transfer flow through to a new fatty acid tube.
Fill column a second time with phospholipid solvent and collect flow‐through.
Combine with first flow‐through in fatty acid tube and evaporate under
nitrogen (will take over‐night).
Proceed with methyl‐esterification with each fraction as per protocol.
7.1.6. Animal experiments
7.1.6.1.

Genotyping

7.1.6.1.1.
•
•
•

DNA isolation

Small piece of ear was collected from each mouse by ear punching
The tissue was lysed in 200µl of DirectPCR® lysis reagent (Viagen Biotech
Inc., Los Angeles, CA) at 55°C overnight
DNA was purified using DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA)
following manufacture’s instruction
7.1.6.1.2.

PCR amplification of DNA
Volume
(1 Reaction)
2 µl
0.5 µl
4 µl
1 µl
1 µl
1 µl
0.3 µl
10.2 µl
20 µl

Components
10 x Thermo Buffer
10 mM dNTPs
GC rich
Primer D2 WT
Primer D2 Common
Primer D2 KO
Taq polymerase
ddH2O
Total volume

Reaction Protocol
Cycle Protocol
1X
1X

Temp
20
95
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Time
5:00
4:00

36X

95
55
72
72
4

1X
1X

7.1.6.1.3.

0:30
0:30
1:00
7:00
hold

DNA Electrophoresis

Sample Preparation:
•

DNA samples can be dissolved in water or TE buffer. For most applications,
simply add appropriate amount of 6X dye to the samples, and they are ready
to load.

Electrophoresis:
•
•
•
•

•
•

•
•
•
•
•

•

Rinse Horizontal Gel Apparatus with Nanopure water.
Assemble gel casting tray by the manufacturers instructions.
Add appropriate amount of 1X TAE and agarose to Erlenmeyer flask.
Heat to a slow boil in microwave oven, hot plate or autoclave. Agarose
should be completely dissolved, and solution should be clear. Do not
overheat as agarose will begin to break down.
Allow solution to cool to 50°C. Solution must be stirred frequently to prevent
localized gelling of the agarose.
Add 10 mg/mL Ethidium Bromide (EtBr) at a rate of 1µL/ 10 mL gel. Note:
EtBr is a powerful mutagen (carcinogen) and gloves should be worn any time
EtBr is used.
Carefully pour the gel into the gel casting tray such that it is free of bubbles.
After the gel has solidified, carefully remove the comb and place the gel in the
gel box.
Add 1X TAE such that the gel is completely submerged with ~1mm of buffer
above the surface of the gel.
Load samples and Marker (If using lambda DNA EcoRI/HindIII fragments, it
must be heated to 42oC for 5 min. prior to loading)
Run the gel at a voltage of 1‐5 V/cm (distance between electrodes) for an
adequate time as judged by migration of bromophenol blue and xylene
cyanol.
Visualize separated DNA by ultraviolet light on a transilluminator.

7.1.6.2.
•

Fasting glucose and glucose tolerance test

Glucometer & Strips: FreeStyle with Test Strips or other commercially
available device
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•
•
•
•
•
•
•
•
•
•
•
•

Transfer mice to individual cages that contain water, but no food, and fast for
four hours beginning shortly after “lights‐on”
Fasting Glucose on Each mouse (Time 0)
Place boxes under hood with a wire rack on the cage
Carefully remove the mouse, weigh and place on the wire rack.
Hold the mouse by the tail and prick the tail vein with a 26 ga needle.
Touch the glucometer strip to the drop of blood that forms on the tail.
Record the result
Inject with 10 ml of glucose per gram body weight (leave at least 2 min
between mouse injections)
Record glucose levels at 30, 60, 90, and 120 min after injections
Calculate Means and Standard Deviations for fasting glucose levels
Calculate % change in blood glucose for each time point
Divide each value by Time 0 and multiply by 100

7.1.7. Histology analysis
7.1.7.1.

Hematoxylin and Eosin (H&E) staining

Deparafinization
•
•
•
•
•
•
•

Xylene 3 min (2 X)
100% EtOH (2 X)
95% EtOH (1 X)
80% EtOH (1 X)
H2O (2 X)
Replace the dirty xylene #1, above with fresh xylene.
Replace the dirty 100% EtOH #1, above with fresh 100% EtOH.

Staining

•
•
•

•
•
•
•

(Notes: Unless otherwise specified, slides should be dipped 10 times in each
solution)
Hematoxylin, 2 min (x1)
Running H2O x 2 min
Acid Alcohol x1 ("Differentiation" lightens the staining, especially outside the
nucleus) Skip this differentiation step for progressive staining with the
weaker Mayer's Hematoxylin stain.
H2O x1
Ammonia solution 10 dips (x1) (changes the stain from purple to blue)
Running H2O 5 min
80% EtOH x1
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•
•
•
•

Eosin 15"
95% EtOH x2
100% EtOH
Xylene 3 min x2

Mounting
•
•
•
•
•
•

Wipe off the xylene off the back of a slide on a paper towel
Using a clean glass rod add a drop of permount to the slide
Cover with a glass slip (use 2 drops of permount for large slips)
Tilt the slide on edge on a paper towel to remove extra xylene or permount
If bubbles are present gently squeeze them out by pressing on slip with a
pencil eraser
Place slides on a paper towel to cure overnight

7.1.7.2.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Oil‐Red‐O staining

Wash: cells 1ml/well PBS. Aspirate
Dehydrate: Add 1ml/well 60% Isopropyl alcohol,
Let sit for 5 minutes, aspirate
Stain: Add 1ml/well Oil Red O Working solution, (cell plate +1 blank well of
empty plate)
Let sit for 15 minutes. Aspirate.
Rinse: both plate samples with 60% Isopropyl alcohol, swish, and aspirate
Wash: both with PBS.
Leave in PBS for viewing under scope at RT (stable for several weeks and
possibly longer).
Extract the red color:
Add 200µl/well of 100% isopropyl alcohol (cell plate +1 blank well of empty
plate)
Rotate slowly for 15 min.
Remove liquid from sample and blank wells, and place in empty 24 well plate
Measure at O.D. of 540 nM. (Tecan Safire equipment)
Data/graph: subtract blank values from each experimental (cell) data point,
take average and plot
Record visual estimate of differentiation, along with passage number and
dates.

Copyright © Jingjing Liu 2011
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